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Abstract  
 
 
 
 
 
 
 
 
 
 
 
xi 
The adult intestinal microbiota comprises a microbial ecosystem of 
approximately 100 trillion microorganisms, with speciﬁc bacterial communities 
exhibiting distinct metabolic capabilities. Bacteria produce a range of bioactive 
compounds to survive unfavourable stimuli and to interact with other organisms, 
and generate several bioactive products during degradation of dietary constituents, 
the host is not otherwise capable of digesting. This thesis addressed the impact of 
feeding potential probiotic bacteria, capable of producing bioactive metabolites, 
such as conjugated linoleic acid (CLA) and gamma-aminobutyric acid (GABA) and 
other dietary strategies such as pure fatty acids and oligosaccharides on gut 
microbiota composition, short chain fatty acid (SCFA) production and modulation of 
metabolism in animal models.   
The aim of the first experimental chapter (Chapter 2) was the optimization 
of a gas chromatography (GC) method for the analysis of SCFA in intestinal samples. 
The method involved a direct aqueous injection into a GC system fitted with a high 
polarity capillary column that proved to be rapid, efficient and accurate for the 
detection of SCFA in faecal/caecal content, provided that extracted samples were 
not stored for long periods and the GC system was maintained in good operating 
conditions. The method was applied in the analysis of SCFA levels in caecal samples 
obtained in animal studies described in Chapters 3, 4 and 6 of this thesis.  
In Chapter 3, t10, c12 CLA, a CLA isomer known to decrease fat mass and 
cause steatosis in rodents, was fed to mice and its effects on intestinal microbiota 
composition and production of SCFA in the large intestine were investigated. 
Animals receiving dietary t10, c12 CLA for 8 wk presented a significantly altered gut 
microbiota composition, harbouring higher proportions of Bacteroidetes (p=0.027), 
 
xii 
including higher proportions of Porphyromonadaceae (p=0.002) previously linked 
with negative effects on lipid metabolism and induction of hepatic steatosis. 
Moreover, significantly higher levels of SCFA (p<0.05) were detected in the t10, c12 
CLA–supplemented group compared with the control group probably due to the 
marked changes in microbiota composition.  The data indicate that the effects of 
dietary t10, c12 CLA on lipid metabolism in mice may be partially mediated by 
alterations in gut microbiota composition and functionality. In the following chapter 
(Chapter 4), human-derived CLA-producing Bifidobacterium breve strains were fed 
to mice for 8 wk to compare their effect on fat composition and distribution and 
the composition of the gut microbiota. Fatty acid metabolism and microbiota 
composition were affected by B. breve DPC 6330 and B. breve NCIMB 702258 
administration compared to unsupplemented controls. However, the responses 
were different indicating that the modulation of the gut microbial community by 
ingested microorganisms is most likely strain-dependent.  
The metabolic and behavioural effects of dietary administration of GABA-
producing Lactobacillus brevis DPC 6108 and pure GABA were investigated in 
Chapter 5. In a first study, dietary Lb. brevis DPC 6108 significantly increased 
(p<0.05) serum insulin and decreased (p=0.0511) anxiety-like behaviour in healthy 
rats. These data led to a second study using diabetic rats (type 1 diabetes induced 
by streptozotocin injection) to evaluate if pure GABA and Lb. brevis DPC 6108 
exerted protective and/or regenerative effects on islet pancreatic β-cells and 
reversed diabetes. Lb. brevis DPC 6108 administration attenuated high levels of 
glucose, but did not change insulin levels in diabetic animals. Behavioural changes 
seen as a result of GABA and Lb. brevis DPC 6108 administration in healthy animals 
 
xiii 
were not observed in diabetic animals. Moreover, one single dose of STZ 
significantly increased glucose (p<0.001) and decreased insulin and c-peptide 
(p<0.05) in diabetic animals indicating an extensive loss of β-cell mass that could 
not be reversed by dietary GABA or Lb. brevis DPC 6108. As GABA beneficial effect 
may be primarily due to modulation of inflammatory response, these data indicate 
that animal models of auto-immune-induced diabetes may constitute better 
models to study protective and/or regenerative effects of pancreatic cells by GABA 
administration.  
In Chapter 6, the effect of dietary bovine milk oligosaccharides (BMO), 
6’sialyllactose (6’SL) and the commercial prebiotic, Beneo Orafti P95 oligofructose 
(P95), on murine gut microbiota composition and functionality was assessed. 
Oligosaccharides supplementation had an impact on gut microbiota composition 
and, overall, P95, BMO and 6’SL supplementations were associated with depletion 
or reduction of less favourable bacteria such as Moraxellaceae, Vibrionaceae and 
Porphyromonaceae. Moreover, levels of SCFA were generally unaffected by dietary 
BMO, 6’SL and P95, and indigenous Bifidobacterium were undetectable in all groups 
tested. The study demonstrated that ingestion of BMO and 6’SL is a safe and 
effective approach to modulate populations of the intestinal microbiota, but future 
studies (e.g using a synbiotic approach) are necessary to assess prebiotic properties 
of these oligosaccharides. In Chapter 7 (General discussion) the major findings of all 
studies were reviewed and discussed. 
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Chapter 1.1 
 
Programming infant gut microbiota: influence of dietary and 
environmental factors 
 
 
 
 
 
 
 
In Current Opinion in Biotechnology, 2010, 21(2):149-156 
 
3 
1.1.1 ABSTRACT 
The neonatal period is crucial for intestinal colonisation, and the 
composition of this ecosystem in early life is influenced by such factors as mode of 
birth, environment, diet and antibiotics. The intestinal microbiota contributes to 
protection against pathogens, maturation of the immune system and metabolic 
welfare of the host, but under some circumstances can contribute to the 
pathogenesis of certain diseases. Because colonisation with non-pathogenic 
microbiota is important for infant health and may affect health in later life, it is 
important to understand how the composition of this microbial organ is established 
and by which dietary means (e.g. supplementation with prebiotics/probiotics/food 
ingredients) it can be programmed in order to achieve an ecosystem that is valuable 
for the host. 
 
1.1.2 INTRODUCTION 
Microbial colonisation of the sterile infant intestine is an intricate process 
which is influenced by many factors (O’Toole et al., 2010) including mode of 
delivery (Grolund et al., 1999), type of feeding (Orrhage & Nord, 1999) and 
antibiotic therapy (Burman et al., 1999; Kalenic et al., 1993). Within the first year of 
life, the enteric microflora is highly dynamic but microbial diversity is low, and after 
the initial year, the microbial population stabilises and resembles that of the adult 
(Palmer et al., 2007). Whilst traditional culture-based techniques have been used in 
the past to determine the microbial load of the infant intestine, less biased DNA-
based techniques including the use of the 16s ribosomal RNA gene have recently 
confirmed the dominance of species of Bifidobacterium, Clostridium and 
 
4 
Bacteroides in the early microbiota (Hopkins et al., 2005; Penders et al., 2006; 
Sakata et al., 2005; Wang et al., 2004). However, using sequencing techniques 
Wang et al. (2004) found that 10% of species from faecal samples of infants after 
the first two months of life were unidentifiable, whereas 30% unidentified species 
were observed after the first year of life, highlighting the complexity of the 
microbiota and the importance of the development of new and more powerful 
fingerprinting techniques. In a more recent study by Rajilic-Stojanovic et al. (2009), 
a phylogenetic microarray (referred to as the human intestinal tract chip or 
‘HITChip’) was developed and applied for comparing the effect of ageing on the 
intestinal microbiota of young and elderly adults. Because of the good 
reproducibility and the possibility for relative quantification of microbial groups, 
this technique might be a suitable tool for determining the microbial diversity of 
the infant gastrointestinal tract in future studies. Another high-throughput 
alternative test is the recently launched GA-mapTM microarray that will enable 
screening of the infant gut microbiota based on sets of unique probes that are 
highly specific to their target group of bacteria. It is envisaged that by providing an 
‘overall map’ of the enteric microbiota, this test will give valuable information to 
assist in disease intervention (Genetic Analysis AS, 2009).  
The mutualistic interactions between the enteric microbiota and the human 
host are essential for health (Dethlefsen et al., 2007). Indeed, the enteric 
microbiota can secrete molecules (so called ‘pharmabiotics’) (Shanahan et al., 2009) 
that inhibit host pathogens, metabolise compounds that harm the host to less toxic 
substances (Dethlefsen et al., 2007; Wall, Ross, Ryan et al., 2009) and produce a 
range of bioactive compounds such as conjugated linoleic acid (CLA), short chain 
 
5 
fatty acids (SCFA) and gamma-aminobutyric acid (GABA) that may play a role in the 
protection from lifestyle illnesses such as cancer, obesity and cardiovascular 
diseases (Wall, Ross, Ryan et al., 2009). Moreover, the microbiota contribute to 
biochemical pathways that humans cannot process because of the lack of proper 
genes (Kovatcheva-Datchary et al., 2009), such as fermentation of indigestible 
dietary polysaccharides, metabolism of complex proteins and synthesis of vitamins 
(Resta, 2009; Wall, Ross, Ryan et al., 2009). The infant gut microbiota can also 
significantly influence the maturation of the immune system in early days of life 
(Gottrand, 2008; Kelly et al., 2007; Shanahan et al., 2009). Remarkably, colonisation 
of the newborn intestine plays a key role in the development and fine-tuning of the 
intestinal immune responses. Disruption to this process, due for example to 
antibiotic therapy, may have long-term health consequences, giving rise to 
immune-related disorders such as eczema, allergic rhinitis and inflammatory bowel 
disease (IBD) (Conroy et al., 2009; Kelly et al., 2007). For example, in a study 
conducted by Wang et al. (2008), the intestinal microbial diversity of 18-month-old 
infants suffering from atopic eczema was reduced in comparison to healthy infants 
of the same age.  
As the infant enteric microbiota is more variable in its composition and less 
stable over time compared to the adult (Palmer et al., 2007), the use of nutritional 
strategies in order to shape/programme its composition to favour a more beneficial 
bacterial population may be a good opportunity to avoid future health problems. 
Probiotics and prebiotics are widely used as supplements in infant formulae and 
many studies have confirmed their efficacy in changing the microbiota composition 
by stimulating the growth of bifidobacteria (Saulnier et al., 2009) and therefore 
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helping in the treatment and prevention of certain illnesses (O’Hara & Shanahan, 
2007; Parracho et al., 2007).  
This review will discuss the current knowledge of the microbial diversity in 
infants and the metabolic capabilities that the enteric microbiota possesses. 
Furthermore, the impact of diet and dietary supplementation (with probiotics and 
prebiotics) on the evolution of the microbial diversity in the developing infant will 
be reviewed. 
 
1.1.3 DEVELOPMENT OF THE INFANT GUT MICROBIOTA 
At birth, the newborn infant gastrointestinal tract is almost sterile (DiGiulio 
et al., 2008; Jimenez et al., 2008; Satokari et al., 2009), but is rapidly colonised in 
the first days of life, reaching a stable population similar to that of an adult when 
the infant is around two years old and there is the introduction of solid foods 
(Dethlefsen et al., 2007; Palmer et al., 2007; Reinhardt et al., 2009; Wall, Ross, Ryan 
et al., 2009). Immediately after birth, the newborn gut environment is colonised by 
facultative anaerobic bacteria such as Enterobacteriaceae, streptococci and 
staphylococci (Adlerberth & Wold, 2009; Morelli, 2008; Penders et al., 2006). These 
first colonisers belong to species with pathogenic potential and might be harmful 
(Morelli, 2008), however most interactions between humans and microorganisms 
do not result in disease (Dethlefsen et al., 2007). Instead, these bacteria gradually 
consume oxygen and produce new metabolites, preparing the intestinal 
environment for the establishment of a strict anaerobic bacterial population 
dominated by Bifidobacterium, Clostridium and Bacteroides, bacterial groups that 
may play a role in the neonatal gut maturation (Adlerberth & Wold, 2009; Morelli, 
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2008; Penders et al., 2006). Recently, the more strict hygienic conditions during 
delivery, short hospital stays and practise of rooming-in (where the mother, not 
health-care workers mainly handles the baby) have reduced bacterial exposure and 
altered the colonisation pattern with skin-derived staphylococci been the first 
colonisers of the infant gut instead of faecal Enterobacteriaceae (Adlerberth & 
Wold, 2009; Morelli, 2008).  
The bacterial community colonising the newborn infant gut is dynamic and 
originates from the environment, mainly from the mother (Dethlefsen et al., 2007; 
Penders et al., 2006). A broad range of factors can affect the bacterial composition 
of the gut including mode of delivery (caesarean section or vaginally), type of 
feeding (exclusive breast-feeding versus formula), gestational age, antibiotic use, 
hospitalisation, surrounding environment and maternal infection or illness 
(Adlerberth & Wold, 2009; Biasucci et al., 2008; Morelli, 2008; Penders et al., 2006; 
Reinhardt et al., 2009) (Fig. 1.1).  
Mode of delivery and type of feeding exert the most significant influences 
on the development of the microbiota in the infant (Butel et al., 2007; Morelli, 
2008; Wall, Ross, Ryan et al., 2009). Vaginally born infants are initially colonised by 
faecal and vaginal bacteria from the mother, whereas infants born via caesarean 
section are colonised by bacteria from the hospital environment (health-care 
workers, air, equipment, other newborns) (Biasucci et al., 2008; Morelli, 2008; 
Penders et al., 2006; Reinhardt et al., 2009). Newborns delivered by caesarean 
section have in general lower numbers of Bifidobacterium, reduced levels of 
members of the Bacteroides fragilis group and higher amounts of Clostridium 
difficile compared to vaginally born infants (Martin & Walker, 2008; Morelli, 2008; 
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Penders et al., 2006). Moreover, the growth of Bacteroides, Bifidobacterium and 
Escherichia coli is delayed in infants born by caesarean section (Adlerberth & Wold, 
2009; Biasucci et al., 2008; Morelli, 2008).  
Traditionally, it has been considered that the microbiota of breast-fed 
infants are dominated by bifidobacteria and also colonised in lesser quantities by 
some facultative anaerobic bacteria such as streptococci, staphylococci, 
enterococci, lactobacilli and enterobacteria, whilst the microbiota of formula-fed 
infants are more diverse and include bacterial groups such as Bacteroides, 
Clostridium and Enterobacteriaceae (Martin et al., 2008; Martin & Walker, 2008; 
Penders et al., 2006; Wall, Ross, Ryan et al., 2009). However, the effect of diet on 
the composition of the infant gut microbiota, more specifically in the predominance 
of bifidobacteria in breast-fed infants is still controversial. Some reports have not 
found differences amongst the types of feeding (Adlerberth & Wold, 2009; Palmer 
et al., 2007) and even suggested that modern formulae are more faithful replicas of 
breast milk, with the addition of prebiotics such as galactooligosaccharides (GOS) 
and fructooligosaccharides (FOS), increasing the number of bifidobacteria and 
lactobacilli in the gut of formula-fed infants to a similar number found in breast-fed 
infants (Adlerberth & Wold, 2009; Boehm & Moro, 2008; Penders et al., 2006).  
The gut colonisation pattern of preterm infants differs from that of full-term 
infants both temporally and qualitatively (Mshvildadze et al., 2008). The several 
immaturities of the preterm infant gut, the long time spent in the neonatal 
intensive care unit and the use of broad spectrum antibiotics delay the 
establishment of a beneficial bacterial community and enable the growth of 
potentially pathogenic bacteria (Martin & Walker, 2008; Mshvildadze et al., 2008). 
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Antibiotics negatively affect the composition of the infant gut microbiota by 
decreasing the numbers of obligate anaerobes (e.g. Bifidobacterium and 
Bacteroides) (Martin & Walker, 2008; Reinhardt et al., 2009). However, the effects 
differ between antibiotics (Penders et al., 2006) and usually most families and 
genera of gut microorganisms return to typical levels within weeks of exposure 
(Dethlefsen et al., 2007). 
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Figure 1.1 Factors affecting the infant gut composition and the differences in the bacterial 
colonisation influenced by the delivery mode and the diet. 
 
 
 
 
 
 
 
 
 
 
11 
1.1.4 IMPLICATIONS OF MICROBIOTA FOR HOST HEALTH 
The enteric microbiota plays an important role in host health, being involved 
in nutritional, immunological and physiological functions. Along the epithelium, 
enteric bacteria complement the natural defence barrier against exogenous 
microbes, thereby preventing invasion by pathogens. In addition, the enteric 
microbiota has an important role in influencing the normal structural and functional 
development of the mucosal immune system (Round & Mazmanian, 2009). The 
molecular interactions between enteric bacteria and the host seem to direct the 
development of immune responses, and in turn the immune system shapes the 
composition of the microbiota. Most of the information regarding the effects of the 
microbiota on the host immune system comes from studies using germ-free 
animals. Germ-free animals show extensive defects in the development of the gut-
associated lymphoid tissue with fewer and smaller Peyer’s patches without 
germinal centres and smaller T cell zones. Furthermore, the lamina propria contains 
essentially no immunoglobulin A (IgA), plasma cells or CD4 cells, and intraepithelial 
lymphocytes are also rare compared with conventional animals (Macpherson & 
Harris, 2004). Germ-free animals are therefore more susceptible to infection 
compared with conventional animals. However, colonisation of animals with a 
single bacterium (Bacteroides fragilis) capable of producing polysaccharide A (PSA) 
has been shown to correct mucosal and systemic immune defects, including 
correcting systemic T cell deficiencies and restoring the balance between TH cell 
subsets (Mazmanian et al., 2005).  
Because the microbiota influences the developing immune system, 
variations from the normal bacterial colonisation pattern through modern 
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strategies such as caesarean section, formula-based diet, hygiene and the excessive 
use of antibiotics in infants, may change the outcome of immune development and 
thus potentially predispose to certain inflammatory diseases in later life. Indeed, 
increased rates of several immune-mediated disorders, such as IBD, atopy, asthma 
and rheumatoid arthritis have occurred in recent years in the ‘Western’ 
populations. This increase may in part, be because of changes in host–microbe 
interactions caused by implementation of different antimicrobial strategies (i.e. 
excessive use of antibiotics, hygiene and Western diets). 
 Recent evidence from animal and human studies indicate that the 
composition of the gut microbiota may also be involved in several extra-intestinal 
disorders such as obesity (Backhed et al., 2004; Ley et al., 2006; Turnbaugh et al., 
2006), insulin resistance (Cani et al., 2008) and non-alcoholic fatty liver disease 
(NAFLD) (Dumas et al., 2006). For example, conventionally raised mice have been 
shown to have 40% more body fat than their germ-free counterparts and 
colonisation with a normal gut microbiota induces hepatic lipogenesis and increases 
lipid storage in adipocytes (Backhed et al., 2004). Moreover, it has been reported 
that differences in the gut microbiota during the first year of life may precede the 
onset of obesity (Kalliomaki et al., 2008). In this study, the numbers of 
Bifidobacterium spp. were higher and the numbers of Staphylococcus aureus were 
lower in children who remained at normal weight than in children who became 
overweight. Thus, a microbiota profile in favour of a higher number of 
bifidobacteria and a lower number of S. aureus in infancy may provide protection 
against overweight and obesity development. Since antibiotic treatment and 
caesarean section result in lower numbers of bifidobacteria (Martin & Walker, 
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2008; Penders et al., 2006), this may lead to an increased risk for the development 
of obesity in later life. It has also been demonstrated that the gut microbiota does 
not only affect fat quantity in the host, but also fat composition. We reported that 
administration of a CLA-producing bifidobacteria strain in combination with linoleic 
acid resulted in modulation of the fatty acid composition of the host, including 
significantly elevated concentrations of c9, t11 CLA in the liver. Furthermore, 
changes in fatty acid composition were not only limited to CLA but included 
changes in the content of eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), alterations that were coupled with an anti-inflammatory cytokine profile 
(Wall, Ross, Shanahan et al., 2009). Another recent study involving a comparison of 
conventionally raised and germ-free mice reported that the gut microbiota have 
the ability to affect lens and retinal lipid composition. The distinct lipid profiles 
suggest that conventional mice are exposed to more oxidative stress than germ-
free mice, decreasing the lens lifespan. These findings open up a new field of 
research for modulating the fatty acid composition of distal tissues (Oresic et al., 
2009). 
 
1.1.5 METABOLITE PRODUCTION BY GUT BACTERIA 
The human enteric microbiota can exert beneficial health effects through 
the production of bacterial metabolites or ‘pharmabiotics’, most often small 
molecules which interact with ‘intelligent communication’ systems in the body 
including those which are immune, endocrine and neuronal-based (Shanahan et al., 
2009). Commensal bacteria have been shown to synthesise vitamins that are 
essential for human survival such as vitamins K2 and B12 (Resta, 2009), 
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polyunsaturated fatty acids (PUFA) such as conjugated a-linolenic acid (CALA) and 
CLA, SCFA, neuroactive compounds such as GABA and histamine (Forsythe et al., 
2010), PSA (Mazmanian et al., 2008) and a variety of other proteins, peptides and 
nucleotides with immunomodulatory and anti-inflammatory properties (Shanahan 
& Kiely, 2007). The effects of some of these compounds on human health are 
briefly reviewed below and summarised in Table 1.1.  
 SCFA are the end products of the bacterial fermentation of carbohydrates in 
the gastrointestinal tract (Forsythe et al., 2010; Kovatcheva-Datchary et al., 
2009). SCFA are important for human metabolism since they increase the 
amount of energy intake, stimulate water and sodium absorption, lower 
luminal pH and the bioavailability of toxic amines (Puccio et al., 2007). In a 
recent study, Maslowski et al. (2009) have shown that SCFA bind to the G-
protein coupled receptor 43 (GPR43) and this interaction may affect 
immune and inflammatory responses. Moreover, butyrate is the primary 
energy source for colonocytes (Saulnier et al., 2009) and has been in the 
focus of studies because of its possible action in the prevention of colon 
cancer (Kovatcheva-Datchary et al., 2009).  
 Vitamin K2 or menaquinone is a lipophilic vitamin that can be found in 
fermented foods and in the colon where it is synthesised by the gut 
microbiota (Greer, 2010; Schurgers et al., 2007). It is an essential cofactor 
for the enzyme responsible for the modification of specific glutamyl residues 
to gamma-carboxyglutamyl (Gla) residues in precursor proteins that possess 
the appropriate gamma-carboxylation recognition signal within the 
propeptide region (Hojo et al., 2007; Kaneda et al., 2008; Schurgers et al., 
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2007; Van Summeren et al., 2009) such as vertebrate proteins involved in 
blood coagulation and bone mineralisation (Schurgers et al., 2007). 
Therefore, menaquinone is important for bone and vascular health, and 
deficiency has been associated with low bone mineral density, increased 
fracture risk, increased risk of cardiovascular diseases, melena neonatorum 
and intracranial hemorrhagic disorders in newborn infants (Greer, 2010; 
Hojo et al., 2007; Schurgers et al., 2007).  
 Vitamin B12 or cobalamin is a compound required by humans but solely 
synthesised by some bacteria and archaea (Hay et al., 2008; Martens et al., 
2002; Santos et al., 2008). During foetal life and infancy, this vitamin is 
important for rapid and normal growth and for the development of the 
nervous system (Dror & Allen, 2008; Hay et al., 2008). Its deficiency in 
infants is related to maternal deficiency and may cause failure to thrive, 
delay development or regression and lead to progressive or permanent 
neurological disorders and haematological abnormalities (Bjorke-Monsen et 
al., 2008; Dror & Allen, 2008; Hay et al., 2008).  
 CLA is a mixture of conjugated isomers of the essential fatty acid linoleic 
acid that have been reported to be produced by some human strains from 
different bacterial groups such as Lactobacillus, Propionibacterium, 
Bifidobacterium, Pediococcus, Enterococcus and Lactococcus (Ross et al., 
2010). CLA has been shown to exert such health properties as 
anticarcinogenic, anti-inflammatory and immunomodulatory effects 
(reviewed in Bhattacharya et al., 2006). Because of its anti-inflammatory 
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properties, CLA may be a potential therapeutic option for the prevention of 
necrotising enterocolitis in preterm infants (Rosberg-Cody et al., 2004).  
 GABA is a non-protein amino acid that acts as a major inhibitory 
neurotransmitter in the central nervous system and exerts several other 
physiological functions such as induction of hypotension and diuresis (Huang 
et al., 2007; Komatsuzaki et al., 2008). GABA is produced by various 
microorganisms, especially lactobacilli (Forsythe et al., 2010) and has been 
used in the development of functional foods such as fermented meats, 
pickles, cheese (Huang et al., 2007; Komatsuzaki et al., 2008) and yogurt 
(Park & Oh, 2007). 
 PSA is a polysaccharide produced by the human symbiotic Bacteroides 
fragilis (Mazmanian & Kasper, 2006). Animal studies have shown that PSA 
has several immunomodulatory activities and can ameliorate inflammatory 
diseases. Treatment with purified PSA protects mice against IBD, avoiding 
weight loss, decreasing levels of cytokines and inhibiting epithelial cell 
hyperplasia and neutrophil infiltration to the gut (Forsythe et al., 2010; 
Mshvildadze et al., 2008). 
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Table 1.1 Examples of metabolite-producing bacterial strains and their possible health 
effects 
Metabolite Bacterial strain Health effects References 
Vitamin K2 Bacteroides  
fragilis 
Modulation of bone mineralization: 
↑Bone mineral density 
↓Fracture risk 
Modulation of blood coagulation: 
↓Risk of cardiovascular disease  
↓Risk of melena neonatarum 
↓Risk of intracranial hemorrhagic 
disease 
 
Greer, 2010 
Kaneda et al., 2008 
Parker et al., 2003 
Schurgers et al, 2007 
van Summeren et al, 
2009 
 
Vitamin B12 Lactobacillus  
reuteri  
Stimulation of nervous system 
development:  
Success to thrive 
↓Risk of neurological disorders 
↓Risk of hematological abnormalities 
  
Dror & Allen, 2008 
Hay et al., 2008 
Martens et al., 2002 
Santos et al., 2008 
 
CLA Bifidobacterium breve  
B. longum 
Modulation of the immune system 
↓Carcinogenesis 
↓Atherosclerosis 
↓Inflammation 
↓Obesity 
↓Diabetes 
 
Barrett et al., 2007 
Bhattacharya et al., 
2006 
Ross et al., 2010 
 
GABA Lactobacillus brevis  
L. paracasei 
 
Central nervous system inhibition 
(inhibitory neurotransmitter): 
↑Hypotension 
↑Diuresis 
 
Huang et al., 2007 
Komatsuzaki et 
al.,2008 
 
PSA Bacteroides  
fragilis 
↓Weight loss 
↓Epithelial cell hyperplasia 
Modulation of the immune system: 
↓Cytokines levels 
↓Neutrophil infiltration 
Mazmanian & Kasper, 
2006 
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1.1.6 DIET AND THE ENTERIC MICROBIOTA 
Diet can influence the composition of the intestinal microbiota, especially in 
the first days of life when the bacterial population is not yet established (Parracho 
et al., 2007). The infant microbiota is naturally shaped during breast-feeding but the 
colonisation pattern can also be manipulated towards a more beneficial community 
using dietary supplementation with probiotics and/or prebiotics.  
Human breast milk is considered the best nutritional option for growth and 
health development of newborn infants, since it contains a wide range of protective 
compounds including carbohydrates, nucleotides, fatty acids, immunoglobulins, 
cytokines, intact immune cells and other immune-modulatory factors (Boehm & 
Moro et al., 2008; Martin et al., 2007; M’Rabet et al., 2008; Puccio et al.,2007; 
Singhal et al., 2008). Moreover, breast milk seems to be a continuous source of 
bacteria for the infant gut (Martin et al., 2008), with milk from healthy mothers 
containing up to 109 microbes/L from different bacterial groups (Morelli, 2008; 
Reinhardt et al, 2009). Commensal bacteria usually present in breast milk include 
staphylococci, streptococci, bifidobacteria and lactic acid bacteria (Martin et al., 
2008; Morelli, 2008; Reinhardt et al, 2009). Bacteria with potential probiotic effects 
have been isolated from human milk such as L. gasseri, L. rhamnosus, L. plantarum, 
L. fermentum, Enterococcus faecium, (Martin et al., 2007) and some bifidobacterial 
species (B. breve, B. adolescentis and B. bifidum) (Martin et al., 2008).  
Due to the positive effects of human breast milk especially in the maturation 
of the immune system of the newborn (Biasucci et al., 2008), many attempts have 
been made to develop artificial formula that stimulate gut colonisation similar to 
that of breast-fed infants, with high numbers of bifidobacteria (Boehm & Moro, 
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2008; Puccio et al., 2007). Strategies used in the supplementation of the basic 
infant formula include the incorporation of probiotics and/or prebiotics. 
 
1.1.7 PROBIOTICS AND PREBIOTICS 
Probiotics are defined as ‘live microorganisms’ which, when administered in 
adequate amounts confer a health benefit on the host’ (FAO/WHO, 2001). The 
most common groups of bacteria used as probiotics are bifidobacteria and 
lactobacilli (Parracho et al., 2007). Multiple mechanisms of probiotic action have 
been suggested; however mechanisms are strain-dependent. Probiotics may 
prevent the penetration of pathogens in the human gut by increasing the 
production of mucin, reducing the gut permeability, releasing antimicrobial 
compounds or modulating the immune system (Saulnier et al., 2009). Several 
studies have demonstrated that probiotic preparations are safe and effective when 
administered to children, aiding in the treatment and prevention of many types of 
diarrhoea (O’Hara & Shanahan, 2007; Parracho et al., 2007; Puccio et al., 2007), 
reducing the incidence and severity of necrotising enterocolitis (AlFaleh & Bassler, 
2008; Deshpande et al., 2007; Martin & Walker, 2008; O’Hara & Shanahan, 2007), 
alleviating symptoms of lactose malabsorption and preventing atopic diseases and 
food allergies in infants (Parracho et al., 2007). However, probiotic concentration 
and viability can be affected during food processing, storage and ingestion 
(Parracho et al., 2007; Saulnier et al., 2009). Therefore, the possibilities of using 
prebiotic as a food supplement are much wider (Parracho et al., 2007). 
Prebiotics are non-digestible food ingredients that selectively stimulate the 
growth of bifidobacteria and lactobacilli (Parracho et al., 2007; Saulnier et al., 
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2009). The two prebiotic substrates commonly added to infant formulae are FOS 
and GOS (Parracho et al., 2007). Administration of prebiotics is often associated 
with a lower faecal pH and changes in the SCFA pattern (Boehm & Moro, 2008). 
Prebiotics increase the production of SCFA, improving the host absorption of 
minerals and facilitating host metabolism (Saulnier et al., 2009). Moreover, by 
changing the composition of the gut microbiota, prebiotics play a role in the 
development of the newborn immune system and protection against pathogens 
(Boehm & Moro, 2008; Saulnier et al., 2009). It has been demonstrated that 
prebiotics can increase the number of bifidobacteria in the gut, and are applicable 
in infant nutrition (Saulnier et al., 2009) 
Another dietary strategy is the combination of probiotics and prebiotics, 
called synbiotic. Synbiotics positively affect the host by introducing new beneficial 
bacteria to the indigenous gut population whilst ensuring its growth and selectively 
stimulating the growth of the other endogenous health-promoting bacteria, such as 
bifidobacteria (Parracho et al., 2007; Puccio et al., 2007). 
 
1.1.8 CONCLUSIONS 
Early colonisation of the infant gut is undoubtedly an important factor for 
the overall health of the infant and may also have effects on the health status in 
later life. Indeed, the commensal microbiota have been implicated in many diseases 
that occur within the gastrointestinal tract and more recently have also been shown 
to be involved in disorders outside the gut such as obesity, diabetes and atopic 
allergies. Several factors have been shown to promote a greater microbial diversity 
in infants including breast milk feeding, vaginal delivery and decreased antibiotic 
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use. Moreover, by programming the infant gut microbiota using prebiotics, 
probiotics and/or synbiotics and thus accomplishing a more beneficial composition, 
several important diseases that develop in early life such as necrotising 
enterocolitis and atopic eczema may be prevented. Although current data support 
the use of probiotics in infants, adequately powered prospective studies that 
document changes in the microbiota in response to diet and antibiotics and 
incorporate long-term health status outcomes are keenly awaited. The intake limits 
(e.g. optimal dose, frequency, timing of administration), variability between 
different probiotic strains and specific effects for different populations (e.g. infants, 
elderly, pregnant women) are some aspects that have to be evaluated. For 
example, in a recent study by Mc Gee et al. (2010), a single oral dose of a probiotic 
led to colonisation of the neonatal intestinal tract in low birth weight infants for an 
extended period of time, which raises the possibility that less than daily dosing may 
be adequate to achieve colonisation of the moderately preterm infant gut with a 
microbiota resembling that of the healthy term infant. However, more research is 
necessary in order to evaluate how such a strategy will affect long-term health 
status. The incidence of childhood obesity has increased during the past years and 
recent studies have suggested that environmental factors such as mode of delivery, 
type of feeding and use of antibiotics which are known to affect the composition of 
the gut microbiota may lead to an increased risk for the development of obesity 
later in life (Backhed et al., 2004; Reinhardt et al., 2009). However, more well-
designed clinical studies are required to confirm the impact of microbiota 
composition on the development of such conditions as obesity. 
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1.2.1 ABSTRACT 
The human intestinal microbiota evolves from an immature and unstable 
ecosystem during infancy into a more complex and stable ecosystem in adulthood. 
Diet is one of the main factors contributing to the composition and diversity of the 
human intestinal microbiota. From birth, breast milk offers the best nutritional 
regime for maturation of the gut, whereas the introduction of solid food selects the 
most adapted bacteria, converging towards an adult-like microbiota. The gut 
microbiota plays an important role in host health, influencing the maturation of the 
immune system and regulating energy metabolism. Moreover, it has become 
evident that the microbiota can affect brain function and behaviour. On this 
bidirectional communication between intestine and the central nervous system 
(CNS), the so called gut-brain axis, the gut influences brain development and 
biochemistry, whereas the brain affects gastrointestinal function. In this context, 
probiotics and prebiotics have been used as dietary strategies aimed at improving 
host health by modulating the gut ecosystem and, consequently, affecting host 
stress-responses, behaviour and cognition. 
 
1.2.2 INTRODUCTION 
Microbial colonisation of the infant intestine begins during birth, with the 
exposure of the newborn to the microbiota of the mother and surrounding 
environment (Adlerberth & Wold, 2009). In the weeks and months following birth, 
the gut microbiota of the infant intestine evolves ultimately into a diverse and 
relatively stable composition by approximately two years of age, remaining thus 
throughout adulthood (Palmer et al.,  2007). The adult intestinal microbiota 
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comprises a microbial ecosystem of approximately 100 trillion organisms, i.e. 10 
times more microbes than human cells, encoding 100-fold more genes than the 
human genome (Qin et al., 2010). The majority of these microorganisms are 
bacteria which cover all host mucosal surfaces within the gastrointestinal tract (GIT) 
(101 microbial cells/g of content in the stomach, 103 to 107 cells/g in the small 
intestine and up to 1012 cells/g in the colon) (Sommer & Backhed, 2013). The adult 
intestinal microbiota is subject-specific, highly variable (Palmer et al., 2007) and 
consists of approximately 500–1000 species, most of them belonging to the phyla 
Firmicutes and Bacteroidetes (Sommer & Backhed, 2013).  The species diversity 
declines with the ageing process and shifts in the dominant species have been 
observed in the elderly; yet the total number of anaerobic bacteria reportedly 
remains relatively stable in individuals over 65 years old (Biagi et al., 2010). Altered 
gut microbiota composition is also associated with premature infancy and such 
medical conditions as obesity (Tremaroli & Backhed, 2012), diabetes (Brown et al., 
2011), atherosclerosis (Koren et al., 2011), inflammatory bowel disease (IBD) 
(Maynard et al., 2012), and necrotizing enterocolitis (NEC) (AlFaleh et al., 2012). 
  While a stable core microbiome exists and is shared among individuals, 
numbers of some transient gut inhabitants fluctuate over time depending on diet, 
antibiotic treatment and other environmental factors (Rajilić-Stojanović et al., 
2012). Dietary habits are among the main factors contributing to the diversity of 
human gut microbiota, as shown in a study by De Filippo et al. (2010) in which 
European children on a Western diet (high in animal protein and fat) were 
compared to children in rural Africa (high-carbohydrate, low animal protein diet). 
Increased gut microbial diversity, with reduced quantities of potentially pathogenic 
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organisms and higher numbers of short chain fatty acid (SCFA)-producing bacteria 
was observed in the African population, and diet seemed to contribute to these 
differences, over other possible variables such as ethnicity, sanitation, hygiene, 
geography and climate. The impact of diet in shaping the gut microbiota was also 
demonstrated in a recent controlled-feeding study by Wu et al. (2011) in which the 
long-term diet regimen was strongly associated with the enterotype partitioning 
suggested by Arumugam et al. (2011). While the microbiota seems to be modulated 
by different types of diet in a continuous mode, aiming to maximize the energy 
intake from fermentable substrates available in the colon (Arumugam et al., 2011; 
De Filippo et al., 2010), a more abrupt change is seen with the use of antibiotics. 
Indeed, antibiotic treatment results in major alterations in gut microbiota 
composition with severe disruption of microbial diversity, as shown in two studies 
where short-term antibiotic treatment significantly affected evolution of the infant 
gut microbiota, disturbing the colonisation pattern of Bifidobacterium in the first 
months of life (Hussey et al., 2011; Fouhy et al., 2012).  The impact of commercial 
antibiotics and bacteriocins on microbiota composition has also been investigated 
in vitro (Rea et al., 2010), and in vivo in an animal model of obesity (Murphy et al., 
2013).  In both studies, treatment with broad-spectrum antibiotics led to drastically 
altered gut microbiota composition, while on the other hand, bacteriocins had a 
more specific effect, inducing more subtle changes in the microbiota, and in a less 
severe manner compared with antibiotics.  These results suggest that the speciﬁcity 
of the antimicrobial agent employed is critical and that bacteria and their products 
may be a useful strategy to modulate the microbiota.  
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Probiotics and prebiotics are dietary components that may positively impact 
on microbiota composition and consequently, host health. Administration of 
probiotics and prebiotics has been shown to enhance the host’s defence system 
against pathogens by stimulation of mucin production, and decreased gut 
permeability (Mennigen et al., 2009; Saulnier et al., 2009). Probiotics have also 
been successfully used to prevent gastrointestinal diseases, to reduce the risk of 
antibiotic-associated diarrhoea (AAD) (Hempel et al., 2012) and to improve irritable 
bowel syndrome (IBS) symptoms (Moayyedi et al., 2010). Moreover, several reports 
have shown that probiotics and prebiotics may modulate brain function and 
behaviour (Bravo et al., 2011; Silk et al., 2009), and in this respect, we recently 
coined the term ‘psychobiotics’ to describe a live organism that, when ingested in 
adequate amounts produces a health benefit in patients suffering from psychiatric 
illness (Dinan et al., 2013). Although more studies are necessary to understand the 
communication between the gut and the CNS, it is suggested that probiotics may 
affect the brain in a direct manner by producing neurotransmitters and 
neuromodulators (Lyte, 2011; Barrett, Dinan et al., 2013) or, by other mechanisms, 
such as activation of the vagus nerve, alteration of gut microbial composition and 
alteration of circulating levels of cytokines (Cryan & Dinan, 2012). 
The interaction between gut microbiota and host is complex and dynamic 
and, although some commensal gut microbes have pathogenic potential (e.g. 
bacterial overgrowth following antibiotic treatment, translocation to other 
tissues/organs), in the majority of cases the symbiotic association offers mutual 
benefits. In a homeostatic state, the host provides protection and a nutrient-rich 
environment for the growth of microorganisms (Maynard et al., 2012), while the 
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microbiota inhibits the growth of potential pathogens, converts harmful 
compounds to less toxic substances and produces bioactive molecules that may 
play a role in host physiology (Marques et al., 2010). The gut microbiota is 
responsible for the development and maturation of the immune system (Maynard 
et al., 2012) and has a role in energy metabolism, thus regulating fat storage in the 
host (Tremaroli & Backhed, 2012). Moreover, the microbiota and its metabolites 
may influence the development and function of the brain (Collins et al., 2012; Cryan 
& Dinan, 2012). 
Here, we review the changes in the microbiota from the colonisation of the 
newborn through adulthood to the elderly stage, with a focus on the importance of 
diet in shaping gut microbiota composition and diversity. The role of early infant 
nutrition on gut maturation is discussed and the use of probiotics and prebiotics as 
dietary strategies to maintain gut ecosystem homeostasis. Moreover, we assess the 
relationship between the gut microbiota and the CNS, exploring the concept of gut-
brain axis, and how probiotics and prebiotics may impact on host brain function and 
behaviour.  
 
1.2.3 GUT MICROBIOTA EVOLUTION IN THE HUMAN BODY 
Gut colonisation and the development of the infant gut microbiota  
Foetal development is believed to occur in a sterile intrauterine 
environment, with bacterial colonisation of the infant intestine beginning during 
birth (Penders et al., 2006; Koenig et al., 2010). The microbiota population that 
develops in the initial stages of colonisation is determined by the types of bacteria 
to which the infant is exposed in the first hours of life and the establishment of a 
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healthy microbiota is believed to have a profound impact on the future well-being 
of the individual (Palmer et al., 2007). During and following birth, the infant is 
exposed mainly to the maternal microbiota (vagina, anus and skin), but also to 
bacterial cells from the hospital environment (health-care workers, air, equipments, 
other newborns). In the earliest stage of community development, the newborn 
microbiota is less complex and stable than the adult microbiota (Adlerberth & 
Wold, 2009; Palmer et al., 2007) and is homogeneously distributed across the body 
(undifferentiated bacterial communities across skin, oral and nasopharyngeal 
cavities, and gut) (Dominguez-Bello et al., 2010). Although a remarkable degree of 
interindividual variation in microbiota population is observed, the microbial 
succession in the infant gut is expected to progress in a similar pattern    initially the 
gastrointestinal tract is colonised by facultative anaerobes such as Staphylococcus, 
Streptococcus and Enterobacteria. The bacterial population expands, and oxygen is 
gradually consumed, creating a more suitable environment for proliferation of strict 
anaerobes, including Clostridium, Bacteroides and Biﬁdobacterium. As the time 
passes, facultative bacteria cannot resist the competition and environmental 
changes and are eventually outnumbered by anaerobes, starting to resemble the 
adult mature gut (Adlerberth & Wold, 2009; Palmer et al., 2007). 
A broad range of factors are known to influence the composition of the 
infant gut microbiota including mode of delivery, feeding regime, gestational age, 
and use of antibiotics and probiotics. In preterm infants, microbial colonisation is 
disrupted because of the gastrointestinal tract immaturity, frequent use of 
antibiotics, delayed nutrition and extended stay in hospital (Arboleya et al., 2011; 
Barrett, Kerr, et al., 2013). Although high inter-individual variability in bacterial 
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levels is also observed in preterm infants, their microbiota is characterised by 
reduced microbial diversity, with higher numbers of potentially pathogenic bacteria 
and lower numbers of commensal microorganisms such as Biﬁdobacterium and 
Bacteroides (Arboleya et al., 2011; Barrett, Kerr, et al., 2013), compared with full-
term infants. Among several factors that may affect infant gut colonisation, mode 
of delivery and feeding regime have been extensively studied. Mode of delivery is 
the primary determinant of a newborn’s bacterial community composition 
(Dominguez-Bello et al., 2010). Vaginally born infants are colonised by faecal and 
vaginal bacteria from the mother, whereas infants born via caesarean section are 
initially exposed to maternal skin microbiota and bacteria from the hospital 
environment (Adlerberth & Wold, 2009; Penders et al., 2006). Indeed, in a study 
conducted by Dominguez-Bello et al. (2010), the dominant taxa found in the infant 
communities were reﬂective of delivery mode, with higher numbers of 
Lactobacillus, Prevotella, Atopobium, or Sneathia spp. found in intestinal samples 
collected from vaginally delivered babies, and typical skin taxa, including 
Staphylococcus spp., in samples from infants born by caesarean section. Penders et 
al. (2006) also reported a significant impact of mode of delivery on infant’s 
microbial population. In this study, infants born by caesarean section harboured 
lower numbers of Bifidobacterium, reduced levels of members of the Bacteroides 
fragilis group and higher amounts of Clostridium difﬁcile when compared to infants 
born vaginally. Interestingly, a study by Aagaard et al. (2012) showed that in a 
pregnancy state, the mother’s vaginal community shifts naturally to a less diverse 
and rich population, but with an increased number of Lactobacillus species that 
might be important for establishing a healthy neonatal microbiota during birth.  
 
41 
Diet is another factor that strikingly impacts gut microbiota composition 
(Adlerberth & Wold, 2009; Koenig et al., 2010). Before weaning, the infant’s diet is 
a relatively constant supply of milk, either breast milk or formula. Breast milk 
contains a complex mixture of oligosaccharides that are believed to inhibit the 
binding of pathogenic bacteria and toxins and to stimulate the growth of beneficial 
bacteria such as Bifidobacterium (Zivkovic et al., 2011). Indeed, Penders et al. 
(2006) reported that breast feeding was associated with an infant microbiota 
dominated by Bifidobacterium and with lower levels of Escherichia coli, C. difﬁcile 
and B. fragilis species, whereas C. difficile, Bacteroides, Enterococcus and 
Enterobacteriaceae were more commonly associated with infant formula-feeding 
(Adlerberth & Wold, 2009). However, recent technological advances in the design 
of infant formula have increased their similarity to breast milk, improving their 
bifidogenic effect and decreasing the differences previously seen between breast- 
and formula-fed infant microbiota (Adlerberth & Wold, 2009). While breast milk 
feeding offers the best nutrition for growth and maturation of the infant gut 
(Zivkovic et al., 2011), the change to a solid type of food during weaning is 
determinant for the transition of an immature, unstable infant microbiota to a 
more complex and stable adult ecosystem (Koenig et al., 2010). The introduction of 
solid food at weaning  imposes increasingly rigorous selection for the most highly 
adapted bacteria (Palmer et al., 2007), inducing an increase in numbers of 
Bacteroidetes and Firmicutes and enrichment in functional genes characteristic of 
the adult gut microbiome (Koenig et al., 2010). 
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The individual-specific microbiota of an adult 
Bacterial diversity increases with age (Yatsunenko et al., 2012). In the gut, 
interactions with the host and competition with other microorganisms select the 
most apt bacteria shaping the microbiota ecosystem (Arumugam et al., 2011). The 
adult gut ecosystem is dominated essentially by Firmicutes and Bacteroidetes phyla 
(Arumugam et al., 2011), but also by Actinobacteria, Proteobacteria and 
Verrucomicrobia (Salonen et al., 2012). Few highly adapted species form the stable 
core component of the microbiota consisting of primarily anaerobic bacteria, 
including Biﬁdobacterium spp., Faecalibacterium spp. and the majority of members 
of the Bacteroidetes phylum. On the other hand, oxygen-tolerant bacteria, such as 
Lactobacillus spp., and members of Proteobacteria phylum are transient gut 
inhabitants appearing at low numbers and fluctuating over time, depending on diet 
and other environmental factors (Arumugam et al., 2011; Rajilić-Stojanović et al., 
2012; Salonen et al., 2012). The adult gut microbiota is individual-specific and 
relatively stable over time (Palmer et al., 2007). In a study conducted by Rajilić-
Stojanović et al. (2012), the subject-specific microbiota pattern was preserved for 
longer than a decade, suggesting that a homeostatic ecosystem can resist several 
aggressive environmental factors. The study showed that the use of antibiotics, for 
example, permanently changes the microbiota composition, but its diversity is 
restored after the end of treatment. 
Despite the individual-specific nature of the intestinal microbiota, and in 
agreement with the idea of a conserved core community that is not susceptible to 
environmental variation (Salonen et al., 2012), a study by Arumugan et al. (2011) 
suggested that the microbiota of all humans can be classified into one of three 
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enterotypes. Each enterotype is identifiable by the abundance of a specific bacterial 
genus  Enterotype 1 is enriched in Bacteroides, Enterotype 2 is enriched in 
Prevotella and Enterotype 3, the most frequent type, is enriched in Ruminococcus. 
Although each enterotype uses a different route to generate energy from 
fermentable substrates available in the gut, its composition is probably not 
influenced by nutritional habits and does not correlate with the host gender, age or 
body mass index (BMI). 
 
The microbiota in the elderly 
The ageing process can seriously affect the composition of the human gut 
microbiota. Besides the complex repertoire of medications used for the treatment 
of several types of illnesses (Claesson et al., 2011), natural changes  in physiology 
such as masticatory dysfunction, swallowing difficulties, digestive problems and 
decreased intestinal motility can lead to ingestion of an imbalanced diet and 
malabsorption of nutrients, compromising intestinal microbiota composition in the 
elderly (Woodmansey, 2007). The decline in functionality of the immune system 
(immunosenescence) is another process that affects the homeostatic equilibrium of 
the gut microbiota in the elderly. Furthermore, the immunosenescence  is  
accompanied  by  a  chronic,  low  grade  overall  inﬂammatory state (inﬂamm-
ageing) that favours  the growth of pathobionts over symbiont bacteria (Biagi et al., 
2010). 
The composition of the intestinal microbiota in the elderly (>65 years) is 
extremely variable between individuals (Claesson et al., 2011), yet the biodiversity 
is reduced and the stability compromised (Biagi et al., 2013). Total numbers of 
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anaerobic bacteria reportedly remain relatively stable, but increases in facultative 
anaerobes and shifts in the dominant species are reported during ageing, with 
Bacteroidetes and Firmicutes still dominating the gut microbiota with smaller 
fractions of Actinobacteria, and Proteobacteria (Biagi et al., 2010). However, the 
effect of age on numbers and diversity of the components of the Firmicutes and 
Bacteroidetes phyla is controversial. The ELDERMET consortium reported a 
dominance of the phylum Bacteroidetes with lower proportion of the phylum 
Firmicutes (Claesson et al., 2011). The same age-related  increase  in  Bacteroidetes  
was  found  in  German,  Austrian and Finnish elderly,  but  this  was  not  confirmed  
in Italian  elderly  and  centenarians (Biagi et al., 2013). Moreover, a clear shift to a 
more Clostridium cluster IV-dominated community was reported for the Irish 
elderly (Claesson et al., 2011), whereas the species Faecalibacterium  prausnitzii, 
belonging to this same cluster, was markedly decreased in Italian elderly (Biagi et 
al., 2013). These variation in gut microbiota composition found among different 
nationalities may be attributed to differences in life style, and type of diet. Indeed, 
the important impact of nutrition on microbiota composition was revealed in a 
recent study by Claesson et al. (2012). Within the same ethnogeographic region 
(Ireland), it was possible to determine an individual segregation of microbiota 
depending on where the elderly lived, with location largely determining the diet.  
The results indicated that a healthy, diverse diet promotes a more diverse gut 
microbiota composition that is more beneficial to the health of the elderly. 
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1.2.4 IMPACT OF DIET  ON HUMAN HEALTH   
Breast milk and microbiota development in infants 
Breast milk is an important source of nutrients for the healthy growth and 
development of infants. It contains a complex and diverse mixture of 
oligosaccharides (Barile & Rastall, 2013; Zivkovic et al., 2011), as well as several 
other factors such as cytokines, lysozyme and lactoferrin, which are essential for 
the optimum development and maturation of the gut (Cabrera-Rubio et al., 2012).  
Various oligosaccharides and glycoconjugates in milk have an anti-adhesive effect, 
inhibiting the binding of pathogenic bacteria and toxins. Breast milk helps to 
prevent infections by shaping the immune system and selectively supporting the 
establishment of the intestinal microbiota (Zivkovic et al., 2011). Breast milk is also 
a source of bioactive compounds as well as microorganisms and their growth 
factors (Cabrera-Rubio et al., 2012). Indeed, in a study conducted by Zivkovic et al. 
(2011), human milk oligosaccharides (HMO) were shown to act as prebiotic 
substrates stimulating the growth of beneficial bacteria such as bifidobacteria. 
HMO may  selectively  promote  the  growth of  certain  Bifidobacterium  strains and 
enhance  their  persistence  in  the  gut (Barile & Rastall, 2013). In a study by 
Cabrera-Rubio and colleagues (2012), the milk microbial community was 
characterised, showing that bacterial cells present in breast milk are not 
contaminants. The authors found that human breast milk is dominated by bacilli, 
with colostrum having higher diversity than mature milk. Interestingly, the results 
also suggested that several factors, such as mode of delivery and maternal BMI can 
signiﬁcantly skew the breast-milk microbiome composition and diversity (Cabrera-
Rubio et al., 2012).  
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Breastfeeding is believed to reduce the incidence of lower respiratory tract 
infections, NEC, sudden infant death syndrome (SIDS), childhood IBD and other 
diseases. An extensive review of the benefits of breastfeeding can be found in the 
American Academy of Pediatrics (AAP) policy statement published in 2012 
(Eidelman et al., 2012). 
The structural complexity of HMO is likely responsible for the several 
benefits attributed to breast milk and is an obstacle for the preparation of prebiotic 
formula with similar properties. Investigations into alternative sources have shown 
that milk from other mammals contains lower concentrations of these complex 
oligosaccharides with varying structures.  Another alternative is the use of the 
prebiotic galacto-oligosaccharides (GOS). Despite the low similarity with  HMO 
structure, commercial GOS in infant formula leads to signiﬁcantly increased 
Bifidobacterium levels in human intestine following ingestion, and it has been 
shown to exert a positive impact on the immune system (Barile & Rastall, 2013). 
 
Dietary interventions using probiotics and prebiotics  
Maintenance of the homeostasis in the gut ecosystem is essential for health, 
and, in this perspective, dietary manipulation may represent a strategy to preserve 
a healthy gastrointestinal microbial community and contribute to the well being of 
the host. Several food products containing probiotics and prebiotics have been 
developed for specific age groups such as infants and elderly. These are important 
target groups because of the immaturity of the infant gut immune system and the 
elderly immunosenescence, respectively. Infant formula containing specific 
oligosaccharides have been shown to be good replicas of breast milk, leading to 
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enhanced levels of  Bifidobacterium (Adlerberth & Wold, 2009), whereas both 
probiotics and prebiotics have been reported to successfully improve intestinal 
microbial composition and immune function in the elderly (Saulnier et al., 2009). 
Probiotics are defined as “live micro-organisms which when administered in 
adequate amounts confer a health benefit on the host” (FAO/WHO, 2001). 
Lactobacillus and Bifidobacterium are the main genera of microorganisms used as 
probiotics in food and are most commonly sold in dairy products (FAO/WHO, 2001). 
Although they belong to a group of bacteria regarded as “Generally Recognized as  
Safe” (GRAS), potential probiotic strains must be isolated as pure microorganisms 
(Preidis & Versalovic, 2009) and must be tested for the presence of transmissible 
antibiotic resistance genes (EFSA, 2004; FAO/WHO, 2001). Several reports suggest 
that probiotics improve intestinal barrier function, modulate the immune system 
and compete for nutrients and binding sites, enhancing the host defence system 
against pathogens (Saulnier et al., 2009). In addition, probiotics can synthesize 
organic acids and other metabolites such as proteins or peptides which may have a 
direct antimicrobial action or which may induce the host to produce a beneficial 
action (Marques et al., 2010; Preidis & Versalovic, 2009; Saulnier et al., 2009). 
Probiotic interventions have been shown to have a role in the prevention or 
improvement of some gastrointestinal diseases such as AAD (Hempel et al., 2012; 
Hickson, 2011), NEC (AlFaleh et al., 2012) and IBS (Moayyedi et al., 2010) (see 
Sanders et al., 2013 for a recent review on the use of probiotics). Moreover, 
probiotic therapy has been reported as an alternative in the treatment of 
neurological and psychiatric disorders, affecting stress-responses, behaviour and 
cognition (Cryan & Dinan, 2012). Probiotics act through diverse mechanisms that 
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may vary from one strain to another or may be a combination of events. Probiotic 
concentrations in foods can be affected in many ways from food processing to 
ingestion since most of them are delivered orally as food or dietary supplements. 
Thus, the strain selected must not only be capable of surviving passage through the 
digestive tract and have the capability to proliferate in the gut, but must also 
remain viable independent of the food matrix or delivery strategy used (FAO/WHO, 
2001; Saulnier et al., 2009). 
Prebiotics are non-viable food components that confer health benefits on 
the host associated with modulation of the microbiota (Pineiro et al., 2008). Thus, 
prebiotics are a dietary approach that target the indigenous bacterial community 
already established in the gut. Prebiotics are typically oligosaccharides or more 
complex saccharides and the majority of studies have so far focused on  inulin, 
fructooligosaccharides (FOS) and GOS because of their safety and efficacy (Pineiro 
et al., 2008; Preidis & Versalovic, 2009). A prebiotic must resist host digestion, 
absorption, and adsorption, reaching the intestine unaltered to be fermented by 
the gut microbiota. Products of fermentation by Lactobacillus and Bifidobacterium, 
such as lactic and acetic acids, are used by other bacteria to generate more SCFA 
and all these compounds have an effect on host metabolism (Preidis & Versalovic, 
2009; Saulnier et al., 2009). In the gut, prebiotics not only enhance the colonisation 
of beneficial bacteria, such as Lactobacillus and Bifidobacterium, but also indirectly 
affect the growth of other important bacteria such as F. prausnitzii (Saulnier et al., 
2009). Moreover, these compounds may directly stimulate immunity, prevent the 
adhesion of pathogens, decrease faecal transit time and facilitate host mineral 
absorption (Pineiro et al., 2008; Saulnier et al., 2009).  
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In addition to the modulation of the gut microbiota composition with the 
stimulation of beneficial gut commensals, prebiotics may help in the colonisation, 
survival, and function of probiotics. Synbiotics refer to synergistic beneficial effects 
derived from a mixture of probiotics and prebiotics. Careful selection of probiotic 
strains and compatible prebiotics will maximize the potential effect of these 
strategies (Preidis & Versalovic, 2009). There are numerous studies showing the 
beneficial effects of probiotics and prebiotics in health and nutrition. However, the 
lack of standardization prevents the comparison of these claims (the probiotic 
effect is strain-specific and the results cannot be extrapolated without new 
experiments (FAO/WHO, 2001)). Both probiotic and prebiotic effects are dependent 
on frequent ingestion, highlighting the importance of optimal dose and duration of 
intake (Saulnier et al., 2009). Therefore, well-designed and carefully conducted 
randomised controlled trials (with relevant inclusion/exclusion criteria, adequate 
sample sizes and information about long safe use) are necessary to evaluate the 
variety of biological effects of probiotics and prebiotics, and their implications for 
the human microbiome. 
 
1.2.5 THE GUT-BRAIN AXIS 
In recent years, interdisciplinary investigation has unveiled strong evidence 
for the existence of a bidirectional signalling between the intestine and the brain, 
the so called “gut-brain axis”. This communication system integrates neural, 
hormonal and immunological signalling between the gut and the brain (Collins et 
al., 2012).  Moreover, the axis concept can be expanded to a “microbiota-gut-brain 
axis”, since not only the intestinal tract itself can affect the brain, but also its 
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microbial inhabitants (Fig. 1.2). While the gut microbiota and its metabolites may 
modulate the peripheral and CNS, influencing brain development and function 
(Forsythe et al., 2010), the brain may affect gastrointestinal functions such as 
motility, secretion, blood ﬂow and mucin production as well as the immune system 
and microbiota composition (Collins et al., 2012; Sudo et al., 2004). 
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Figure 1.2 The microbiota-gut-brain axis. The communication system is bidirectional 
and integrates neural, hormonal and immunological signalling. Dietary strategies, 
such as probiotics and prebiotics, aim to modulate the gut microbiota and may 
affect host’s stress-responses, behaviour and cognition. 
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Different strategies have been used to elucidate the role of the gut 
microbiota on behaviour and cognition, including the use of germ-free (GF) animals, 
animals with pathogenic bacterial infections, and animals exposed to probiotic 
agents and antibiotics (Cryan & Dinan, 2012). Studies using germ-free animals have 
shown that the complete absence of gut bacteria can affect behavioural functions 
and CNS neurotransmission. Heijtz and colleagues (2011) demonstrated that GF 
mice display increased motor activity and reduced anxiety-like behaviour, 
compared with mice with a normal gut microbiota. Supporting these results, a 
study by Clarke et al. (2012) showed the same reduction in anxiety on male GF 
animals, a significant elevation in the hippocampal concentration of 5-
hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) and an 
increased concentration of plasma tryptophan, the precursor of 5-HT. These 
alterations on the serotonergic system, which is particularly relevant to stress, 
anxiety and depression, suggest that CNS signalling may be modulated by 
microbiota manipulation (Clarke et al., 2012). Another study, conducted by Sudo et 
al. (2004), used a GF animal model to evaluate how the commensal microbiota 
regulates the development of the hypothalamus-pituitary-adrenal (HPA) axis 
response. The HPA axis is a neuroendocrine system that controls reactions to stress 
and is subjected to programming by early life events. The data showed an enhanced 
HPA response to stress in GF mice with an exaggerated release of 
adrenocorticotropic hormone and corticosterone. Interestingly, the increase in the 
HPA response was partially reversed by early colonisation of the GF group with 
faeces from a control-specific pathogen free group or completely reversed by 
monoassociation with Biﬁdobacterium infantis.  
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Bercik, Denou, et al. (2011) used an antibiotic (ATB) treatment approach to 
provide evidence for a microbiota–gut–brain axis. Treatment with antibiotics for 
one week affected murine gut bacterial composition, increasing the levels of 
Firmicutes and Actinobacteria, and decreasing g-proteobacteria and Bacteroidetes. 
The authors hypothesized that the changes in the microbiota were responsible for 
the increased exploratory behaviour on ATB mice, since the same antibiotic 
treatment did not affect the GF group. Furthermore, it was suggested that the 
altered behaviour was consistent with an increase in brain-derived neurotrophic 
factor (BDNF) levels in the hippocampus and decreased levels in the amygdala. 
Alterations in BDNF levels have been implicated in changes in anxiety behaviour, 
and its regulation probably involves multiple mechanisms (Duman, 2004). An 
exaggerated HPA axis response to stress with release of corticosterone decreases 
BDNF expression, as was observed in a study by Sudo and colleagues (2004). 
However, removal of the adrenal glands where corticosterone is synthesized did 
not block BDNF downregulation, indicating that other factors are required for the 
effects of stress (Duman, 2004). Furthermore, high levels of hippocampal BDNF are 
associated with anxiolytic and antidepressant behaviour and increased BDNF 
expression in the amygdala are observed during fear learning (Bercik, Park, et al., 
2011). BDNF levels are decreased in patients who are depressed and administration 
of one of the several different classes of antidepressants, 5-HT or noradrenaline 
(NA) selective reuptake inhibitors, has been shown to increase neurogenesis in 
adult hippocampus (Duman, 2004). However, in contrast, both Clark et al. (2012) 
and Heitz et al. (2011) have shown significantly lower BDNF mRNA expression in the 
hippocampus of GF mice and this was accompanied by a decrease in anxiety-like 
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behaviour. Intriguingly, the higher levels of 5-HT and tryptophan in the male GF 
mice did not increase BDNF levels as observed for antidepressants treatment. As 
BDNF reduction was sex-dependent, and only associated with male animals, it may 
be that sexual hormones are involved in the regulation. Stress is also reported to 
increase levels of interleukin (IL)-1β and it is possible that BDNF downregulation is 
mediated by this cytokine (Duman, 2004). A study conducted by Gareau et al., 
(2010) demonstrated a correlation between hippocampal BDNF and memory, 
reinforcing the concept  of the  gut-brain axis. Mice infected with Citrobacter 
rodentium displayed stress-induced memory impairment, with reduced BDNF levels 
in the hippocampus. These changes were accompanied by an increase in serum 
corticosterone and changes in microbiota composition. Administration of a 
probiotic mixture containing Lactobacillus rhamnosus R0011 and Lactobacillus 
helveticus R0052 restored the hippocampal-dependent memory, ameliorated 
stress-induced increases in serum corticosterone, normalized the microbiota and 
recovered BDNF expression. Moreover, the experiment showed that, although GF 
animals are not anxious, they lack non-spatial and working memory and exhibit 
decreased BDNF, demonstrating the importance of the microbiota for the 
development of hippocampal-dependent memory. 
Several other studies have used probiotic administration in an attempt to 
better understand the mechanisms involved in the gut-brain axis signalling (Table 
1.2). In a study conducted by Zareie et al. (2006), the effects of psychological stress 
on intestinal mucosa integrity and the ability of a probiotic strain to prevent the 
damage were evaluated. Chronic stress induced ion secretion and barrier 
dysfunction with increased bacterial adhesion and penetration into surface 
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epithelial cells. Pre-treatment with Lactobacillus species prevented the bacterial 
adherence induced by stress and, more importantly, abolished the bacterial 
translocation to mesenteric lymph nodes. The authors concluded that 
administration of the probiotic during chronic psychological stress enhanced 
mucosal defence against luminal bacteria, a desirable feature for the treatment of 
patients with IBD. IBD and IBS are two different conditions that cause significant 
gastrointestinal and psychological discomfort and are both characterised by 
impaired gut barrier function and changes in gut microbiota diversity (Spiller & Lam, 
2011). IBS is the most common gastrointestinal dysfunction, yet little is known 
about its aetiology (Silk et al., 2009). Given the few options for treatment and the 
evidence that modulation of gut microbiota may ameliorate inflammation and 
reduce psychological distress, a human trial was conducted to investigate efficacy 
of a trans-galactooligosaccharide in IBS (Silk et al., 2009). Treatment with the 
prebiotic affected intestinal microbiota composition and stimulated growth of 
bifidobacteria. Moreover, IBS symptoms were alleviated, with changes in stool 
consistency, improvement of ﬂatulence and bloating, and improved composite 
symptom score (abdominal pain/discomfort, bloating⁄distension and bowel 
movement difficulty). Anxiety scores were significantly reduced in diarrhoea 
predominant IBS (IBS-D) patients during treatment with the highest concentration 
of prebiotic.  In general, administration of prebiotic improved the quality of life of 
patients suffering with IBS, supporting the concept of dietary interventions as an 
alternative treatment for gastrointestinal disorders. A reduction in anxiety scores 
was also reported in two other human trials in which healthy subjects (Messaoudi 
et al., 2011) and patients suffering from chronic fatigue syndrome (CFS) (Rao et al., 
 
56 
2009) were treated with probiotics. It is possible that the decreased anxiety was a 
consequence of improved bowel function, especially for the conditions of IBS and 
CFS. Desbonnet et al. (2008) investigated the impact of chronic administration of B. 
infantis 35624 on behaviour and neuronal signalling. The probiotic administration 
had no effect on swim behaviours of naive rats, while lower levels of pro-
inflammatory cytokines and higher concentrations of serotonin precursor 
tryptophan were observed in probiotic-treated rats compared to the control group. 
These findings suggest that the B. infantis strain may possess antidepressant 
properties and, in a second study, the same authors used a maternal separation 
(MS) model to evaluate this hypothesis (Desbonnet et al., 2010). In contrast to the 
first study, postnatal MS induced a state of behavioural despair that was attenuated 
by the treatment with the probiotic. However, probiotic treatment had no effect on 
tryptophan levels as previously demonstrated , indicating that maybe  MS 
compromises other biological systems involved in the synthesis of this metabolite. 
Both studies provided evidence of a probiotic beneficially affecting the neuronal 
system and behaviour, but also highlighted the complexity of the role of the 
microbiota in the regulation of mood. Bercik, Park, et al. (2011) used a murine 
model of chemical colitis induced by administration of dextran sodium sulfate (DSS) 
to explore how the strain B. longum NCC 3001 would affect behaviour. 
Administration of the probiotic reversed the anxiety-like behaviour in DSS-treated 
mice but did not affect BDNF mRNA expression or gut inflammation. The 
behavioural change was lost when the animals were vagotomised. The authors 
concluded from these results that the anxiolytic effect of B. longum involves vagal 
integrity but is independent of gut immuno-modulation or production of BDNF by 
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neuronal cells. Bravo et al. (2011) reported similar findings when exploring the 
activation of the vagus nerve using the probiotic Lactobacillus rhamnosus JB-1. Mice 
receiving the probiotic were less anxious and displayed antidepressant-like 
behaviours in comparison with broth-fed controls. There were also alterations in 
the mRNA expression of gamma-aminobutyric acid (GABA) receptors associated 
with anxiety and depression in several brain regions. All these changes were 
abolished when the animals were vagotomised, demonstrating the role of the 
vagus nerve in communicating visceral changes to the CNS. However,  other 
mechanisms independent of the vagus nerve activation must be also considered as, 
for example, autonomic pathways are not involved in the behavioural alterations 
that accompanied antibiotic treatments (Bercik, Denou, et al., 2011). We have also 
recently reported that the administration of a Bifidobacterium strain to mice had a 
significant impact on the fatty acid composition of the brain (Wall et al., 2012). 
Mice that received the bacteria for 8 weeks exhibited significantly higher 
concentrations of arachidonic acid (ARA) and docosahexaenoic acid (DHA) when 
compared to unsupplemented control mice. ARA and DHA are critical in the 
development of the brain, having a role in neurotransmission and protection 
against oxidative stress (Innis, 2007; Maekawa et al., 2009). These fatty acids are 
also neuroprotective agents, involved in the improvement of cognitive function, 
including memory and learning (Henriksen et al., 2008; Yurko-Mauro et al., 2010). 
Accordingly, these data indicate that probiotic ingestion may be effective for 
achieving optimal brain health, leading to enhanced cognitive function.  
In a study  in which probiotics and prebiotics were not used, a beef-
containing diet significantly changed bacterial diversity and improved working and 
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reference memory in mice (Li et al., 2009).  The beef-enriched diet contained a 
higher content of fat and taurine in comparison to the standard diet and these 
components could potentially be responsible for the differences observed during 
the experiment. The dietary components could act directly on the brain, or induce 
changes in the microbiota composition stimulating the production of microbial 
metabolites that would affect behaviour. Bioactive compounds produced by the 
host microbiota may induce local changes in the gut epithelium and the enteric 
nervous system, as well as the immune system, with an impact in CNS signalling 
(Cryan & Dinan, 2012; Forsythe et al., 2010; Lyte, 2011). Different species of 
bacteria have been shown to produce neuroactive molecules such as GABA (Barrett 
et al., 2012), vitamins such as cobalamin (Santos et al., 2008) and biogenic amines 
such as histamine, serotonin and dopamine (Özogul, 2011), molecules that may 
directly affect the brain. Indeed, the production of histamine by lactic acid bacteria 
isolated from wine is well documented, and is perceived as problematic, as it can 
cause undesirable symptoms such as headaches and nausea when ingested 
(Landete et al., 2007). Other bacterial metabolites may impact the CNS indirectly by 
changing the microbiota composition (antimicrobial bacteriocins) (Rea et al., 2010) 
or by modulating the immune response (polysaccharide A, SCFA)  (Maslowski et al., 
2009; Mazmanian et al., 2008). The broad range of metabolites produced by 
bacteria may exert beneficial effects on the host or disturb its homeostasis 
(Forsythe et al., 2010; Lyte, 2011). However, the mechanisms of action are diverse 
and not well understood, and more studies are necessary to understand the highly 
complex pathways that link the gut to the brain.  
 
  
Table 1.2 Effects of probiotics and prebiotics on the immune system, gut microbiota and the peripheral and central nervous system 
Probiotic strain Model 
Trial  
duration 
Effects 
Reference 
 
Lb. helveticus R0052 and  
Lb. rhamnosus R0011 
Brown Norway rats 17 days 
Prevented stress induced bacterial adherence to enterocytes 
Prevented bacterial translocation to mesenteric lymph nodes 
Inhibited chronic stress induced elevated intestinal ion secretion 
Zareie et al., 2006 
B. infantis 35624 Sprague Dawley rats 2 weeks 
Decreased concentration of pro-inﬂammatory cytokines  
Increased levels of tryptophan in plasma 
Desbonnet et al., 
2008 
Lb. casei strain Shirota 
Humans with chronic fatigue  
syndrome 
8 weeks 
Increased Bifidobacterium and Lactobacillus numbers 
Decreased anxiety symptoms 
Rao et al., 2009 
Lb. rhamnosus R0011 and 
Lb. helveticus R0052 
C57BL/6 mice infected with  
Citrobacter rodentium 
10/30 days 
Prevented memory dysfunction after exposition to acute  
stress 
Gareau et al., 2010 
 
B. infantis 35624 
SD rats 
(maternal separation model) 
45 days 
Normalized the immune response  
Reversed the behavioural deficits 
Restored the basal noradrenaline concentrations in the brainstem 
Desbonnet et al., 
2010 
B. longum NCC3001 
AKR mice 
colitis model 
14 days Reduced anxiety-like behaviour in DSS-treated mice 
Bercik, Park, et al., 
2011 
Lb. helveticus R0052 and 
B. longum R0175 
Wistar rats and 
humans 
14 days/ 
30 days 
Reduced anxiety-like behaviour in rats 
Alleviated psychological distress in humans 
 
Messaoudi et al., 
2011 
Lb. rhamnosus JB-1 BALB/c mice 28 days 
Reduced stress-induced corticosterone  
Reduced anxiety- and depression-related behaviour 
Altered GABA receptors expression in different brain regions 
Bravo et al., 2011 
B. breve NCIMB702258 C57BL/6 mice 8 weeks Increased arachidonic acid and docosahexaenoic acid in the brain Wall et al., 2012 
Prebiotic: trans-
galactooligosaccharide mixture 
Humans with IBS 12 weeks 
Increased Bifidobacterium numbers 
Improved quality of life 
Decreased anxiety scores in the IBS-D patients group (diarrhoea 
predominant) 
Silk et al., 2009 
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1.2.6 CONCLUSIONS 
The gut microbiota evolves from birth, changing from an immature and 
unstable state during infancy to a more complex, diverse and stable ecosystem in 
adulthood. Disturbance of its homeostatic state may have a negative impact on 
host health, leading to gastrointestinal, immunological and even neurological 
disorders. In this context, the use of dietary approaches such as probiotics, 
prebiotics and diets enriched with fatty acids or proteins to modulate the 
microbiota may beneficially affect host health. While these strategies have been 
shown to be effective in several different studies, the lack of standardization in 
terms of optimal dosage and treatment duration limits comparison between studies 
and makes it difficult to draw solid conclusions. Moreover, the mechanisms of 
action by which probiotics and prebiotics may affect host health are not well 
understood. These limitations highlight the need for well designed human 
intervention studies employing multidisciplinary approaches, aiming to better 
understand the interactions between gut microbiota and brain, and the 
identification of specific mechanisms of action, leading to new dietary strategies 
targeting the gut-brain axis for enhanced mental health. 
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Chapter 2 
 
Gas chromatography method optimization for analysis of 
SCFA levels in intestinal samples 
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2.1 ABSTRACT 
Background: Short chain fatty acids (SCFA), the main products of bacterial 
fermentation in the gut, have been shown to exert a wide range of beneficial 
effects to the host. 
Objective: To optimize a gas chromatography method described by Tangerman & 
Nagengast (1996) in order to obtain good peak resolution and assay sensitivity 
when analyzing SCFA levels in faecal and caecal samples from animal and human 
studies. 
Method: SCFA was extracted from faecal or caecal samples with Milli-Q water, 
centrifuged and filtrate to eliminate bacteria and solids and injected into the GC-FID 
system fitted with a capillary GC column instead of a packed glass column. High 
injector and detector temperatures (240oC and 250oC, respectively), programmed 
oven temperature and a narrow glass liner to simulate an on-column injection were 
used. Internal and external standards were used for calibration purpose. Recovery 
and reproducibility test were done to validate the method. 
Results: SCFA level detected in caecal sample was as expected, with higher 
concentration of acetate (82.56 umol/g), followed by n-butyrate (34.55 umol/g), 
propionate (11.4 umol/g) and isobutyrate (1.29 umol/g). Recovery rates were 
around 100% for all the SCFA tested. The intra-assay reproducibility test showed 
consistent results after multiple repetitions (RSD < 5%), whereas the inter-assay 
variation was higher than 10% after 3 wks storage.  
Conclusion: The optimized method applying direct aqueous injection of samples 
into the GC-FID proved to be efficient and accurate for the detection of acetate, 
propionate and butyrate in faecal/caecal contents, provided that sample storage at 
 
75 
-20oC did not exceed 2 weeks and the GC system was maintained in good operating 
conditions. 
 
2.2 INTRODUCTION 
The gut microbiota synthesizes many enzymes for processing of ingested 
food substrates, yielding energy for microbial growth and metabolic end products 
such as short chain fatty acids (SCFA). Approximately 100-200 mM of SCFA are 
produced daily by humans consuming a Western diet, with the major ones being 
acetate, propionate and butyrate (Cook & Sellin, 1998). Total SCFA concentration in 
the human proximal colon is around 70–140 mM falling to 20–70 mM in the distal 
colon, although alterations in production and absorption may occur with dietary 
changes (Topping & Clifton, 2001). Several factors may affect bacterial metabolism 
and SCFA production in the gut, such as substrate type and availability, the 
composition of the gut microbiota and the length of time that partially digested 
food takes to pass through the bowel (Cook & Sellin, 1998; Macfarlane & 
Macfarlane, 2003). Moreover, drugs, ageing, diseases and stress may affect SCFA 
concentrations due to their effects on microbiota population and host health 
(Macfarlane & Macfarlane, 2003; Reilly & Rombeau, 1993).  
Butyrate is almost completely used as energy source by colonocytes (Cook & 
Sellin, 1998), whereas acetate is used for lipogenesis and most of the propionate is 
consumed for hepatic gluconeogenesis (Reilly & Rombeau, 1993; Wolever et al., 
1991). SCFA also affect various physiological and pathophysiological functions in the 
organism by stimulating gut motility and intestinal transit (Fukumoto et al., 2003; 
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Grider & Piland, 2007), regulating gut hormone release and suppressing food intake 
(Lin et al., 2012) and lowering colon cancer risk (O’Keefe et al., 2009; Ou et al., 
2013; Waldecker et al., 2008). SCFA activate GPR41 and GPR43 receptors present in 
immune cells, adipocytes and enteroendocrine cells (Brown et al., 2003; Lee et al., 
2008; Le Poul et al., 2003), decreasing gut inflammation (Maslowski et al., 2009), 
controlling cancer cell proliferation in tissues outside the gut (Bindels et al., 2012), 
reducing intestinal transit time and increasing SCFA absorption (Samuel et al., 
2008), inhibiting lipolysis in adipocytes (Ge et al., 2008; Hong et al., 2005), 
increasing circulating levels of hormones (e.g. peptide YY, leptin) and affecting 
appetite (Karaki et al., 2008; Samuel et al., 2008). 
Considering the effects of SCFA on health and disease, their accurate 
analysis in intestinal samples is vitally important, and different analytical techniques 
have been developed and applied in the measurement of SCFA. SCFA have been 
indentified and quantified by high performance liquid chromatography (HPLC) 
(Chen & Lifschitz, 1989; Kotani et al., 2009), ion-exclusion chromatography (Dias et 
al., 2009), gas-chromatography with flame ionization detector (GC-FID) (Brinkworth 
et al., 2009; Chen & Lifschitz, 1989; Schwiertz et al., 2009; Schafer, 1995; Zhao et 
al., 2006), gas-chromatography with mass spectrometer (GC-MS) (Garcia-Villalba et 
al., 2012; Mills et al., 2000) and NMR spectroscopy (Monleon et al., 2008). GC-MS 
and NMR techniques are greatly limited by high cost of instruments and GC-MS by 
the complexity of sample preparation. GC-MS may improve the sensitivity and 
selectivity of the analysis, but for an effective use of the system, it is desirable to 
avoid the use of water in the sample (Garcia-Villalba et al., 2012). Among all these 
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techniques, GC-FID analysis is the most frequently used due to SCFA volatile nature 
and equipment high resolution, sensitivity and inexpensive costs.  
Several published methods have applied pre-treatments that are laborious, 
requiring complex sample preparations such as extractions with organic solvents 
(Henningsson et al., 2001; Garcia-Villalba et al., 2012), extraction with acidic and 
basic solutions (Claus et al., 2003; Kruse et al., 1999; Scheppach et al., 1987; 
Schwiertz et al., 2009; Zhao et al., 2006), steam distillation (Chen & Lifschitz, 1989), 
vacuum distillation (Brinkworth et al., 2009; McOrist et al., 2008), 
ultrafiltration/ultracentifugation (Chen & Lifschitz, 1989; Schafer, 1995) and solid 
phase micro-extraction (SPME) (Garcia-Villalba et al., 2012; Mills et al., 2000). 
Moreover, some protocols also performed derivatisation of SCFA with n-(tert-
butyldimethylsilyl)-n-methyltriﬂuoro-acetamide (MTBSTFA) (Henningsson et al., 
2001; Walker et al., 2005) or boron trifluoride  (BF3) (Collin et al., 1974). Although 
pre-treatments may generate good results with higher performance, they are 
relatively time-consuming and may reduce recovery rates due to the loss of more 
volatile SCFA. Moreover, some of these methods require large amount of samples 
and use large volumes of solvents and hazardous reagents that should be avoided. 
The extraction of SCFA with water is simple, rapid and efficient, decreasing 
the loss of volatile compounds. In the intestines, at physiological pH around 6-7, 
more than 90% of SCFA exist in the anionic, dissociated form. SCFA are weak acids 
(pKa ~ 4.8) and, therefore, are more soluble in their anionic than their protonated 
forms (Velazquez et al., 1996). pH is the most significant variable affecting the 
partition coefficient for SCFA and, at pH around 6-7 (Milli-Q water pH ~7), most 
SCFA will be dissolved in the aqueous phase (Reinsel et al., 1994) (Fig 2.1). To 
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analyze SCFA diluted in aqueous solution a specific fused silica capillary column has 
to be used. FFAP (nitroterephthalic acid modified polyethylene glycol) columns are 
made of high polarity stationary phase and are modified with acid to provide a very 
inert column that is not decomposed in the presence of strong acids and water 
used as solvents. 
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Figure 2.1 Relationship between solution pH and dissociation status of SCFA. 
Extraction with Milli-Q water generates a solution with pH ~ 7, when most of SCFA 
are in their anionic, hydrophilic form. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
In this study, a simple and reliable method previously described by 
Tangerman & Nagengast (1996) was optimized with some adaptations, as follows    
capillary GC column was used instead of a packed glass column, programmed oven 
temperature instead of isothermal, higher injector and detector temperatures 
(observing the column limits given by the manufacturer) and narrow glass liner to 
simulate an on-column injection. Capillary columns are thermally and chemically 
stable and produce more precise results when compared to packed glass columns, 
especially for active molecules such as free fatty acids. Moreover, due to its thermal 
strength capillary columns allow the use of higher temperatures leading to better 
peak resolution. A programmed oven temperature reduces analysis time and 
produces sharper peaks, whereas, on column injection increases the assay 
reproducibility. However, on column injection can just be applied to clean samples, 
as non-volatile compounds may accumulate into the GC column. Using a narrow 
glass liner we simulated an on column injection focusing the analytes of interest 
into the head of the column, but trapping the non-volatile compounds in the liner 
instead of the column. Liners are cheap and can be easily replaced, avoiding 
interferences in the assay reproducibility.     
The method applied involved the direct injection of faecal/caecal 
supernatants into the GC system without any pre-treatment. The faecal or caecal 
sample was extracted with water, the solid pellet discarded after centrifugation and 
the supernatant injected into the GC-FID system after the addition of an internal 
standard. The method and the instrument system were validated by recovery and 
reproducibility tests (intra-assay and inter-assay). Reproducibility tests were 
repeated between batches of samples. The internal standard, 2-ethylbutyric acid, 
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and an external standard mixture containing acetate, propionate, isobutyrate and 
n-butyrate were used for quantitative purposes.  
 
2.3 MATERIALS AND METHODS 
Sample preparation 
Fresh mice faecal or caecal contents were snap-frozen in liquid nitrogen or 
dry ice immediately after collection and stored at -80oC until analysis. Samples 
(approximately 100 mg) were vortex-mixed with 1.0 mL Milli-Q water and the 
mixture was kept at room temperature for 10 min and centrifuged at 10000 x g for 
5 min to pellet bacteria and other solids. Fresh internal standard solution of 2-
ethylbutyric acid in formic acid was prepared and added to the supernatant to a 
final concentration of 3.0 mM. After homogenization, samples were filtered using a 
0.2 µm syringe filter, and the light-brown supernatant transferred to a glass GC vial.  
 
Gas chromatography 
Analyses were carried out using a Varian 3500 GC system equipped with a 
flame-ionisation detector (FID) and fitted with a FFAP column (30 m x 0.32 mm 
coated with 0.5 µm film thickness). Helium was supplied as the carrier gas at a flow 
rate of 1.3 mL/min. The initial oven temperature was set at 100oC for 0.5 min, 
raised to 180oC at 8oC/min and held for 1.0 min, then increased to 200oC at 
20oC/min and kept for 7.5 min. The injector temperature was set to 240oC and the 
detector to 250oC. The injected sample volume was 0.5 µL, and the total running 
time was 20 min. Calibration curves were built with a standard mixture containing 
acetate, propionate, isobutyrate and n-butyrate at concentrations of 0.5, 1.0, 2.0, 
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4.0, 6.0, 8.0 and 10.0 mM. Injections of 10% formic acid in water were made to 
clear the column of unknown impurities. Data analysis was performed using the 
Varian Star Chromatography Workstation Software version 6.0.  
All chemicals used were of analytical grade, from Sigma-Aldrich, and the 
columns used for SCFA analysis were made of the same stationary phase (FFAP) and 
no significant differences were observed between different manufacturers (TRB-
FFAP, Teknokroma, Spain; ZB-FFAP, Phenomenex, UK; Nukol-FFAP, Sigma-Aldrich, 
St. Louis, MO) (data not shown). 
 
Recovery and reproducibility tests 
The recovery test was conducted by spiking caecal samples with three 
different concentrations of the external standard mix and recovered compounds 
were quantified by GC as described above. To test for intra-assay variation, the 
same caecal sample and 2.0 mM standard were run repeatedly at the same day and 
for the inter-assay variation, these same samples were tested on different days 
over 3 weeks (stored at -20oC between tests). Data are presented as mean values ± 
standard deviation (SD), and relative standard deviation (RSD). 
 
2.4 RESULTS AND DISCUSSION 
In the present study, a GC method was optimised for determining SCFA 
levels in faecal and caecal samples. SCFA produced in the colon are absorbed while 
passing through the large intestine, and as expected, highest SCFA concentrations 
were measured in mice caecal samples, while in faecal samples only acetate could 
be detected at significant concentrations (data not shown).  
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The chromatogram peaks obtained were sharp, symmetric and well 
resolved. The baseline was stable and there were no problems with split peaks. A 
good linear correlation was found between the peak area ratio and the 
corresponding standard SCFA (r2 > 0.99 for all SCFA). 
In the recovery test, the original amount of each SCFA detected in the caecal 
sample was as expected with higher concentration of acetate (82.56 umol/g), 
followed by n-butyrate (34.55 umol/g), propionate (11.4 umol/g) and lastly, the 
branched chain SCFA, isobutyrate (1.29 umol/g) (Table 2.1). Moreover, the recovery 
of each compound was around 100% for all the SCFA tested and the 
chromatograms overlaid perfectly with a very similar retention time (Fig. 2.2). Some 
protocols use acidified water to extract SCFA from samples in order to obtain better 
recovery (Claus et al., 2003; Kruse et al., 1999; Scheppach et al., 1987; Schwiertz et 
al., 2009; Zhao et al., 2006). However, in a study conducted by Claus et al. (2003), 
the adaptation of the method by Tangeman & Nagengast (1996) using a FFAP 
column and sample extraction with sulphuric acid solution yielded recovery rates 
lower than 100% (82%, 79%, and 80% for acetate, propionate, and butyrate, 
respectively). In this study, no difference was observed between extractions with 
acidified water or Milli-Q water (data not shown).  
Two small peaks were detected between the n-butyrate and 2-ethylbutyric 
acid peaks (Fig. 2.2). They corresponded to the isovalerate and valerate 
respectively; however their values were not calculated in this study.  
The reproducibility test showed consistent results after multiple repetitions, 
with the relative standard deviation (RSD) being lower than 5% in the intra-assay 
test. However the variation of the concentration during the inter-assay, especially 
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for acetate (RSD > 10% after 3 weeks storage), suggest that samples should not be 
stored at -20oC during periods longer than 2 weeks (Tables 2.3 and 2.4).  
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Table 2.1 Recovery of SCFA from caecal samples spiked with different amounts of SCFA 
standard mix 
 Acetate Propionate Isobutyrate N-butyrate 
Original amount (umol/g) 82.56 ± 7.4 11.4 ± 0.74 1.29 ± 0.03 34.55 ± 1.43 
Amount added (umol/g) 23.68 23.68 23.68 23.68 
Amount recovered (umol/g) 109.7 ± 4.11 36.42 ± 0.8 24.94 ± 0.24 59.70 ± 1.46 
Recovery (%) 103 104 100 102 
     
Amount added (umol/g) 71.04 71.04 71.04 71.04 
Amount recovered (umol/g) 154.71 ± 0.71 82.76 ± 0.93 71.63 ± 0.61 106.48 ± 0.04 
Recovery (%) 101 100 99 101 
     
Amount added (umol/g) 118.40 118.40 118.40 118.40 
Amount recovered (umol/g) 207.37 ± 2.36 133.20 ± 0.76 122.11 ± 1.89 155.90 ± 1.10 
Recovery (%) 103 103 102 102 
Values are means ± SDs. 
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Acetate
Propionate
Isobutyrate N-Butyrate
2-Ethylbutyric acid
(internal standard)
Original 
amount
+ 23.68 µmol/g STD
+ 71.04 µmol/g STD
+ 118.4 µmol/g STD
  
 
Figure 2.2 Recovery test overlaid chromatograms 
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Table 2.2 Intra-assay reproducibility test 
 Acetate Propionate Isobutyrate N-butyrate 
Caecal sample 
(umol/g) (n=14) 
87.34 ± 3.48 
(4.0%) 
11.79 ± 0.55 
(4.7%) 
1.21 ± 0.07  
(5.7%) 
35.40 ± 1.18 
(3.3%) 
2.0 mM Standard 
(umol/g) (n=6) 
2.13 ± 0.07  
(3.5%) 
2.00 ± 0.03 
 (1.5%) 
2.03 ± 0.03 
 (1.2%) 
2.09 ± 0.03  
(1.3%) 
Retention time 
(min) 
4.38 4.87 5.22 6.05 
Values are means ± SDs. Relative standard deviation (RSD%) represented between brackets 
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Table 2.3 Inter-assay reproducibility test 
  Acetate Propionate Isobutyrate N-butyrate 
Caecal sample 
(umol/g) (n=14) 
After 1  
week 
83.54 ± 5.65 
(6.8%) 
11.56 ± 0.74 
(6.4%) 
1.18 ± 0.06 
(5.2%) 
34.79 ± 1.63 
(4.7%) 
After 2 
weeks 
90.14 ± 5.29 
(5.9%) 
11.80 ± 0.81 
(6.9%) 
1.19 ± 0.12 
(9.8%) 
35.77 ± 1.17 
(3.3%) 
After 3 
weeks 
84.3 ± 9.72 
(11.5%) 
11.38 ± 1.49 
(13.1%) 
1.21 ± 0.1 
(8.1%) 
33.89 ± 1.13 
(3.3%) 
2.0mM Standard 
(umol/g)  
(n=6) 
After 1  
week 
2.19 ± 0.13 
(6.2%) 
2.09 ± 0.09 
(4.1%) 
2.05 ± 0.02 
(1.2%) 
2.10 ± 0.05 
(2.4%) 
After 2 
weeks 
2.54 ± 0.28 
(10.8%) 
2.26 ± 0.12 
(5.2%) 
2.07 ± 0.07 
(3.3%) 
2.16 ± 0.05 
(2.4%) 
After 3 
weeks 
2.81 ± 0.35 
(12.6%) 
2.40 ± 0.09 
(3.9%) 
2.11 ± 0.03 
(1.4%) 
2.29 ± 0.06 
(2.7%) 
Values are means ± SDs. Relative standard deviation (RSD%) represented between brackets 
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The extraction of SCFA with water was fast, efficient and appropriate for 
analysis of small samples such as mice intestinal contents. However, supernatant 
filtration did not eliminate all impurities present in the samples and brown non-
volatile faecal material adhered onto the wall of the glass liner after multiple runs. 
Intestinal samples are complex and contain a variety of non-volatile compounds 
such as proteins and carbohydrates and, therefore, accumulation of a brown 
coloured layer on the glass liner surface is a common problem in this type of 
analysis. In a study conducted by Schafer (1995), samples were subjected to 
ultrafiltration or ultracentrifugation, but the  precision  of  the  SCFA  determination  
was  not improved  by  the  application  of  this  separation step and the same 
brown deposits of non-volatile materials were seen in the glass liners. Moreover, 
Chen & Lifschitz (1989) determined that multiple-step distillation for sample clean-
up was as effective as one-step ultrafiltration of faecal aqueous extract, indicating 
that complex pre-treatments do not necessarily yield superior results. Therefore, in 
an effort to obtain accurate SCFA analysis, glass liners were changed routinely, each 
sample injection was followed by a cleaning procedure, involving injection of 10% 
(v/v) formic acid solution in water, and samples were always run in triplicate. 
Furthermore, repetition vials were run in separate batches,  fresh set of standards 
were used with each run and reproducibility tests were carried out frequently.  
 
2.5 CONCLUSIONS 
SCFA are among the most important gut microbial products, affecting a 
range of host processes from gut motility to modulation of inflammation, fat 
metabolism and appetite. Further research is required on the study of SCFA flux 
 
90 
between intestines and other sites of the body, their role in health and disease, and 
how the interactions between gut microorganisms may affect their production in 
the gut. Therefore, simple and rapid analytical methods are required in order to 
identify and quantify SCFA in biological samples efficiently. 
The method tested in this study involved a direct aqueous injection of 
faecal/caecal samples into GC/FID fitted with a FFAP capillary column and proved to 
be rapid and efficient for the detection of acetate, propionate, isobutyrate and 
butyrate. Other SCFA, such as isovalerate and valerate were also detected, and, 
therefore, the method can be expanded for the detection of these compounds if 
using appropriate standard mix. The optimized method produced high resolution 
chromatograms with sharp, well separated peaks (no coelutions), and no peak 
distortions (split peaks). Moreover, the good recovery of SCFA from spiked samples 
and the consistent results obtained after multiple runs during the intra-assay 
reproducibility test demonstrated the accuracy of the assay. Provided that sample 
storage at -20oC did not exceed 2 weeks and the GC system was maintained in good 
operating conditions, the method could be used in the analysis of large number of 
faecal/caecal samples as a routine assay. However, other tests are necessary for the 
analyses of SCFA in other kind of matrices, such as serum and tissues.  
Considering the results obtained, the method was applied in the studies 
described in the following Chapters 3, 4 and 6 and in the published papers annexed 
at the end of this thesis.  
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Chapter 3 
Dietary intake of trans-10, cis-12 conjugated linoleic acid 
alters fatty acid metabolism and microbiota composition in 
mice 
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3.1 ABSTRACT 
Background: A number of studies in rodent have revealed that dietary  trans10, 
cis12 conjugated linoleic acid (CLA) supplementation is associated with reduced 
visceral fat mass, accompanied by severe hepatic steatosis (Clément et al., 2002; Liu 
et al., 2012; Vyas et al., 2012).   
Objective: To investigate the effects of dietary t10, c12 CLA supplementation on 
intestinal microbiota composition and production of short chain fatty acids (SCFA) 
in the large intestine. 
Methods: C57BL/6 mice (n=8/group) were fed standard diet supplemented with 
either t10, c12 CLA (0.5% w/w) or no supplementation (control), daily, for 8 weeks. 
Metabolic markers (serum glucose, leptin, insulin and triglycerides and liver 
triglycerides) were assessed by ELISA commercial kits, tissue long chain fatty acids 
(LCFA) and caecal SCFA by gas chromatography and microbial composition by 16S 
rRNA pyrosequencing and bioinformatics analysis.   
Results: Animals receiving t10, c12 CLA exhibited lower visceral fat mass (p<0.001) 
and higher liver mass (p<0.01) than unsupplemented controls. Serum triglycerides 
(p<0.01) and leptin (p<0.05) were reduced, whereas glucose (p<0.01) and insulin 
(p<0.05) were increased in the t10, c12 CLA group compared with the control 
group. Moreover, dietary t10, c12 CLA affected lipid mass and composition with 
higher n-6/n-3 ratio in brain, liver and epididymal adipose tissue, and lower 
MUFA/SFA ratio in brain, kidney and epididymal adipose tissue. Caecal 
concentrations of total SCFA, acetate, propionate and isobutyrate were higher 
(p<0.05) in the t10, c12 CLA–supplemented group compared with the control 
group. Analysis of microbiota composition following 8 weeks of t10, c12 CLA 
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supplementation revealed lower proportions of Firmicutes (p=0.003) and greater 
proportions of Bacteroidetes (p=0.027) compared with no supplementation. 
Furthermore, the CLA supplemented group had lower proportions of 
Desulfovibrionaceae, Lachnospiraceae, Family XIII Incertae Sedis and 
Peptococcaceae (p<0.05), and higher proportions of Porphyromonadaceae 
(p=0.002) compared with unsupplemented control group. 
Conclusions:  Dietary t10, c12 CLA supplementation for 8 wk was associated with 
significantly altered gut microbiota composition, harbouring significantly higher 
proportions of Bacteroidetes, including Porphyromonadaceae bacteria previously 
linked with negative effects on lipid metabolism and induction of hepatic steatosis. 
The data indicate that the mechanism of dietary t10, c12 CLA on lipid metabolism in 
mice may be at least partially mediated by alterations in gut microbiota 
composition and functionality.  
 
3.2 INTRODUCTION 
Conjugated linoleic acid (CLA) is a class of isomers of linoleic acid that occur 
naturally in dairy products and meat from ruminant animals due to bacterial 
biohydrogenation of ingested polyunsaturated fatty acids (PUFA) in the rumen 
(Bhattacharya et al., 2006). CLA has been shown to be produced in vitro and in vivo 
by different species of bacteria (Coakley et al, 2003; Barrett et al, 2007; Lee et al, 
2007; Wall et al., 2009). Although c9, t11 CLA (rumenic acid) is the major natural 
form/isomer of CLA in foods, accounting for more than 90% of CLA intake in the 
diet, mixtures containing equal amounts of c9, t11 and t10, c12 CLA isomers are 
produced industrially and sold as supplements. Both these isomers exhibit 
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significant biological activities, which may exert synergistic or antagonistic effects 
(Bhattacharya et al., 2006). CLA has been shown to inhibit carcinogenesis (Kelley et 
al., 2007), prevent atherosclerosis in different animal models (Kritchevsky et al., 
2004; Wilson et al., 2000; Toomey et al., 2006), modulate the immune system (Yang 
& Cook, 2003; Yu et al., 2002), and affect body composition, by reducing body fat 
and increasing lean body mass (Clément et al., 2002; Liu et al., 2012). T10, c12 CLA 
has been shown to be the isomer responsible for the anti-obesity effect attributed 
to CLA and over the past years its impact on body fat modulation have been largely 
studied in different animal models and in humans (Clément et al., 2002; Liu et al., 
2012; Salas-Salvado et al., 2006). There is evidence to suggest that fat mass 
reduction is the result of multiple interactions of t10, c12 CLA with numerous 
metabolic signalling pathways leading to decreased energy intake and increased 
energy expenditure, inhibition of adipogenesis and lipogenesis, modulation of 
adipokines and cytokines and increased fatty acid β-oxidation in skeletal muscle 
(Park and Pariza, 2007). 
The response to CLA supplementation appears to be highly species-specific, 
with mice generally being more sensitive than other animal models and humans. 
These differences are attributed to the dose levels used (human trials use lower 
doses), age (animal trials usually use young subjects), rate of body fat turnover 
(small animals have faster metabolism) and dietary regimes (ad libitum in animal 
models vs. calorie restriction in human trials) (Park & Pariza, 2007; Wang & Jones, 
2004). In most studies using mice, body fat reduction induced by t10, c12 CLA 
supplementation is accompanied by such adverse effects as hepatic steatosis and 
hyperinsulinemia (Clément et al. 2002; Liu et al., 2009). These are features 
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frequently associated with metabolic syndrome and commonly observed in obese 
and diabetic individuals (Le Roy et al., 2012; Tamura & Shimomura, 2005). Hepatic 
steatosis is characterized by an increase in liver mass with accumulation of 
intracellular lipids, primarily in the form of triglycerides. Increased uptake of 
circulating fatty acids (FA), increased hepatic de novo lipogenesis (DNL), reduced 
rate of fatty acid oxidation and reduced FA secretion are the multiple mechanisms 
leading to increased accumulation of lipids in the liver (Vyas et al., 2012). Moreover, 
recent studies have indentified the gut microbiota as an environmental factor with 
an important role in host fat metabolism and the development of hepatic steatosis 
(Le Roy et al., 2012). In a continuous bidirectional communication between gut and 
liver, hepatic products can directly influence microbiota composition, whereas 
bacterial metabolites may have both direct and indirect effects on liver function 
and physiology (Bajaj, Hylemon, et al, 2012; Quigley et al., 2013). Thus, in this study 
we investigated the impact of dietary t10, c12 CLA on intestinal microbiota 
composition and the production of SCFA.  
 
3.3 MATERIALS AND METHODS 
Animals and diets 
Experiments involving animal were approved by the University College Cork 
Animal Ethics Committee, and experimental procedures were conducted under the 
appropriate license from the Irish Government. Male C57BL/6 mice, 7-8 weeks of 
age were obtained from Charles River and housed under barrier-maintained 
conditions within the Biological Services Unit, University College Cork. After one 
week of acclimatization, animals were divided into 2 groups (n=8/group). Both 
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groups were fed ad libitum with Teklad Global rodent standard diet (#2018S; Harlan 
Laboratories) and allowed free access to water. The fatty acids present in the diet 
included palmitic acid (0.7%), stearic acid (0.2%), oleic acid (1.2%), linoleic acid 
(3.1%), and linolenic acid (0.3%). The treatment group received 0.5% (w/w) t10, c12 
CLA incorporated into the diet. Body weight was assessed weekly. After 8 weeks of 
dietary intervention, fasted animals were sacrificed by decapitation and blood 
samples were collected, allowed to clot for 2 h at 4oC and centrifuged at 2000 x g 
for 20 min. Liver, brain, fat pads (epididymal, perirenal and mesenteric), heart, 
kidney and intestines were removed, blotted dry on filter paper, weighed and flash-
frozen in liquid nitrogen. Caecal content was collected for pyrosequencing and SCFA 
analyses. All samples were stored at -80oC prior to analyses.  
 
Lipid extraction and fatty acid analysis 
Fatty acid profiles were determined for liver, brain, epididymal adipose 
tissue, heart and kidney. Lipids were extracted with chloroform:methanol (Fisher 
Scientific, UK) according to the method by Folch et al. (1957). After extraction, 
samples were methylated by using 0.5 N NaOH (Sigma) in methanol for 10 min at 
90°C followed by 10 min incubation at 90°C with 14% boron trifluoride (BF3) in 
methanol (Sigma) (Park and Goins, 1994). Fatty acid methyl esters (FAME) were 
recovered with hexane (Fisher Scientific). Before gas-liquid chromatographic 
analysis, samples were dried over anhydrous sodium sulfate (Sigma) for 1 h and 
stored at -20°C. FAME were separated using a Varian 3800 GC flame-ionization 
system, fitted with a Chrompack CP Sil 88 column (Chrompack; 100 m x 0.25 mm 
internal diameter, 0.20 um film thickness) and helium as carrier gas. The column 
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oven was programmed initially at 80°C for 8 min and then increased 8.5°C/min to a 
final column temperature of 200°C. The injection volume used was 0.6 uL, with 
automatic sample injection on a SPI 1093 splitless on-column temperature-
programmable injector. Peaks were integrated using the Varian Star 
Chromatography Workstation version 6.0 software, and peaks were identified by 
comparison of retention times with pure FAME standards (Nu-Chek Prep Inc., 
Elysian, MN). The percentage of individual fatty acids was calculated according to 
the peak areas relative to the total area (total fatty acids were set at 100%). All fatty 
acid results are shown as mean ± standard error of the mean (SEM) in g/100 g 
FAME. 
 
SCFA analysis 
Caecal content was vortex-mixed with Milli-Q water, incubated at room 
temperature for 10 min and centrifuged at 10000 x g to pellet bacteria and other 
solids. The supernatant was filtered and transferred to a clear GC vial. 2-
ethylbutyric acid (Sigma) was used as internal standard. The concentration of SCFA 
was measured by using a Varian 3500 GC flame-ionization system, fitted with a 
Nukol-FFAP column (30 m x 0.32 mm x 0.25 um; Sigma). The initial oven 
temperature was set at 100oC for 0.5 min, raised to 180oC at 8oC/min and held for 1 
min, then increased to 200oC at 20oC/min, and finally held at 200oC for 5 min. The 
temperature of the injector and the detector were set at 240oC and 250oC, 
respectively. Helium was used as carrier gas at a flow rate of 1.3 mL/min. A 
standard curve was built with different concentrations of a standard mix containing 
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acetate, propionate, isobutyrate and n-butyrate (Sigma). Peaks were integrated by 
using the Varian Star Chromatography Workstation version 6.0 software.  
 
Measurement of hepatic triglycerides  
Hepatic lipids were extracted according to the method by Folch et al. (1957). 
After extraction, samples were dried under a stream of nitrogen and resuspended 
in 5% (v/v) solution of Triton X-100 in distilled water. Triglyceride concentrations 
were determined using a commercial kit (EnzyChrom Triglyceride Assay, BioAssay 
Systems, Hayward, CA).  
 
Serum analyses  
Commercial kits were used for measurement of metabolic markers in 
serum. Glucose was determined using the QuantiChrom glucose assay (BioAssay 
Systems), triglycerides by using EnzyChrom Triglyceride Assay kit (BioAssay 
Systems), insulin using the Ultra Sensitive Mouse ELISA kit (Crystal Chem Inc, 
Downers Grove, IL), and leptin was determined  using the Mouse Leptin ELISA kit 
(Crystal Chem Inc). 
 
Gut microbiota composition 
Amplicon Sequencing 
DNA extraction and high-throughput amplicon sequencing DNA was purified 
from faecal samples using the QIAmp DNA Stool Mini Kit (Qiagen, Crawley, West 
Sussex, UK) according to manufacturer’s instructions with addition of a bead-
beating step (30s x 3) and stored at -20oC. The microbiota composition of the 
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samples was established by amplicon sequencing of the 16S rRNA gene V4; 
universal 16S rRNA primers estimated to bind to 94.6% of all 16S genes (i.e. the 
forward primer F1 (5’-AYTGGGYDTAAAGNG) and a combination of four reverse 
primers R1 (5’-TACCRGGGTHTCTAAAGNG), R2 (TACCAGAGTATCTAATTC), R3 (5’-
CTACDSRGGTMTCTAATC) and R4 (5’-TACNVGGGTATCTAATC) (RDP’S 
Pyrosequencing Pipeline: http://pyro.cme.msu.edu/pyro/help.jsp) were employed 
for PCR amplification. Molecular identifier tags were attached between the 454 
adaptor sequence and the target-specific primer sequence, allowing for 
identification of individual sequences from the pooled amplicons. Ampure 
purification system (Beckman Coulter, Takeley, UK) was used to clean the amplicons 
before being sequenced on a 454 Genome Sequencer FLX platform (Roche 
Diagnostics Ltd, Burgess Hill, West Sussex, UK) in line with 454 protocols at the 
Teagasc high throughput sequencing centre. 
 
Sequence Analysis 
Raw sequences were quality trimmed and filtered using the Qiime Suite of 
programs (Caporaso et al 2010). Resulting trimmed fasta sequences were assigned 
to taxa through BLAST analysis against the SILVA database (version 106) for 16S 
reads. BLAST outputs were parsed using MEGAN (Huson et al., 2007) with a bit-
score of 86; taxonomy was assigned to phylum, family and genus level.  Sequence 
reads were clustered, aligned and chimera checked with Qiime and phylogenetic 
analysis was implemented with FastTreeMP (Price et al., 2010). Alpha and beta 
diversities were calculated again using Qiime and subsequently principal coordinate 
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analysis (PCoA) was performed on the distance matrices. PCoA plots were visualised 
with KiNG viewer (Chen et al., 2009). 
 
Statistical analysis 
To assess whether differences between treatment groups were significant, 
statistical analysis was performed by Student t test (Graph-Pad Software, San 
Diego, CA, USA). Treatment effects with p<0.05 were considered significant. 
Kruskal–Wallis and Mann–Whitney tests, implement in SPSS statistical software 
package were used to find significant differences in microbial taxa and alpha 
diversity. Significance was taken as p<0.05. Data in the text, tables, and figures are 
presented as mean values ± SEM. 
  
3.4 RESULTS 
Dietary t10, c12 CLA decreases fat storage, increases liver weight and impact on 
host metabolism, but does not alter body weight 
After 8 weeks of dietary supplementation with t10, c12 CLA, a 2-fold 
decrease in visceral body fat (sum of epididymal, mesenteric and perirenal fat pads; 
p<0.001) and a significant increase in liver mass (p<0.01; Table 3.1) was obtained, 
compared with unsupplemented mice.  Body weight gain and final body weight did 
not differ between the groups (Table 3.1). The greater liver weight observed in mice 
supplemented with t10, c12 CLA was accompanied by a 7-fold increase in hepatic 
triglycerides (p<0.001; Table 3.1). In contrast, serum triglycerides were lower in 
mice fed t10, c12 CLA when compared with unsupplemented controls (p<0.01). T10, 
c12 CLA supplementation was also associated with higher serum glucose 
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concentrations (p<0.01) and serum insulin (p<0.05). The concentration of leptin in 
serum, which is proportional to the amount of fat in the body, was lower in CLA 
supplemented animals compared with unsupplemented controls (p<0.05) (Table 
3.1). 
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Table 3.1 Effect of t10, c12 CLA on body mass, liver mass and visceral fat mass, and 
on metabolic markers  
 T10,c12 CLA Unsupplemented 
Final body weight (g) 31.3 ± 1.0 30.6 ± 0.9 
Body weight gain (%) 16.0 ± 3.0 20.5 ± 3.1 
Liver weight (g) 2.2 ± 0.1** 1.5 ± 0.1 
Visceral fat weight (g) 0.6 ± 0.06*** 1.2 ± 0.1 
Leptin (ng/mL) 0.7 ± 0.2* 2.4 ± 0.7 
Glucose (mg/dL) 200.4 ± 4.8** 183.3 ± 2.8 
Insulin (ng/mL) 4.0 ± 0.9* 1.7 ± 0.4 
Serum triglycerides (mg/dL) 28.6 ± 4.3** 61.3 ± 8.2 
Liver triglycerides (mg/g) 20.6 ± 2.9*** 2.9 ± 0.2 
All values are means ± SEMs; n=8 mice per group. Numbers with (*) are significantly 
different (Student t test; *p<0.05; **p<0.01; ***p<0.001). Visceral fat= sum of epididymal, 
perirenal, and mesenteric fat pads. 
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Host fatty acid composition is affected by dietary t10, c12 CLA 
Fatty acid profiles were determined in brain, epididymal adipose tissue, 
liver, heart and kidney, following 8 weeks of dietary t10, c12 CLA supplementation. 
T10, c12 CLA was incorporated into epididymal adipose tissue, liver, heart and 
kidney tissues, but was not detected in the brain (Table 3.2). T10, c12 CLA was not 
detected in any tissues in the unsupplemented group. Fatty acid composition of all 
tissues tested was altered in the t10, c12 CLA group compared with 
unsupplemented controls, with the greatest impact on brain, epididymal adipose 
tissue and liver (Table 3.2, Fig. 3.1). Mice supplemented with t10, c12 CLA had 
significantly higher amounts of total saturated fatty acids (SFA) in brain and 
epididymal adipose tissue, compared with unsupplemented animals (p<0.001,  Fig. 
3.1), including 1.6-fold increase in myristic acid (C14:0; p<0.05) and 1.2-fold 
increase in palmitic acid (C16:0; p<0.001) in brain and 2-fold increases in myristic 
(p<0.01) and palmitic acids (p<0.001) in epididymal adipose tissue (Table 3.2). 
Moreover, mice that received t10, c12 CLA had significantly lower myristic acid in 
the heart (57%; p<0.05), and lower stearic acid (C18:0) in epididymal adipose tissue 
(17%; p<0.05) and liver (41%; p<0.001), whereas palmitic acid was higher in the 
liver (13%; p<0.001). No differences were observed in the levels of SFA in the 
kidney of the t10, c12 CLA group compared with the unsupplemented group. T10, 
c12 CLA supplementation was associated with reduced monounsaturated fatty 
acids (MUFA) in both epididymal adipose tissue and kidney, while increased levels 
were found in liver and brain (Table 3.2, Fig 3.1). Palmitoleic acid (C16:1c9) was 
detected in higher amounts in brain (11%; p<0.05), and lower concentrations in 
liver (31%; p<0.05), heart (74%; p<0.05) and kidney (56%; p<0.001) of mice 
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supplemented with t10, c12 CLA compared with unsupplemented controls. CLA 
supplementation also led to increased concentrations of oleic acid (C18:1c9) in liver 
(50%; p<0.001) and brain (8%; p<0.01), and decreased oleic acid concentration in 
epididymal adipose tissue (30%; p<0.01) and kidney (19%; p<0.05). Omega-3 
polyunsaturated fatty acids (n-3 PUFA) were also affected by t10, c12 CLA 
supplementation, with the brain of mice receiving t10, c12 CLA having 24% less 
docosahexaenoic acid (DHA) (22:6n-3) than unsupplemented controls (p<0.001) 
and epididymal adipose tissue having 58% less linolenic acid (C18:3n-3; p<0.001), 
32% less docosapentaenoic acid (DPA) (C22:5n-3; p<0.05) and 67% less DHA 
(p<0.001) than unsupplemented mice. Eicosapentaenoic acid (EPA) was 50% lower 
(p<0.001), DHA 55% lower (p<0.001) and DPA 33% higher (p<0.05) in liver of the 
t10, c12 CLA group compared with unsupplemented controls. Moreover, the heart 
of mice fed t10, c12 CLA had 57% less linolenic acid (p<0.05) and 60% more DPA 
(p<0.001), whereas the kidney had 43% less linolenic acid (p<0.01) and 45% more 
DPA (p<0.01) when compared to the same tissues from the unsupplemented group. 
Significant differences in n-6 PUFA composition were also observed after 
supplementation with t10, c12 CLA in all tissues analysed. In the brain of mice fed 
t10, c12 CLA, arachidonic acid (AA; C20:4n-6) content was decreased by 21% 
(p<0.001) while dihomo-γ-linolenic acid (C20:3n-6) content was increased by 67% 
(p<0.001). Linoleic acid (C18:2n-6), dihomo-γ-linolenic acid and AA concentrations 
were decreased by 32% (p<0.001), 50% (p<0.001) and 29% (p<0.01), respectively, in 
the epididymal adipose tissue of animals receiving t10, c12 CLA, compared with 
unsupplemented controls. Significantly lower amounts of γ-linolenic acid (33%; 
p<0.001), dihomo-γ-linolenic acid (22%; p<0.001) and AA (49%; p<0.001) were also 
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detected in liver of mice receiving t10, c12 CLA, compared with unsupplemented 
controls. Less linoleic acid was detected in the heart (14%; p<0.05) and kidney 
(17%; p<0.05) of the t10, c12 CLA-fed group, whereas dihomo-c-linolenic acid was 
detected in higher amounts in the kidney (50%; p<0.01) of mice receiving CLA 
supplementation when compared with unsupplemented controls. Furthermore, the 
relative proportion of saturated to monounsaturated fatty acids, an important 
aspect of phospholipid compositions and membrane fluidity, was altered in all 
tissues of mice receiving t10, c12 CLA except the heart, and the ratio of n-6 PUFA to 
n-3 PUFA was also changed, with higher (p<0.05) proportions of n-6 PUFA in the 
brain, epididymal adipose tissue and liver (Table 3.2) of CLA supplemented animals, 
compared with unsupplemented controls. 
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Figure 3.1 Tissue fatty acid composition is altered by t10, c12 CLA supplementation, 
with a greater impact on brain, epididymal adipose tissue and liver. Columns with 
(*) are significantly different (Student t test; *p<0.05; **p<0.01; ***p<0.001). 
 
 
 
 
 
 
 
 Table 3.2 Effect of dietary t10, c12 CLA or unsupplemented diet on fatty acid composition (g/100g FAME) of mouse tissues  
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T10, c12 CLA intake stimulates the production of SCFA 
Microbial fermentation in caecum was enhanced by dietary 
supplementation with t10, c12 CLA.  Acetate, propionate and isobutyrate levels 
were significantly higher (p<0.05; Table 3.3) in mice fed t10, c12 CLA compared with 
unsupplemented controls, whereas no difference between groups was observed for 
n-butyrate. Moreover, total SCFA concentration (sum of acetate, propionate, 
isobutyrate and n-butyrate) was 34% higher in the caecal content of mice that 
received t10, c12 CLA compared with unsupplemented group (p<0.05) (Fig. 3.2).    
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Table 3.3 Short chain fatty acids in the caecum content of mice fed t10, c12 CLA or 
an unsupplemented diet for 8 weeks 
 T10, c12 CLA Unsupplemented 
Acetate 54.5 ± 4.2* 40.7 ± 2.4 
Propionate 10.7 ± 1.1* 7.1 ± 0.4 
N-butyrate 17.1 ± 2.1 13.7 ± 1.6 
Isobutyrate  0.9 ± 0.09* 0.7 ± 0.01 
Total SCFA 83.2 ± 7.1* 62.2 ± 4.1 
All values are means ± SEMs; n=8 mice per group. Numbers with (*) are significantly 
different (P<0.05; Student t test). 
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Figure 3.2 Caecal SCFA concentration in mice receiving a diet supplemented with 
t10, c12 CLA or with no supplementation; n=8 per group (Student t test; *p<0.05) 
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Dietary t10, c12 CLA significantly alters gut microbiota composition 
A total of 416,309 V4 16S amplicon sequence reads were generated; 
corresponding to a mean of 23,200 reads per mouse post quality checking. All 
rarefaction curves were approaching parallel (data not shown) indicating sufficient 
depth of sequencing. Reads were clustered into operational taxonomical units 
(OTUs) of 97% identity and diversity metrics estimated. Of the five alpha diversity 
metrics used (Shannon, Simpson, chao1, phylogenetic diversity and observed 
species), no significant differences were observed between CLA-supplemented and 
unsupplemented groups. Beta-diversity was calculated with both weighted and un-
weighted Unifrac distance matrices. Subsequent PCoA revealed a distinct 
separation of the two groups for both measures (Fig. 3.3). 
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Figure 3.3 PCoA analysis based on weighted Unifrac  (A) and unweighted Unifrac (B) 
distances; t10, c12 CLA supplemented group (red circles) and unsupplemented 
group (blue circles); n=8 per group. 
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The mouse gut microbiota was dominated by members of the Firmicutes 
and Bacteroidetes phyla. Microbial composition assignment revealed several 
significant differences between CLA-supplemented and unsupplemented groups. At 
the phylum level, t10, c12 CLA supplementation was associated with significantly 
reduced proportions of Firmicutes (p=0.003) and increased amounts of 
Bacteroidetes (p=0.027) when compared with unsupplemented controls. At the 
family level, members of Desulfovibrionaceae (p=0.027), Lachnospiraceae 
(p=0.006), Family XIII Incertae Sedis (p=0.016) and Peptococcaceae (p=0.009) were 
all significantly decreased in t10, c12 CLA group compared with unsupplemented 
controls, whilst members of Porphyromonadaceae (p=0.002) were significantly 
increased in t10, c12 CLA group (Fig. 3.4).  At the genus level, populations of 
Desulfovibrio (p=0.021), Lachnospiraceae Incertae Sedis (p=0.006) and 
Ruminococcus Incertae Sedis (p=0.027) were significantly decreased and 
Odoribacter (p=0.002) populations were significantly increased in t10, c12 CLA 
group when compared with the unsupplemented group. 
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Figure 3.4 The gut microbiota composition is altered in mice receiving t10, c12 CLA 
supplementation, as determined by pyrosequencing of 16S rRNA (n=8 per group). 
Pie charts represent the mean percentage read number for the corresponding 
colour coded family (only reads ≥1% are shown). 
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3.5 DISCUSSION 
The effects of dietary CLA on body fat have been largely studied in mice and, 
although t10, c12 CLA effects seems to be independent of genetic strain (House et 
al, 2005), the C57BL/6 mouse has been shown to be very sensitive and constitutes 
an interesting model for studying lipid metabolism dysfunctions (Degrace, 2006). In 
this study, C57BL/6 mice developed severe lipoatrophy with concomitant liver 
steatosis after 8 weeks of dietary supplementation with 0.5% (w/w) t10, c12 CLA. 
Previous studies have shown that feeding t10, c12 CLA triggers changes in the 
pattern of gene expression, reducing fatty acid uptake and storage in the 
adipocytes and favouring lipid accumulation in the liver of mice (Clément, 2002; 
Jourdan 2009; Vyas et al., 2012).   
The fat lowering effect of t10, c12 CLA is complex, involving multiple 
mechanisms and seems to be related to the development of hepatic steatosis in 
mice. In the adipose tissue, t10, c12 CLA has been reported to increase 
(pre)adipocyte apoptosis and reduce adipogenesis and lipogenesis by inhibition of 
key transcription factors such as peroxisome proliferator-activated receptor γ 
(PPAR-γ), CAAT/enhancer binding protein (C/EBP), sterol regulatory element 
binding protein 1c (SREBP-1c), liver X receptor α (LXR-α) and adipocyte-specific fatty 
acid binding protein (aP2) (Kennedy et al, 2010). With the nearly complete absence 
of adipose tissue, leptin is produced at very low rates by adipocytes, and the 
release of free FA is decreased, reducing lipid flux to the liver and subsequent VLDL 
secretion rates (Degrace et al., 2006). Indeed, in the current study, lower 
triglycerides and leptin serum levels were observed in the t10, c12 CLA-
supplemented group compared with unsupplemented controls. Another 
 
123 
modification induced by t10, c12 CLA supplementation was the markedly increased 
serum glucose concentration, compared with no supplementation. T10, c12 CLA 
supplementation may impair insulin signalling and glucose uptake via inflammatory 
cytokines such as tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6), 
affecting the expression of lipogenic proteins, including lipoprotein lipase (LPL),  
acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), stearoyl-CoA desaturase 
(SCD1) and the insulin-dependent glucose transporter 4 (GLUT4) (Kennedy et al, 
2010). Thus, impaired glucose uptake by adipocytes is expected to be a 
consequence of adipose tissue atrophy and lower expression of GLUT4. Moreover, 
higher serum insulin levels were found in the t10, c12 CLA group compared with 
unsupplemented controls. High levels of circulating insulin and glucose have been 
reported to induce the expression of SREBP1c and carbohydrate response element-
binding protein (ChREBP) in the liver and therefore stimulate hepatic de novo 
lipogenesis (Shimomura, et al., 1999; Yamashita et al., 2001).  Accordingly, a study 
conducted by Clément et al. (2002) suggested that liver steatosis induced by t10, 
c12-CLA is secondary to hyperinsulinemia, which causes high levels of FA uptake 
and synthesis in the liver. They observed an increase in PPARγ mRNA levels and its 
target genes fatty acid transporter (FAT/CD36) and aP2, both involved in FA uptake. 
Moreover, FAS and SREBP-1 genes were upregulated by t10, c12 CLA feeding.  
Another study using diabetic mice demonstrated that t10, c12 CLA induces liver 
steatosis in the absence of insulin (Jourdan, 2009). Apparently, t10,c12 CLA may 
exert its effects through a concomitant induction of hepatic expression of VLDLR, 
LPL and FAT/CD36, improving FA utilization by the liver and increasing plasma 
lipoprotein clearance (Degrace et al., 2006; Jourdan et al.,2009) (Fig. 3.5).  
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Another factor that may contribute to the development of liver steatosis is 
the profound change in LCFA composition of liver, caused by t10, c12 CLA 
supplementation. As seen in this study, t10, c12 CLA supplementation was 
associated with increased n-6 PUFA/n-3 PUFA ratio in the liver. Reduced availability 
of n-3 PUFA may increase SREBP-1 expression and reduce PPARα expression, 
stimulating lipogenesis over lipid oxidation, with accumulation of TG in the liver (El-
Badry et al., 2007). Furthermore, besides changing liver FA profiles, t10, c12 CLA 
supplementation was associated with altered FA composition of other tissues. Our 
observations confirmed previous reports demonstrating that t10, c12 CLA 
supplementation decreased AA and altered the ratio of SFA to MUFA, especially 
increasing the amount of palmitic acid over palmitoleic acid (Evans et al., 2002; 
House et al., 2005; Kelley et al., 2006). Although the exact mechanism of CLA action 
on tissue FA composition has not been elucidated, some studies suggest that the 
reduction in SCD-1 activity may impair the conversion of SFA to MUFA (Evans et al., 
2002; House et al., 2005), whereas the inhibition of linoleic acid elongation and 
desaturation may impact on n-6 PUFA synthesis (Eder et al., 2002; Lin et al., 2011).  
The current study also showed that while there were no significant 
differences in diversity between groups (data not shown), supplementation with 
t10, c12 CLA had an effect on the composition of the murine gut microbiota when 
compared to no supplementation, as demonstrated by divergent clustering pattern 
in the PCoA analysis (Fig. 3.3). Perturbations of gut microbiota composition may 
play an important role in the development of diseases associated with altered 
metabolism such as obesity, diabetes and cardiovascular diseases (Tremaroli and 
Bäckhed, 2012). For example, studies using germ free animals have shown that the 
 
125 
absence of microbiota is accompanied by increased fatty acid oxidation and 
decreased lipogenesis, making these animals resistant to diet-induced obesity, 
steatosis and insulin resistance (Bäckhed et al., 2004; Bäckhed et al., 2007). 
Furthermore, some evidence suggest that body weight gain is associated with 
higher proportions of Firmicutes and lower Bacteroidetes among gut microbiota 
(Bäckhed et al., 2004; Ley et al., 2005; Turnbaugh et al., 2009), while body weight 
loss has been correlated with increased abundance of Bacteroidetes (Ley et al., 
2006). In this study, we observed that decreased body fat in mice receiving t10, c12 
CLA was associated with higher proportions of Bacteroidetes and lower abundance 
of bacteria from the Firmicutes phylum. Interestingly, a study by Larsen et al. (2010) 
demonstrated the same compositional changes in the intestinal microbiota of 
humans with type-2 diabetes.  Moreover, they showed that higher Bacteroidetes to 
Firmicutes ratio correlates positively with higher blood glucose levels and lower 
body mass. As type 2 diabetes is usually associated with increased body weight, 
these findings led to the suggestion that overweight and diabetes are associated 
with different groups of intestinal microbiota and that levels of glucose tolerance 
should be considered when linking microbiota with obesity and other metabolic 
diseases. Furthermore, Membrez et al. (2008) demonstrated that modulation of gut 
microbiota with antibiotics influences whole body glucose homeostasis, 
independent of body weight/body fat mass. In antibiotic-treated mice, reduced 
liver triglycerides correlated with improved insulin resistance, suggesting that the 
influence of gut microbiota on glucose and liver metabolism may have similar 
mechanisms. The mechanism suggested for these changes was an increase in 
lipopolysaccharides (LPS), the main compound of the outer membrane of Gram-
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negative bacteria, such as bacteria from the Bacteroidetes phylum. LPS have been 
shown to cause acute whole body insulin resistance (Virkamaki et al., 1994) and is a 
potent stimulator of inflammation. In the gut, LPS activate Toll-like receptor 4 
(TLR4), leading to the expression of TNF-α (Membrez 2008). Increased TNF-α has 
been shown to exert potent antiadipogenic effects (Petruschke et al., 1993) and 
induce hepatic steatosis (Yang et al, 1997). In a study by Le Roy et al. (2012), it was 
further confirmed that insulin resistance develops separately from obesity. 
However, they did not observe differences in TNF-α levels and suggested that the 
gut microbiota may affect hepatic metabolism through other mechanisms, 
independent of the immune system (Fig. 3.5).  As an example of a different 
mechanism, in a lipidomic study, Velagapudi et al. (2010) suggested that the 
increase in phosphatidylcholine (16:0/18:1) induced by the microbiota may activate 
LPL, resulting in reduced serum triglyceride levels together with increased storage 
of lipids in adipose tissue and the liver. Although we did not examine single lipid 
classes in this study, we observed an increase in C16:0 and C18:1 fatty acids in the 
liver of mice fed t10, c12 CLA and therefore, there is a possibility that these animals 
could have more 16:0/18:1 phospholipds.  
We also observed other important changes in gut microbiota composition as 
a result of dietary supplementation with t10, c12 CLA including increased 
proportions of Porphyromonadaceae and decreased abundance of Lachnospiraceae 
and Desulfovibrionaceae. Porphyromonadaceae have previously been associated 
with non-alcoholic fatty liver disease (NAFLD), atherosclerosis and diabetes (Henao-
Mejia et al., 2012). Members of the family Lachnospiraceae have been shown to 
protect mice against colonisation by Clostridium difficile (Reeves et al., 2012), 
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whereas enhanced levels of bacteria from the Desulfovibrionaceae family was 
associated to impaired glucose tolerance and serious metabolic syndrome 
phenotype (Zhang et al., 2010). Moreover, in a study by Bajaj, Ridlon, et al. (2012), 
Lachnospiraceae abundance was reported to be lower in patients with cirrhosis, 
while Porphyromonadaceae abundance was positively correlated with cognitive 
impairment and inflammation in patients with hepatic encephalopathy.  
SCFA are the end-products of bacterial fermentation, acetate, propionate 
and butyrate being the major SCFA in the mammalian gut. The type and amount of 
SCFA produced depends on diet, intestinal transit and microbiota composition 
(Macfarlane and MacFarlane, 2012). In the current study, SCFA levels were altered 
by t10, c12 CLA supplementation even though both groups received similar amount 
of carbohydrates and proteins, with higher levels of acetate, propionate and 
isobutyrate detected in the caecal content of mice receiving t10, c12 CLA 
supplementation. Thus, the higher amount of SCFA detected in the t10, c12 CLA fed 
group was probably due to the marked changes in microbiota composition induced 
by dietary t10, c12 CLA. SCFA are considered important energy sources for the host 
and some studies have suggested a link between increased levels of SCFA and 
obesity (Turnbaugh et al, 2006; Turnbaugh et al, 2008). However, in our study the 
higher levels of SCFA were detected in mice with lower fat mass. The precise 
mechanism involved in SCFA modulation of host metabolism is not clear and the 
results in literature are conflicting. Thus, for this study we propose three 
explanations to the role of SCFA in t10, c12 CLA-induced lipoatrophy/liver steatosis: 
1) increased propionate induces gluconeogenesis (Wolever et al., 1991); 2) SCFA 
activate GPR41 receptor, stimulating hepatic lipogenesis (Samuel et al., 2008); and  
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3) SCFA activate GPR43 receptor that regulates energy uptake by adipose tissue and 
promotes the utilization of excess energy in other tissues instead of storage in the 
adipocytes (Kimura et al., 2013) (Fig. 3.5). 
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Figure 3.5 Schematic summary of all the mechanisms of action of t10, c12 CLA, as 
proposed by the different studies cited in this paper. There are a variety of 
proposed mechanisms through which t10, c12 CLA supplementation may cause 
hepatic steatosis and lipoatrophy in mice. T10, c12 CLA up- and down-regulate 
genes involved in fatty acid synthesis, uptake and oxidation in adipose tissue and 
liver in a direct and indirect manner (black arrows). In this study we propose that 
the gut microbiota and its products are extra environmental factors affecting host 
lipid metabolism (red arrows). 
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3.6 CONCLUSIONS 
Several studies investigating the anti-obesity effect of CLA supplements 
have studied gene regulation in the liver and adipose tissue but, to our knowledge, 
this is the first study to show the impact of dietary t10, c12 CLA on gut microbiota 
composition and SCFA production. Long dietary exposure to t10, c12 CLA 
transformed the gut microbiota, favouring the growth of harmful bacteria, thus 
increasing host susceptibility to a variety of diseases. The greater proportions of 
Bacteroidetes and Porphyromonadaceae bacteria found in the t10, c12 CLA 
supplemented mice most likely had an influence on lipid metabolism and induction 
of hepatic steatosis, with higher levels of SCFA contributing to enhanced lipogenesis 
and gluconeogenesis in the liver. 
Diet plays an important role in modulating the gut microbiota composition, 
and, as seen in this study, a single dietary fatty acid is capable of inducing a 
systemic effect on the host. Therefore, dietary approaches targeting beneficial 
bacteria and suppressing harmful species may be a new strategy to prevent or treat 
hepatic steatosis and associated metabolic disorders. The use of fatty acid mixtures 
with equal proportions of CLA isomers or alternatively, the use of probiotics and 
prebiotics to balance the potentially negative effects of t10, c12 CLA on microbiota 
composition may be safer alternatives for individuals looking for anti-obesity 
dietary solutions. Future studies comparing the effects of dietary t10, c12 CLA with 
dietary c9, t11 CLA and other trans-fatty acids on human intestinal microbiota 
composition would provide important information about the mechanisms of action 
of these fatty acids on metabolic pathways. Moreover, future studies using germ-
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free animals would help further our understanding of the impact of microbiota on 
lipid metabolism. 
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4.1 ABSTRACT 
Background: We previously showed that microbial metabolism in the gut influences 
the composition of bioactive fatty acids in host adipose tissue. 
Objective: This study compared the effect of dietary supplementation for 8 wk with 
human-derived Bifidobacterium breve strains on fat distribution and composition 
and the composition of the gut microbiota in mice. 
Methods: C57BL/6 mice (n=8 per group) received B. breve DPC 6330 or B. breve 
NCIMB 702258 (109 microorganisms) daily for 8wk or no supplement (controls). 
Tissue fatty acid composition was assessed by gas-liquid chromatography while 16S 
rRNA pyrosequencing was used to investigate microbiota composition. 
Results: Visceral fat mass and brain stearic acid, arachidonic acid (AA), and 
docosahexaenoic acid (DHA) were higher in mice supplemented with B. breve 
NCIMB 702258 than in mice in the other 2 groups (p<0.05). In addition, both B. 
breve DPC 6330 and B. breve NCIMB 702258 supplementation resulted in higher 
propionate concentrations in the caecum than did no supplementation (p<0.05). 
Compositional sequencing of the gut microbiota showed a tendency for greater 
proportions of Clostridiaceae (25%, 12%, and 18%; p=0.08) and lower proportions 
of Eubacteriaceae (3%, 12%, and 13%; p=0.06) in mice supplemented with B. breve 
DPC 6330 than in mice supplemented with B. breve NCIMB 702258 and 
unsupplemented controls, respectively. 
Conclusion: The response of fatty acid metabolism to administration of 
bifidobacteria is strain-dependent, and strain-strain differences are important 
factors that influence modulation of the gut microbial community by ingested 
microorganisms.  
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4.2 INTRODUCTION 
The human gut microbiota comprises trillions of microorganisms, reaching 
cell numbers that outnumber that of host cells, and contains ≥100-fold more genes 
than the human genome (Qin et al., 2010). The collective genome of these 
microorganisms (the metagenome) contributes to a broad range of metabolic and 
biochemical functions that the host could not otherwise perform (Ley et al., 2006). 
Recent research has shown an interaction between the gut microbiota and host 
metabolism, energy utilization, and fat storage, which suggests that intestinal 
microbes play a direct role in the development of obesity (Backhed et al., 2004; Ley 
et al., 2005; Ley et al., 2006; Turnbaugh et al., 2006). Metagenomic analyses have 
also shown that the caecal microbiota of ob/ob mice and obese individuals are 
more efficient at energy extraction from the diet and at producing short-chain fatty 
acids (SCFA) than are those of normal phenotype (Schwiertz et al., 2010; Turnbaugh 
et al., 2006). These SCFA can then be used for de novo synthesis of lipids and 
glucose (Wolever at al., 1989), thus providing an additional source of energy for the 
host. Whereas some studies of bacterial communities in the gut microbiota in both 
mouse models and in humans, using compositional sequencing, have shown an 
increase in the ratio of Firmicutes to Bacteroidetes in obese subjects (Ley et al., 
2006; Turnbaugh et al., 2009), the identity of the microbial populations that are 
associated with obesity continues to be the subject of much debate, with others 
reporting a decreased Firmicutes to Bacteroidetes ratio in overweight and obese 
individuals (Murphy et al., 2010; Schwiertz et al., 2010). Another study reported no 
link between the proportion of Firmicutes and Bacteroidetes and human obesity 
(Duncan et al., 2008). Whether alterations in the microbiota are a cause or 
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consequence of obesity is furthermore controversial, and the role of the gut 
microbiota in fat metabolism and obesity is more complex than first considered 
(Duncan et al., 2008; Hildebrandt et al., 2009; Murphy et al., 2010). Thus, the 
interrelation between the gut microbial composition, diet, and host adiposity has to 
be further investigated. Knowledge of the interactions between energy intake and 
specific microbial populations, and their influence on body weight, is limited to 
small-scale clinical trials (Ley et al., 2006). Among the gastrointestinal bacteria, 
Bifidobacterium is an important commensal group, accounting for an estimated 3% 
of the intestinal microbiota from an average adult (Turroni, Foroni, et al., 2009; 
Turroni, Marchesi, et al., 2009). Because of their well-documented beneficial health 
effects (Leahy et al., 2005), bifidobacteria have attracted significant interest for 
probiotic applications in pharmaceutical and dairy products. In relation to host 
energy metabolism, higher numbers of bifidobacteria have been documented in 
normal-weight adults and adolescents than in their overweight counterparts 
(Collado et al., 2008; Kalliomaki et al., 2008). However, some recent studies suggest 
that the role of bifidobacteria in weight management may be species-specific. Thus, 
Santacruz et al. (2009) reported that weight loss was associated with a reduction in 
the numbers of Bifidobacterium breve and Bifidobacterium bifidum and an increase 
in the numbers of Bifidobacterium catenulatum.  
A promising mechanism by which the manipulation of the gut microbiota 
can affect host metabolism and fat storage is the modulation of fatty acid 
composition of host cellular membranes. We previously showed that dietary 
supplementation with a conjugated linoleic acid (CLA)–producing Bifidobacterium 
strain of human origin (B. breve NCIMB 702258) influenced the composition of 
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bioactive fatty acids in host liver and adipose tissue in different animal species (Wall 
et al., 2009; Wall at al., 2010). Thus, in this study, we compared the effect of 
administering 2 different CLA-producing strains of the same species (i.e., B. breve 
DPC 6330 and B. breve NCIMB 702258) on host fat distribution and composition. 
Furthermore, we performed a high-throughput pyrosequence based assessment of 
the effect of oral administration of these B. breve strains on the diversity of the 
resident gut microbiota. 
 
4.3 MATERIALS AND METHODS 
Animals and treatment 
Wild-type C57BL/6 male mice aged 7–8 wk were obtained from Charles 
River and housed under barrier-maintained conditions within the Biological Services 
Unit, University College Cork. All animal experiments were approved by the 
University College Cork Animal Ethics Committee, and experimental procedures 
were conducted under the appropriate license from the Irish Government. Mice 
were allowed to acclimatize for 1 wk before the start of the study and were fed ad 
libitum with Teklad Global rodent standard diet (#2018S; Harlan Laboratories) and 
allowed free access to water at all times. Mice were housed in groups of 4 per cage 
and kept in a controlled environment at 25oC under a 12-h-light/12-h-dark cycle. 
After 1 wk of acclimatization, the mice were divided into 3 groups (n=8 per group): 
a control group fed with standard diet and placebo freeze-dried powder (15% 
wt:vol trehalose in dH2O), a group fed with standard diet and B. breve DPC 6330 
(approximate daily dose of 109 microorganisms), and a group fed a standard diet 
and B. breve NCIMB 702258 (approximate daily dose of 109 microorganisms). The 
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diet contained the following nutrient composition: crude protein (18.6%), 
carbohydrate (44.2%), fat (6.2%), crude fiber (3.5%), neutral detergent fiber 
(14.7%), and ash (5.3%). The fatty acids present in the diet included palmitic acid 
(16:0, 0.7%), stearic acid (18:0, 0.2%), oleic acid (18:1n29, 1.2%), linoleic acid 
(18:2n26, 3.1%), and linolenic acid (18:3n23, 0.3%). Body weight and food intake 
were assessed weekly. After 8 wk on the experimental diets, the animals were killed 
by decapitation. Liver, brain, fat pads (epididymal, perirenal, and mesenteric), 
gastrointestinal tract from stomach to anus, and caecal contents were removed, 
blotted dry on filter paper, weighed, and flash-frozen immediately in liquid 
nitrogen. All samples were stored at -80oC until processed. Blood samples were 
collected from starved animals and allowed to clot for 2 h at 4oC before 
centrifugation for 20 min at 2000 x g.  
 
Preparation and administration of B. breve NCIMB 702258 and B. breve DPC 6330  
We previously showed that B. breve NCIMB 702258 and B. breve DPC 6330 
are efficient CLA producers, converting up to 65% and 76%, respectively, of linoleic 
acid to c9, t11 CLA when grown in 0.5 mg linoleic acid/mL in vitro (Barrett et al., 
2007; Coakley et al., 2003). Rifampicin resistant variants of B. breve NCIMB 702258 
and B. breve DPC 6330 were isolated by spread-plating ~109 colony forming units 
(CFU) from an overnight culture onto mMRS agar (Difco Laboratories) 
supplemented with 0.05% (wt:vol) L-cysteine hydrochloride (98% pure; Sigma 
Chemical Co) containing 500 ug rifampicin/mL (Sigma). After anaerobic incubation 
(anaerobic jars with Anaerocult A gas packs; Merck) at 37oC for 3 d, colonies were 
stocked in de Man, Rogosa, and Sharpe (MRS) broth containing 40% (vol:vol) 
 
146 
glycerol and stored at -80oC. To confirm that the rifampicin-resistant variant was 
identical to the parent strain, pulse-field gel electrophoresis was used for molecular 
fingerprinting. Before freeze-drying, B. breve NCIMB 702258 and B. breve DPC 6330 
were grown in MRS by incubating overnight at 37oC under anaerobic conditions. 
The culture was washed twice in phosphate-buffered saline and resuspended at a 
concentration of ~2 x 1010 cells/mL in 15% (wt:vol) trehalose (Sigma) in dH2O. One-
milliliter aliquots were freeze-dried by using a 24-h program (freeze temperature, -
40oC; condenser set point, -60oC; vacuum set point, 600 mTorr). Each mouse that 
received the bacterial strains consumed ~1 x 109 live microorganisms/d. This was 
achieved by resuspending appropriate quantities of freeze-dried powder in water, 
which mice consumed ad libitum. Mice that did not receive the bacterial strains 
received placebo freeze-dried powder [15% (wt:vol) trehalose in dH2O]. Water 
containing either the bacterial strains or placebo freeze-dried powder was the only 
water supply provided to the animals throughout the trial. Freeze-dried powders 
with the bacterial strains underwent continuous quality control of cell counts for 
the duration of the trial by plating serial dilutions on MRS agar supplemented with 
100 ug mupirocin/mL (Oxoid) and 100 ug rifampicin/mL (Sigma) and incubating 
plates anaerobically for 72 h at 37oC.  
 
Culture-dependent microbial analysis  
Fresh faecal samples were taken from C57BL/6 mice every week for 
microbial analysis. Microbial analysis of the faecal samples involved enumeration of 
the B. breve strains by plating serial dilutions on MRS agar supplemented with 100 
ug mupirocin (Oxoid)/mL, 100 ug rifampicin/mL (Sigma), and 50 U nystatin/mL 
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(Sigma). Agar plates were incubated anaerobically for 72 h at 37oC. In addition, 
proximal colonic contents were sampled at the time the mice were killed for 
enumeration of the administered B. breve strains. 
 
Lipid extraction and fatty acid analysis  
Lipids were extracted with chloroform:methanol (2:1, vol:vol; Fisher 
Scientific) according to the method of Folch et al. (1957). Fatty acid methyl esters 
(FAMEs) were prepared by using first 10 mL 0.5 N NaOH (Sigma) in methanol for 10 
min at 90oC followed by 10 mL 14% BF3 in methanol (Sigma) for 10 min at 90oC 
(Park & Gois, 1994). FAMEs were recovered with hexane (Fisher Scientific). Before 
gas-liquid chromatographic analysis, samples were dried over 0.5 g anhydrous 
sodium sulfate (Sigma) for 1 h and stored at -20oC. FAMEs were separated by gas-
liquid chromatography (Varian 3800; Varian) fitted with a flame ionization detector 
by using a Chrompack CP Sil 88 column (Chrompack; 100 m x 0.25 mm internal 
diameter, 0.20 um film thickness) and helium as carrier gas. The column oven was 
programmed to be held initially at 80oC for 8 min and then increased by 8.5oC/min 
to a final column temperature of 200oC. The injection volume used was 0.6 uL, with 
automatic sample injection on a SPI 1093 splitless on-column temperature-
programmable injector. Peaks were integrated by using the Varian Star 
Chromatography Workstation version 6.0 software, and peaks were identified by 
comparison of retention times with pure FAME standards (Nu-Chek Prep). The 
percentage of individual fatty acids was calculated according to the peak areas 
relative to the total area (total fatty acids were set at 100%). All fatty acid results 
are shown as means ± SEMs in g/100 g FAMEs.  
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SCFA analysis 
 Approximately 100 mg caecal content was vortex-mixed with 1.0 mL Milli-Q 
water and, after standing for 10 min at room temperature, centrifuged at 10000 x g 
for 5 min to pellet bacteria and other solids. The supernatant fluid was collected, 
3.0 mM 2-ethylbutyric acid (Sigma) was added as internal standard, and samples 
were filtered before being transferred to clean vials. Standard solutions containing 
10.0 mmol/L, 8.0 mmol/L, 6.0 mmol/L, 4.0 mmol/L, 2.0 mmol/L, 1.0 mmol/L, and 
0.5 mmol/L of acetic acid, propionic acid, isobutyric acid, and butyric acid (Sigma), 
were used for calibration. The concentration of SCFA was measured by using a 
Varian 3500 GC flame-ionization system, fitted with a Nukol-FFAP column (30 m x 
0.32 mm x 0.25 um; Sigma). Helium was used as the carrier gas at a flow rate of 1.3 
mL/min. The initial oven temperature was 100oC for 0.5 min, raised to 180oC at 
8oC/min and held for 1 min, then increased to 200oC at 20oC/min, and finally held at 
200oC for 5 min. The temperature of the detector and the injector were set at 
250oC and 240oC, respectively. Peaks were integrated by using the Varian Star 
Chromatography Workstation version 6.0 software. Standards were included in 
each run to maintain the calibration.  
 
Measurement of triglycerides in liver  
Liver lipids were extracted and purified according to the method of Folch et 
al. (1957). After being mixed thoroughly, the samples were dried under nitrogen 
and resolubilized in 5% (vol:vol) Triton X-100 in dH2O. The concentration of 
triglycerides was measured by using a commercial kit (EnzyChrom Triglyceride 
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Assay kit; BioAssay Systems). The results were normalized to the weight of the 
samples.  
 
Measurements of serum variables  
Serum variables were measured with commercial kits. Serum glucose was 
measured by using a QuantiChrom glucose assay kit (BioAssay Systems), serum 
insulin was measured by using the Ultra Sensitive Mouse ELISA kit (Crystal Chem 
Inc), serum leptin was measured by using the Mouse Leptin ELISA kit (Crystal Chem 
Inc), and serum triglycerides were measured by using EnzyChrom Triglyceride Assay 
kit (BioAssay Systems).  
 
Culture-independent microbial analysis 
For analysis of the microbial community composition of the caecal contents, 
total DNA was extracted from the caecal contents of all mice by using the QIAamp 
DNA stool mini kit according to the manufacturer’s instructions (Qiagen) coupled 
with an initial bead-beating step. Universal 16s rRNA primers, designed to amplify 
from highly conserved regions corresponding to those flanking the V4 region, i.e., 
the forward primer F1 (5’-AYTGGGYDTAAAGNG) and a combination of 4 reverse 
primers— R1 (5’ TACCRGGGTHTCTAATCC), R2 (5’-TACCAGAGTATCTAATTC), R3 (5’-
CTACDSRGGTMTCTAATC) and R4 (5’-TACNVGGGTATCTAATC) (RDP’s 
Pyrosequencing Pipeline: http://pyro.cme.msu.edu/pyro/help.jsp)—were used for 
Taq-based polymerase chain reaction amplification. Sequencing was performed on 
a Roche 454 GS-FLX by using Titanium chemistry with the Teagasc 454 Sequencing 
Platform. Resulting raw sequences reads were quality trimmed as previously 
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described (Claesson et al., 2009). Trimmed FASTA sequences were then BLASTed 
(Altschul et al., 1997) against a previously published 16S-specific database (Urich et 
al., 2008) by using default parameters. The resulting BLAST output was parsed by 
using MEGAN (Huson et al., 2007). MEGAN assigns reads to NCBI taxonomies by 
using the Lowest Common Ancestor algorithm. Bit scores were used from within 
MEGAN for filtering the results before tree construction and summarization. A bit 
score of 86 was selected as previously used for 16S ribosomal sequence data (Urich 
et al., 2008). Phylum and family counts for each subject were extracted from 
MEGAN. Clustering and alpha diversities were generated with the MOTHUR 
software package (Schloss & Handelsman, 2008). Beta diversities and principal 
coordinate analysis (PCoA) of sequence reads were calculated by using the Qiime 
suite of tools (Caporaso et al., 2010).  
 
Statistical analysis  
Results in the text, tables, and figures are presented as means ± SEMs (per 
group). To assess whether differences between treatment groups were significant, 
data were analyzed by using one-factor ANOVA followed by post hoc Tukey’s 
multiple comparisons test with the use of GraphPad Prism version 4.0 for Windows 
(GraphPad Software). Compositional data were statistically analyzed by using 
Minitab release 15.1.1.0 (www.minitab.com). The nonparametric Kruskal-Wallis 
test was used to estimate the relations between different groups. Statistical 
significances were accepted at p<0.05, and trends for statistically significant 
differences were recognized at p<0.10. 
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4.4 RESULTS 
Survival and transit of B. breve DPC 6330 and B. breve NCIMB 702258 in C57BL/6 
mice  
Quantification of the numbers of the administered B. breve strains in the 
faeces of mice confirmed their gastrointestinal transit and survival. Stool recovery 
of B. breve DPC 6330 and B. breve NCIMB 702258 were ~1.1 x 106 CFU/g faeces and 
8.2 x 106 CFU/g faeces after 2 wk of feeding the respective strain and remained at 
similar numbers for weeks 4 and 6. At week 8, there was a decline in the numbers 
of excreted B. breve strains, with stool recovery of B. breve DPC 6330 and B. breve 
NCIMB 702258 being 1.2 x 105 CFU/g faeces and 3.4 x 105 CFU/g faeces in the 
respective groups.  
At sacrifice, B. breve DPC 6330 and B. breve NCIMB 702258 were detected in 
the large intestine at 7 x 105 CFU/g content and 1 x 106 CFU/g content, respectively, 
in the mice administered the strains.  
 
Dietary supplementation with B. breve NCIMB 702258, but not B. breve DPC 6330, 
increases visceral host fat storage  
The weight of visceral body fat—the sum of epididymal, mesenteric, and 
perirenal fat pads—was significantly higher in mice fed B. breve NCIMB 702258 
than in unsupplemented mice (1.71 ± 0.13 and 1.20 ± 0.10 g; p<0.05; Table 4.1). 
This increase in visceral fat mass correlated with a tendency for greater circulating 
leptin in mice supplemented with B. breve NCIMB 702258 than in unsupplemented 
controls (5.2 ± 0.9 and 2.4 ± 0.7 ng/mL; p=0.06; Table 4.2). No significant difference 
in body mass was found between the groups over the 8-wk feeding period (Table 
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4.1). No effect on liver mass or liver triglycerides was observed after administration 
of B. breve NCIMB 702258. In contrast, administration of B. breve DPC 6330 was 
associated with a higher concentration of liver triglycerides than was no 
supplementation (p<0.05; Table 4.1). Neither of the administered B. breve strains 
affected the concentrations of circulating insulin, glucose, or triglycerides relative to 
no supplementation (Table 4.2). In addition, no difference in food intake was 
observed between the groups (data not shown).  
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Table 4.1  Body mass, fat mass, liver mass and liver triglyceride levels of mice fed B. 
breve DPC 6330, B. breve NCIMB 702258 and unsupplemented diet for 8 weeks 
 
B. breve DPC 6330 
fed mice 
B. breve NCIMB 
702258 fed mice 
Unsupplemented 
mice 
Initial weight (g) 26.5 ± 0.6 26.7 ± 0.6 25.4 ± 0.5 
Final weight (g) 31.7 ± 0.8 33.4 ± 0.7 30.6 ± 0.8 
Weight gain (%) 20.3 ± 4.5 25.1 ± 3.7 20.5 ± 3.1 
Visceral fat (g) 1.51 ± 0.16A,B 1.71 ± 0.13A 1.20 ± 0.10B 
Liver mass (g) 1.64 ± 0.05 1.55 ± 0.06 1.47 ± 0.05 
Liver triglycerides (mg/g) 4.64  ± 0.73A 3.44 ± 0.29A,B 2.93 ± 0.14B 
Visceral fat mass include epididymal, perirenal, and mesenteric fat pads. Results are expressed as 
Means  SEM, n=8 mice/group. Means not sharing a common superscript letter are significantly 
different at p0.05 based on ANOVA followed by post hoc Tukey’s multiple comparison tests.  
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Table 4.2 Serum parameters in mice fed B. breve DPC 6330, B. breve NCIMB 702258 
and unsupplemented diet for 8 weeks 
Serum parameter 
B. breve DPC 6330 
fed mice 
B. breve NCIMB 
702258 fed mice 
Unsupplemented 
mice 
Triglycerides (mg/dL) 78.1 ± 12.8 56.2 ± 11.8 61.3 ± 8.2 
Glucose (mg/dL) 217.6  ± 17.6 186.0  ± 6.4 183.3  ± 2.8 
Insulin (ng/mL) 1.4  ± 0.2 2.5  ± 0.8 1.7  ± 0.3 
Leptin (ng/mL) 3.9  ± 0.8 5.2  ± 0.91 2.4  ± 0.71 
Blood samples were collected after fasting. Results are expressed as Means  SEM, n=8 
mice/group. No significant differences were observed. 1p=0.06, based on ANOVA followed by 
post hoc Tukey’s multiple comparison tests.  
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Higher gut concentrations of SCFA after administration of B. breve DPC 6330 and 
B. breve NCIMB 702258  
Analysis of caecal SCFA, the major fermentation end products and source of 
energy for the host, showed that propionate was significantly higher in mice fed B. 
breve DPC 6330 and B. breve NCIMB 702258 than in nonsupplemented mice 
(p<0.05; Table 4.3). Higher concentrations of isobutyrate were also observed in 
mice supplemented with B. breve NCIMB 702258 than in unsupplemented controls 
(p<0.05; Table 4.3). In addition, the mean total SCFA concentration (acetate, 
propionate, butyrate, and isobutyrate) detected in the caecal contents was 24% 
higher in mice fed B. breve DPC 6330 than in unsupplemented controls (p=0.07; 
Table 4.3).  
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Table 4.3 SCFA concentrations (mol/g) of caecum content 
SCFA 
B. breve DPC 6330 
fed mice 
B. breve NCIMB 
702258 fed mice 
Unsupplemented 
mice 
Acetate 48.05 ± 3.58 45.05 ± 2.73 40.71 ± 2.43 
Propionate 9.80 ± 0.51A 9.28 ± 0.49A 7.14 ± 0.40B 
Butyrate 18.24 ± 2.67 13.44 ± 1.45 13.71 ± 1.59 
Isobutyrate 0.80 ± 0.09A,B 0.88 ± 0.05A 0.67 ± 0.02B 
Total acids 76.88 ± 6.39 68.65 ± 4.03 62.23 ± 4.14 
Results are expressed as Means  SEM; B. breve DPC 6330 (n=8), B. breve NCIMB 702258 (n=7), 
unsupplemented mice (n=8). Means not sharing a common superscript letter are significantly 
different at p0.05 based on ANOVA followed by post hoc Tukey’s multiple comparison tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
157 
Contrasting effects on host tissue fatty acid composition of dietary 
supplementation with B. breve DPC 6330 and B. breve NCIMB 702258  
To investigate the effects of dietary supplementation with B. breve DPC 
6330 and B. breve NCIMB 702258 on the fatty acid composition of host tissues, 
fatty acid profiling was performed on brain, epididymal adipose tissue, and liver. 
Significant differences in tissue fatty acid composition were observed after 
supplementation with the B. breve strains (Tables 4.4–4.6). Mice fed B. breve 
NCIMB 702258 had significantly higher stearic acid (18:0), AA (20:4n26), and DHA 
(22:6n23) contents in the brain than did the unsupplemented mice (p<0.05) and the 
mice supplemented with B. breve DPC 6330 (p<0.05; Table 4.4), whereas dietary 
supplementation with B. breve DPC 6330 resulted in higher myristic acid (14:0) in 
the brain compared with both unsupplemented mice and mice supplemented with 
B. breve NCIMB 702258 (p<0.05; Table 4.4). However, both groups of B. breve–
supplemented mice had significantly lower palmitic acid (16:0), palmitoleic acid 
(16:1c9), and dihomo-c-linolenic acid (20:3n26) in the brain than did the 
unsupplemented controls (p<0.05; Table 4.4).  
Mice that received B. breve DPC 6330 had significantly higher myristic acid, 
palmitic acid, palmitoleic acid, and DHA in epididymal adipose tissue than did 
unsupplemented mice (p<0.05; Table 4.5). In contrast, these fatty acids were not 
higher in the epididymal adipose tissue of the mice supplemented with B. breve 
NCIMB 702258. Mice that received B. breve DPC 6330 also had significantly lower 
oleic acid (18:1c9) in epididymal adipose tissue than did both the unsupplemented 
mice and mice supplemented with B. breve NCIMB 702258 (p<0.05; Table 4.5). In 
contrast to a higher concentration of DHA in epididymal adipose tissue of mice fed 
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B. breve DPC 6330, these mice had a lower concentration of DHA in liver than did 
unsupplemented mice (p<0.05; Table 4.6). There was a tendency for higher 
concentrations (p=0.06) of c9, t11 CLA in the livers of mice receiving B. breve NCIMB 
702258 (0.031 ± 0.006g/100g FAME) than in mice supplemented with B. breve DPC 
6330 (0.015 ± 0.007g/100g FAME) and in unsupplemented controls (0.013 ± 0.006 
g/100 g FAME).  
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Table 4.4 Fatty acid profile in brain of mice fed B. breve DPC 6330, B. breve NCIMB 
702258 or unsupplemented diet for 8 wk1 
Fatty acid 
Mice fed B. breve 
DPC 6330 
Mice fed B. breve 
NCIMB 702258 
Unsupplemented 
mice 
 g/100g FAME g/100g FAME g/100g FAME 
Myristic acid, 14:0 3.66 ± 0.21A 1.36 ± 0.05B 1.90 ± 0.08C 
Palmitic acid, 16:0 22.34 ± 0.80A 21.46 ± 0.18A 26.75 ± 0.45B 
Palmitoleic acid, 16:1c9 0.69 ± 0.03A 0.72 ± 0.03A 0.90 ± 0.04B 
Stearic acid, 18:0 10.80 ± 0.18A 11.99 ± 0.15B 11.08 ± 0.16A 
Oleic acid, 18:1c9 9.83 ± 0.17A 10.48 ± 0.07B 10.22 ± 0.13A,B 
Linoleic acid, 18:2n-6 0.49 ± 0.02A 0.58 ± 0.02B 0.49 ± 0.01A 
Linolenic acid, 18:3n-3 ND ND ND 
ɤ-Linolenic acid, 18:3n-6 ND ND ND 
Dihomo-c-linolenic acid, 20:3n-6 0.33 ± 0.01A 0.37 ± 0.01A 0.27 ± 0.01B 
Arachidonic acid, 20:4n-6 5.70 ± 0.31A 6.55 ± 0.07B 5.27 ± 0.07A 
EPA, 20:5n-3 ND ND ND 
Docosapentaenoic acid, 22:5n-3 0.24 ± 0.04 0.21 ± 0.04 0.20 ± 0.09 
DHA, 22:6n-3 17.22 ± 0.35A 18.58 ± 0.32B 17.19 ± 0.10A 
1 All values are means ± SEMs; n=8 mice per group. Values in the same row with different 
superscript letters are significantly different, p<0.05 (ANOVA followed by post hoc Tukey’s multiple 
comparisons tests). FAME, fatty acid methyl ester; ND, not detected. 
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Table 4.5 Fatty acid profile in epididymal adipose tissue of mice fed B. breve DPC 
6330, B. breve NCIMB 702258 or unsupplemented diet for 8 wk1 
Fatty acid 
Mice fed B. breve 
DPC 6330 
Mice fed B. breve 
NCIMB 702258 
Unsupplemented 
mice 
 g/100g FAME g/100g FAME g/100g FAME 
Myristic acid, 14:0 1.96 ± 0.24A 1.44 ± 0.27A,B 1.10 ± 0.15B 
Palmitic acid, 16:0 15.19 ± 0.94A 12.78 ± 0.68A,B 10.68 ± 0.52B 
Palmitoleic acid, 16:1c9 4.31 ± 0.39A 3.75 ± 0.53A,B 2.85 ± 0.12B 
Stearic acid, 18:0 2.04 ± 0.13 2.26 ± 0.12 2.31 ± 0.03 
Oleic acid, 18:1c9 28.71 ± 0.92A 32.22 ± 0.89B 33.47 ± 0.48B 
Linoleic acid, 18:2n-6 33.57 ± 1.18 34.93 ± 1.13 36.66 ± 0.68 
Linolenic acid, 18:3n-3 2.44 ± 0.16 2.42 ± 0.10 2.57 ± 0.10 
ɤ-Linolenic acid, 18:3n-6 0.16 ± 0.01 0.15 ± 0.01 0.17 ± 0.005 
Dihomo-c-linolenic acid, 20:3n-6 0.42 ± 0.02 0.42 ± 0.02 0.42 ± 0.01 
Arachidonic acid, 20:4n-6 0.77 ± 0.04 0.71 ± 0.05 0.72 ± 0.03 
EPA, 20:5n-3 0.093 ± 0.01 0.072 ± 0.01 0.085 ± 0.01 
Docosapentaenoic acid, 22:5n-3 0.29 ± 0.02 0.26 ± 0.03 0.25 ± 0.02 
DHA, 22:6n-3 0.77 ± 0.04A 0.66 ± 0.05A,B 0.62 ± 0.05B 
1 All values are means ± SEMs; n=8 mice per group. Values in the same row with different 
superscript letters are significantly different, p<0.05 (ANOVA followed by post hoc Tukey’s 
multiple comparisons tests). FAME, fatty acid methyl ester; ND, not detected. 
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Table 4.6 Fatty acid profile in liver of mice fed B. breve DPC 6330, B. breve NCIMB 
702258 or unsupplemented diet for 8 wk1 
Fatty acid 
Mice fed B. breve 
DPC 6330 
Mice fed B. breve 
NCIMB 702258 
Unsupplemented 
mice 
 g/100g FAME g/100g FAME g/100g FAME 
Myristic acid, 14:0 0.65 ± 0.08 0.67 ± 0.03 0.67 ± 0.05 
Palmitic acid, 16:0 31.87 ± 0.33 30.53 ± 0.66 30.37 ± 0.40 
Palmitoleic acid, 16:1c9 2.81 ± 0.26 2.91 ± 0.24 2.60 ± 0.23 
Stearic acid, 18:0 9.32 ± 0.48 9.03 ± 0.30 9.61 ± 0.45 
Oleic acid, 18:1c9 13.48 ± 0.82 13.05 ± 0.92 10.85 ± 0.35 
Linoleic acid, 18:2n-6 21.55 ± 0.56A 19.40 ± 0.84A,B 19.07 ± 0.31B 
Linolenic acid, 18:3n-3 0.83 ± 0.05 0.71 ± 0.05 0.71 ± 0.03 
ɤ-Linolenic acid, 18:3n-6 0.30 ± 0.01 0.26 ± 0.02 0.28 ± 0.01 
Dihomo-c-linolenic acid, 20:3n-6 0.91 ± 0.05 0.96 ± 0.06 0.94 ± 0.02 
Arachidonic acid, 20:4n-6 7.07 ± 0.48 7.25 ± 0.24 7.81 ± 0.35 
EPA, 20:5n-3 0.22 ± 0.01 0.22 ± 0.02 0.22 ± 0.01 
Docosapentaenoic acid, 22:5n-3 0.38 ± 0.03 0.42 ± 0.03 0.41 ± 0.02 
DHA, 22:6n-3 3.57 ± 0.27A 3.82 ± 0.12A,B 4.48 ± 0.16B 
1 All values are means ± SEMs; n=8 mice per group. Values in the same row with different 
superscript letters are significantly different, p<0.05 (ANOVA followed by post hoc Tukey’s 
multiple comparisons tests). FAME, fatty acid methyl ester; ND, not detected. 
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Contrasting effects on gut microbiota composition of dietary supplementation 
with B. breve NCIMB 702258 and B. breve DPC 6330  
At the end of the 8-wk study, the microbial composition of the gut 
microbiota of individual mice was elucidated through high throughput 
pyrosequencing (Roche-454 Titanium) of 16S rRNA (V4) amplicons generated from 
DNA extracted from the caecal content. A total of 103,711 reads were sequenced, 
averaging at 4509 reads per animal. Species-richness, coverage, and diversity 
estimations were calculated for each data set (data not shown). At the 97% 
similarity level, the Shannon index—a metric for community diversity showed a 
high level of overall biodiversity within all samples with values exceeding 5.1. The 
Good’s coverage at the 97% similarity level ranged between 88% and 95% for all the 
data sets. Chao1 richness also indicated a sufficient level of overall diversity (data 
not shown). Rarefaction curves for each data set were parallel or approaching 
parallel with the x axis, which indicated that the total bacterial diversity present 
within these was well represented and that additional sampling would yield a 
limited increase in species richness (Supplementary Figure 4.1).  
In agreement with previous work (Ley et al., 2005; Ley et al., 2006; 
Turnbaugh et al., 2006), taxonomy-based analysis showed that, at the phylum level, 
the mouse gut microbiota was dominated by Firmicutes and Bacteroidetes 
(together harboring on average 94% of sequences; Figure 4.1). At the family level, 
the most dominant groups were Bacteroidaceae, Clostridiaceae, Eubacteriaceae, 
and Lactobacillaceae (Figure 4.2).  
A comparison of the composition of the microbiota of mice supplemented 
with B. breve NCIMB 702258, mice supplemented with B. breve DPC 6330, and 
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unsupplemented mice showed that administration of these strains altered the 
composition of the gut microbiota differently at the phylum, family, and genus 
levels. There was a tendency for a reduction in the Firmicutes population from 74% 
in the unsupplemented mice to 68% in the mice supplemented with B. breve NCIMB 
702258 and 67% in mice supplemented with B. breve DPC 6330 (p=0.08; Figure 4.1). 
All other phyla remained at relatively similar proportions across the groups. At the 
family level, administration of both B. breve DPC 6330 and B. breve NCIMB 702258 
resulted in a signiﬁcantly lower proportion of Lachnospiraceae than did no 
supplementation (p<0.05; Figure 4.2). Furthermore, Eubacteriaceae tended to be 
less abundant in the caecum of mice supplemented with B. breve DPC 6330 than in 
mice supplemented with B. breve NCIMB 702258 and unsupplemented controls 
(3%, 12%, and 13%, respectively; p=0.06; Figure 4.2). Other observed differences at 
the family level included a tendency for an apparent enrichment in the 
Clostridiaceae population in mice supplemented with B. breve DPC 6330 (25%) than 
in mice supplemented with B. breve NCIMB 702258 (12%) and unsupplemented 
mice (18%; p=0.08; Figure 4.2). At the genus level, Eubacterium tended to be lower 
after dietary supplementation with B. breve DPC 6330 than after no 
supplementation or supplementation with B. breve NCIMB 702258 (p=0.06; Figure 
4.3).  
PCoA generated using unweighted UNIFRAC distances showed that mice 
clustered into relatively distinct groups based on whether they received B. breve 
DPC 6330, B. breve NCIMB 702258, or no supplementation (Figure 4.4). Mice fed B. 
breve DPC 6330 clustered closely together and showed a clear separation from the 
unsupplemented mice and the mice supplemented with B. breve NCIMB 702258. 
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This suggests that supplementation with B. breve DPC 6330 had a greater effect on 
the gut microbiota than did supplementation with B. breve NCIMB 702258. 
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Figure 4.1 Phylum-level distributions of the microbial communities in caecal 
contents, expressed as a percentage of the total population of assignable tags, in 
mice supplemented with B. breve DPC 6330 (n=7) or B. breve NCIMB 702258 (n=7) 
and in unsupplemented mice (n=8). No significant differences were observed. 
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Figure 4.2 Family-level taxonomic distributions of the microbial communities in 
caecal contents, expressed as percentage of total tags assignable at family level, in 
mice supplemented with B. breve DPC 6330 (n=7) or B. breve NCIMB 702258 (n=7) 
and in unsupplemented mice (n=8). *p<0.05 (Kruskal-Wallis test). 
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Figure 4.3 Genus-level taxonomic distributions of the microbial communities 
present in caecal contents, expressed as a percentage of total tags assignable at the 
genus level, in mice supplemented with B. breve DPC 6330 (n=7) or B. breve NCIMB 
702258 (n=7) and in unsupplemented mice (n=8). No significant differences were 
observed. 
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Figure 4.4 Principal coordinate analysis using unweighted UniFrac distances in mice 
supplemented with Bifidobacterium breve DPC 6330 (n=7) or B. breve NCIMB 
702258 (n=7) and in unsupplemented mice (n=8). 
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4.5 DISCUSSION 
This study showed that the response of fatty acid metabolism to 
administration of bifidobacteria is strain-dependent and furthermore highlights the 
importance of strain-strain differences in modifying the gut microbiota composition 
of the host. Administration of B. breve NCIMB 702258 increased visceral fat mass 
and weight gain in C57BL/6 mice, whereas administration of B. breve DPC 6330 did 
not. In general, beneficial effects have been attributed to Bifidobacterium in 
connection with obesity and weight management, and some reports support the 
preventative role of bifidobacteria in promoting fat mass development and body 
weight gain (Cani et al., 2007; Collado et al., 2008; Kalliomaki et al., 2008). However, 
other studies contradict the preventative role of Bifidobacterium in body weight 
gain (Furet et al., 2010; Santacruz et al., 2009) and question the role of specific 
Bifidobacterium species in obesity and weight management (Santacruz et al., 2009). 
Because the Bifidobacterium genus is complex, it is possible that certain 
bifidobacterial species, or even strains, as observed in the current study, promote 
fat mass storage and body weight more efficiently than others through diverse 
regulatory roles in fat absorption and distribution. Notably, strains of B. breve were 
previously shown to improve weight gain in very-low–birthweight infants (Kitajima 
et al., 1997). However, it must be acknowledged that this study was limited to 2 
strains of B. breve; therefore, further studies are required to draw conclusions 
about the role of specific Bifidobacterium species and strains in fat/energy 
absorption and their effect on weight gain in animal models of obesity and in 
humans.  
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Previous studies have shown that the gut microbiota affect the composition 
and quality of fat in the host as well as the quantity of fat (Velagapudi et al., 2010). 
We showed that manipulation of the gut microbiota by administering a single 
metabolically active strain, B. breve NCIMB 702258, to different animal species 
influenced the composition of bioactive fatty acids in host liver and adipose tissue 
(Wall et al., 2009). In the current study, we compared the effect of B. breve NCIMB 
702258 and B. breve DPC 6330 on fatty acid composition of different host tissues in 
mice. We observed that administration of these B. breve strains altered the fatty 
acid composition in distinct ways. Whereas administration of B. breve DPC 6330 had 
a greater influence on the fatty acid composition of epididymal adipose tissue, with 
higher palmitic acid, palmitoleic acid, and DHA, administration of B. breve NCIMB 
702258 had a greater effect on the fatty acid composition of the brain. Intriguingly, 
mice supplemented with B. breve NCIMB 702258 had significantly higher 
concentrations of ARA and DHA in brain than did both mice supplemented with B. 
breve DPC 6330 and unsupplemented mice. This observation of increased ARA and 
DHA in the brain of mice administered B. breve NCIMB 702258 is consistent with 
our previous findings in a different model (Wall et al., 2009). ARA and DHA play 
important roles in neurogenesis, neurotransmission, and protection against 
oxidative stress (Innis, 2007; Maekawa et al., 2009), and their concentrations in the 
brain influence cognitive processes such as learning and memory (Henriksen et al., 
2008; Yurko-Mauro et al., 2010). The importance of these fatty acids in 
neurodevelopment has led to their supplementation in infant formula (EFSA, 2009). 
The current study supports our previous observations (Wall et al., 2009; Wall et al., 
2010), and findings by others (Kankaanpaa et al., 2002; Kaplas et al., 2007), in which 
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manipulation of the gut microbiota altered the composition of fat in the host. 
Interactions between fatty acids and members of the gut microbiota might affect 
the biological roles of both, and such interactions may therefore result in 
physiologic consequences for the host.  
The mechanism by which these ingested strains mediate the changes in fatty 
acid composition observed in the current study is unclear and remains to be 
elucidated. Possible explanations include modulations of fat-absorption processes 
in the small intestine and/or desaturase activities involved in the metabolism of 
fatty acids to the longer-chain unsaturated derivatives caused either directly by the 
strains administered or by alterations in the gut microbiota. Interestingly, a 
previous study in lactating goats showed that administration of a Lactobacillus 
plantarum strain resulted in changes in the faecal microbiota and modulated the 
milk fatty acid composition with a higher content of PUFAs (Maragkoudakis et al., 
2010). Furthermore, a recent study by Hoppu et al. (2011) reported that dietary 
supplementation of lactating women with Lactobacillus rhamnosus GG and 
Bifidobacterium lactis Bb12, in combination with rapeseed oil, resulted in higher ɤ-
linolenic acid concentrations in breast milk than did fatty acid supplementation 
alone.  
The current study showed not only significant differences in the composition 
of the gut microbiota between mice fed or not fed B. breve, but also differences 
between mice fed different strains of B. breve. At the phylum level, the Firmicutes 
population tended to be more abundant in the caecum of mice supplemented with 
B. breve DPC 6330 and B. breve NCIMB 702258 than in unsupplemented mice. At 
the family level, the proportions of Eubacteriaceae were reduced in the animals 
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receiving B. breve DPC 6330, but not in those receiving B. breve NCIMB 702258, 
compared with unsupplemented controls. In addition, administration of B. breve 
DPC 6330 led to an apparent enrichment in Clostridiaceae compared with the 
unsupplemented mice, whereas this enrichment was absent in mice supplemented 
with B. breve NCIMB 702258. Penicillium was found in the mice supplemented with 
B. breve NCIMB 702258; however, this genus is not considered to be a typical 
member of the gut microbiota, and factors contributing to its presence in the gut, 
as found in this instance, require further investigation. PCoA analysis showed that 
mice fed B. breve DPC 6330 had a more divergent clustering pattern and were 
separated from the unsupplemented mice and from mice fed B. breve NCIMB 
702258. This suggests that supplementation with B. breve DPC 6330 has a greater 
effect on the composition of the murine gut microbiota than does supplementation 
with B. breve NCIMB 702258. Our observations suggest that administration of a 
single strain can play a role in determining the composition of gut bacterial 
populations in vivo and furthermore that strain-strain differences are important 
factors with respect to modulation of the gut microbial community. Although 
changing the intestinal microbiota may be more difficult in free-living individuals 
than in laboratory models, it is important to perform extensive microbiota related 
studies on bifidobacteria-associated probiotics in human trials, especially in groups 
in which shifts in the composition have been observed due to the state of 
physiology (i.e., obesity and diabetes), particularly because an alteration of the gut 
microbiota at lower taxonomic levels is still likely to have important functional 
consequences for the host. Whereas it is acknowledged that pyrosequencing of the 
16S rRNA genes, as undertaken in this study, did not provide quantitative 
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population data, it did yield an overview of the effects of administration of these 
strains on the entire microbial population.  
SCFA (acetate, propionate, butyrate, and isobutyrate) are major products of 
the fermentation processes of the gut microbiota on nondigestible carbohydrates in 
the intestine. These fatty acids have recently attracted significant interest because 
of their positive effect on human gastrointestinal health and diseases, including 
colon cancer, gastrointestinal infections, and inflammatory bowel disease 
(D’Argenio et al., 1996; Emenaker et al., 2001; Galvez et al., 2005; Topping & 
Clifton, 2001). SCFA are also believed to be a driver of energy-sparing and are 
portrayed as a potential mechanism involved in the increase of fat mass storage in 
microbiota-bearing mice (Turnbaugh et al., 2006). The differences in stool SCFA 
concentrations between lean and obese people have been considerable. The mean 
total SCFA concentration in faecal samples of obese volunteers was shown to be 
>20% higher than in lean volunteers, with the highest increase observed for 
propionate, which was 41% higher in obese volunteers (Schwiertz et al, 2010). 
Administration of B. breve DPC 6330 and B. breve NCIMB 702258 led to an increase 
in propionate in the caecum that was 37% higher in mice supplemented with B. 
breve DPC 6330 and 30% higher in mice supplemented with B. breve NCIMB 702258 
than in unsupplemented mice. Noteworthy, neither of these B. breve strains 
produce propionate in vitro, which suggests that administration of these strains 
may result in an increase in propionate-producing bacteria in the gastrointestinal 
tract. Well-known propionate producers belong to the genera Bacteroides spp., 
Prevotella spp., and Propionibacterium spp. (Hosseini et al., 2011; Schwiertz et al, 
2010). However, because many metabolic properties are shared between lower 
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microbial taxa, it is difficult to link the capacity of producing specific SCFA, such as 
propionate, to the phylogenetic information obtained in the current study 
(Zoetendal et al., 2008). Increases in propionate in the B. breve–fed mice could also 
be due to crossfeeding, in which one bacterial species metabolizes the 
fermentation products of another, thus producing a different end product, a 
common cooperation in a complex microbial community. Indeed, Bifidobacterium 
are known to produce lactate, ethanol, and succinate (Macfarlane & Macfarlane, 
2003; Van der Meulen et al., 2006), all of which could be used as substrates for the 
production of propionate by other bacteria, such as Bacteroides spp., 
Propionibacterium spp., and Clostridium propionicum in a sequential fermentation, 
thus increasing the propionate concentration in the gut (Hosseini et al., 2011; Satms 
at al., 1998).  
In conclusion, our results indicate that the effect of bifidobacteria on host 
fatty acid metabolism is dependent on the strain administered and that strain-
strain differences are important factors that influence the modulation of the gut 
microbial community by ingested microorganisms. Additional studies are needed to 
draw conclusions about the role of specific Bifidobacterium species and strains in 
obesity and weight management. 
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Chapter 5 
Effects of dietary administration of GABA and GABA-
producing bacteria Lactobacillus brevis DPC 6108 on the 
development of diabetes in a streptozotocin rat model 
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5.1 ABSTRACT 
Background: Gamma-aminobutyric acid (GABA) has been shown to attenuate or 
prevent type 1 diabetes (Soltani et al., 2011). GABA-producing bacteria have been 
isolated from several types of food sources (Cho et al., 2006; Komatsuzaki et al., 
2005; Siragusa et al., 2007) and from the human gut (Barrett et al., 2012). 
 Objective: To investigate whether dietary administration of GABA-producing 
Lactobacillus brevis DPC 6108 and pure GABA (as commercial powder) exert 
protective and/or regenerative effects on islet β-cells and reverse diabetes in 
Sprague Dawley rats in which diabetes was induced by streptozotocin (STZ) 
injection. 
Methods: Male Sprague Dawley rats received pure GABA or Lb. brevis DPC 6108 
mixed in the drinking water daily.  In a first experiment, healthy rats were divided in 
3 groups (n=10/group) receiving placebo, 2.6 mg/Kg body weight (BW) pure GABA 
or Lb. brevis DPC 6108 (~109 microorganisms) and differences in body weight, 
serum glucose and insulin, corticosterone, liver cholesterol and brain amines were 
accessed. Animals were also tested for anxiety and depressant-like behaviours. In a 
second experiment, rats (n=15/group) were randomized to five groups and 4 of 
these received an injection of STZ to induce type 1 diabetes while the fifth (non-
diabetic control) group received injection of citrate buffer vehicle only. Diabetic and 
non-diabetic control groups received placebo [4% (w/v) yeast extract in dH2O], 
while the other three diabetic groups received one of the following dietary 
supplements: 2.6 mg/Kg BW GABA (low GABA), 200 mg/Kg BW GABA (high GABA) 
or ~109 Lb. brevis DPC 6108 bacterial cells. Serum samples were analysed for 
glucose, triglycerides, cholesterol, insulin, glucagon, c-peptide, peptide YY (PYY), 
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active glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and 
leptin, circulating GABA, and stress hormones (corticosterone and melatonin). Liver 
samples were analysed for cholesterol and triglycerides. Open field, forced swim 
test and elevated plus maze behavioural tests were performed to evaluate anxiety 
and anti-depressants effects. 
Results: Lb. brevis DPC 6108 supplementation was associated with increased serum 
insulin levels (p<0.05), but did not alter other metabolic markers in healthy animals. 
Moreover, healthy animals receiving GABA or Lb. brevis DPC 6108 were less anxious 
in comparison with placebo control group, whereas rats receiving the GABA 
treatment displayed a depressant-like behaviour during the forced swim test. GABA 
powder and Lb. brevis DPC 6108 supplementation did not change brain 
monoamines levels in healthy rats. Diabetes induced by STZ injection decreased 
body weight, increased intestinal length and stimulated water and food intake and 
these features were not altered by dietary GABA or Lb brevis DPC 6108 
administration. Moreover, corticosterone levels were increased in diabetic rats 
(p<0.05) when compared to non-diabetic rats and levels were not normalized by 
GABA or Lb. brevis DPC 6108 supplementation. Insulin and c-peptide levels were 
significantly decreased (p<0.05), whereas glucose (p<0.001) was increased in all 
diabetic groups when compared with the non-diabetic control group. However, a 
significant decrease (p<0.01) in glucose levels was observed in diabetic rats 
receiving Lb. brevis DPC 6108 when compared with the diabetic-control group. STZ-
induced diabetic rats were more anxious compared to non-diabetic rats, but dietary 
intervention with Lb. brevis DPC 6108 or GABA did not alter this. 
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Conclusions: Lb. brevis DPC 6108 attenuated high levels of glucose cause by 
diabetes, but additional studies are needed to understand the mechanisms involved 
in this reduction. Furthermore, as GABA protective effect may be primarily due to 
modulation of inflammatory response, animal models of auto-immune-induced 
diabetes may constitute better models for studying this type of treatment than 
single-high-dose STZ injections in rats.  
 
5.2 INTRODUCTION 
Type 1 diabetes (T1D) is a chronic and progressive disorder in which 
genetically susceptible individuals may develop an autoimmune response leading to 
pancreatic β-cell damage and insulin insufficiency (Atkinson and Einsenbarth, 2001). 
T1D is associated with complications such as diabetic nephropathy, retinopathy and 
neuropathy (Ahmadpour, 2012; Vujicic et al., 2012), and may exert deleterious 
effects on structure and functions of the brain (Huang et al., 2012; Northam et al., 
2009).  
Insulin administration is the main therapeutic strategy for T1D and, although 
there have been improvements in treatment, achieving euglycaemia without risk of 
severe hypoglycaemia is difficult and requires strict control of glucose levels 
(Atkinson & Eisenbarth, 2001). Evidence indicates that the most effective 
interventions involve the early treatment of individuals, when the β-cell mass is not 
damaged and the accuracy for disease prediction is low. However, this type of 
preventive therapy would have to be safe and benign as some individuals 
diagnosed at such early stage might never develop T1D (Atkinson & Eisenbarth, 
2001). Another approach involves the identification of endogenous growth factors 
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that could stimulate the regeneration and expansion of residual β-cells after T1D 
onset (Bosi 2010). Among those, incretin-based agents have been shown to 
promote β-cell proliferation and inhibit apoptosis, delaying the onset of T1D in 
rodents (Drucker 2006; Hadjiyanni et al., 2008). However, although this type of 
treatment is safe and effective in patients with type 2 diabetes (T2D), it does not 
prevent the autoimmune process seen in T1D (Bosi 2010). On the other hand, 
gamma-aminobutyric acid (GABA) may constitute a very effective therapy for T1D. 
In a study conducted by Soltani et al. (2011), injections of GABA not only promoted 
β-cells proliferation, but also inhibited immune responses, reversing the disease in 
severely diabetic mice. 
GABA is the major inhibitory neurotransmitter in the central nervous system 
(CNS) and plays a role in the sensation of pain and anxiety. In peripheral tissues, 
GABA acts not only as a neurotransmitter in the enteric and parasympathetic 
nervous system but also as a hormone in non-neuronal tissues (Erdo, 1992). In the 
endocrine pancreas, GABA is produced by β-cells and once released, activates 
GABAA and GABAB receptors in both α- and β-cells (Bonaventura et al., 2007; Dong 
et al., 2006). Through a paracrine signal, GABA released from β-cells inhibits 
glucagon release from α-cells (Bailey et al., 2007), whereas an autocrine signal 
increases or decreases insulin secretion from β-cells, depending on extracellular 
glucose levels (Dong et al., 2006). 
GABA is produced through the conversion of L-glutamate by the enzyme 
glutamate decarboxylase (GAD) and is widely distributed in nature, from single cell 
microorganisms to plants and animals (Ueno, 2000). GABA has been found in 
different types of bacteria and its synthesis is believed to be a response to adverse 
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conditions such exposure to acidic environments (Jung & Kim, 2003; Sanders et al., 
1998). Indeed, potential probiotic bacteria isolated from different food sources 
(Cho et al., 2006; Komatsuzaki et al., 2005; Siragusa et al., 2007) and from the 
human gastrointestinal tract (Barrett et al., 2012) can efficiently convert glutamate 
to GABA in vitro.  
A disturbed microbiota has been shown to be a potential environmental 
factor contributing to metabolic diseases, affecting the immune system and even 
influencing the perception of pain and animal behaviour (Brown et al., 2011; Cryan 
and Dinan, 2012; Lam et al., 2011). Interestingly, the use of dietary strategies such 
as probiotics and prebiotics may be effective for the alleviation of these disorders 
by the inhibition of pathogens growth, attenuation of immune responses (Saulnier 
et al., 2009), modulation of brain function and behaviour (Bravo et al., 2011) and by 
the production of bioactive compounds that may have a direct or indirect action on 
the host’s metabolism (Lyte, 2011). Thus, considering the role of GABA on glucose 
homeostasis and the evidence showing how probiotics may affect host’s health, we 
investigated the impact of oral administration of pure GABA and GABA-producing 
bacteria Lactobacillus brevis DPC 6108 on the prevention or alleviation of 
streptozotocin (STZ)-induced diabetes in rats. Furthermore, we explored the 
behavioural changes caused by such treatments on healthy and STZ-induced 
diabetic animals. 
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5.3 MATERIALS AND METHODS 
Animals 
All experimental procedures were carried out in accordance with the 
protocols approved by the University College Cork Ethics Committee, under a 
license issued from the Department of Health and Children. Male Sprague Dawley 
rats, 5 weeks of age, were obtained from Harlan UK and housed under barrier-
maintained conditions. All animals were allowed to acclimate for one week in the 
housing facility before the experiments. Animals were group-housed, with 5 
animals per cage at standard conditions (room temperature of 21°C, with a 12-h 
light–dark cycle, lights on at 07:00). All groups were fed ad libitum with Teklad 
Global rodent standard diet (#2018S; Harlan Laboratories) and allowed free access 
to water. Water containing either Lactobacillus brevis DPC 6108, GABA (Sigma) 
and/or placebo freeze-dried powder was the only water supply provided to the 
animals throughout the experiments. Bottles were replaced daily. Two experiments 
were conducted in this study – Experiment 1 using healthy rats and Experiment 2 
using streptozotocin-induced diabetic rats. 
 
Lactobacillus brevis DPC 6108 and placebo preparation  
Lb. brevis DPC 6108 is an efficient GABA producer, with maximum 
conversion in vitro when growing on MRS broth supplemented with 30 mg/mL 
monosodium glutamate (MSG) (Barrett et al, 2012). Rifampicin-resistant variants of 
Lb. brevis DPC 6108 were isolated by spread-plating ~109 CFU (colony forming units) 
from an overnight culture onto MRS agar (Difco Laboratories) containing 500 µg 
rifampicin/mL (Sigma) and stocked at -80oC. Before freeze-drying, frozen stocks 
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were plated in MRS agar, and then inoculated in small aliquots of fresh MRS broth 
supplemented with 30 mg/mL MSG and incubated overnight at 37oC under 
anaerobic conditions. The overnight culture aliquots were then inoculated into 
large volumes of MRS containing MSG and allowed to grow overnight at 37oC under 
anaerobic conditions. The overnight culture was washed twice in phosphate 
buffered saline (Sigma) and the pellet resuspended in 15% (w/v) trehalose (Sigma) 
in dH2O (Experiment 1) or 4% (w/v) yeast extract (Difco Laboratories) in dH2O 
(Experiment 2). One-millilitre aliquots of bacterial culture were freeze-dried by 
using a 24-h program (freeze temperature, -40oC; condenser set point, -60oC; 
vacuum set point, 600 mTorr). Vials containing one millilitre of placebo solution 
(15% (w/v) trehalose or 4% (w/v) yeast extract) were freeze-dried using the same 
program. All the vials containing freeze-dried powder were stored at -20oC until 
use. Each animal that received the bacterial strain consumed ~1 x 109 live 
microorganisms/day. This was achieved by resuspending appropriate quantities of 
freeze-dried powder in water, which rats consumed ad libitum. The groups that did 
not receive the bacterial strain received placebo freeze-dried powder [15% (w/v)  
trehalose or 4% (w/v) yeast extract in dH2O]. Freeze-dried powder underwent 
continuous quality control of cell counts for the duration of the experiments by 
plating serial dilutions on MRS agar supplemented with 100 µg/mL rifampicin and 
incubating plates anaerobically for 48 h at 37oC.  
 
Faecal sample microbial analysis and GABA production assay 
Fresh faecal samples were taken every week for microbial analysis in order 
to verify if the strain survived gut transit, animals were receiving enough bacterial 
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cells and there was cross-contamination in the groups not receiving the strain. 
Microbial analysis involved enumeration of the Lb. brevis DPC 6108 strain after 
plating serial dilutions on MRS agar supplemented with 100 µg rifampicin/mL 
(Sigma) and incubating anaerobically for 48 h at 37oC. In addition, isolated colonies 
were tested for GABA production as described previously (Barrett et al., 2012). 
Briefly, isolated colonies were grown anaerobically in MRS containing 3% (w/v) 
MSG at 37oC for 55 h. Samples were then deproteinized by mixing equal volumes of 
24% (w/v) trichloroacetic acid (TCA) and culture, allowed to stand for 10 min and 
centrifuged at 14000 x g for 10 min. Supernatants were removed and diluted with 
0.2 mol/L sodium citrate buffer, pH 2.2 to yield 250 nmol of each amino acid 
residue. Samples were then diluted with the internal standard, norleucine, to give a 
final concentration of 125 nm/mL. Amino acids were quantiﬁed using a Jeol JLC-
500/V amino acid analyzer (Jeol Ltd, Garden City, Herts, UK) ﬁtted with a Jeol Na+ 
high-performance cation exchange column. 
 
Experiment 1: Effects of GABA powder and Lb. brevis DPC 6108 on healthy rats 
Animals were divided in 3 groups with 10 rats each, receiving either GABA 
(2.6 mg/Kg BW + 15% w/v trehalose), Lb. brevis DPC 6108 (~109 cells in 15% w/v 
trehalose) or placebo (15% trehalose) mixed in the drinking water for 5 weeks. All 
groups received 15% (w/v) trehalose as this solution was used as cryoprotectant 
while freeze-drying Lb. brevis DPC 6108. The standard diet used contained 3.4% 
(w/w) glutamic acid in its composition and was sufficient substrate for the 
conversion to GABA by Lb. brevis DPC 6108 (Barrett et al., 2012). Body weight was 
assessed weekly. After 5 weeks dietary intervention, animals were sacrificed by 
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decapitation and blood samples were collected, allowed to clot at 4oC, centrifuged 
for 20 min at 2 000 x g and the serum collected into clean microtubes. The brain 
was rapidly removed from the cranium and dissected out on an ice-cold plate into 
the following areas: amygdala, brain stem, cerebellum, cortex, hippocampus, 
striatum and hypothalamus. These brain regions were weighed and placed in 1.5-
mL tubes, which contained 1 mL of chilled homogenizing high performance liquid 
chromatography (HPLC) buffer spiked with an internal standard (n-methyl 5-HT). 
Liver was removed and flash-frozen on dry ice. All samples were stored at -80oC 
prior to analysis. 
 
Experiment 2: Effects of GABA powder and Lb. brevis DPC 6108 on streptozotocin-
induced diabetic rats 
Animals were divided in 5 groups with 15 rats each: non-diabetic control 
group and diabetic control group received only placebo freeze-dried powder [4% 
(w/v) yeast extract], diabetic low dose GABA group received 2.6 mg/Kg BW GABA 
powder, diabetic high dose GABA group received 200 mg/Kg BW GABA powder, and 
diabetic Lb. brevis DPC 6108 group received ~109 bacterial cells in 4% (w/v) yeast 
extract. GABA, Lb. brevis DPC 6108 and placebo freeze-dried powders were diluted 
in fresh drinking water every day during the 9 weeks trial. Every group received 4% 
(w/v) yeast extract as this solution was used as cryoprotectant while freeze-drying 
Lb. brevis DPC 6108. On experimental week 3, type 1 diabetes was induced in rats in 
four of the groups by intraperitoneal injection with a single dose of 60 mg/kg 
streptozotocin (STZ; ≥ 75% α-anomer basis; Sigma) freshly prepared in 50 mM 
sodium citrate buffer (pH 4.5) and injected within 10 to 15 min after dissolving, 
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according to a previously described procedure (Wu and Huan, 2008). Non-diabetic 
control group received an injection of citrate buffer. After 7 days of STZ-injection, 
glucose level was measured in triplicate using a Contour Next blood glucose meter 
(Bayer) in blood samples collected from a tail vein. Rats with glucose levels higher 
than 200 mg/dL were considered diabetic and STZ-induced rats that had lower 
glucose level were excluded. From a total of 60 rats treated with STZ, three died 1-2 
days after injection, whereas ten rats did not develop diabetes and were excluded. 
In the remaining 47 animals, body weight and glucose levels were assessed weekly, 
before and after inducing diabetes. After 9 weeks of dietary intervention animals 
were killed by decapitation and blood samples were collected, allowed to clot at 
4oC, centrifuged for 20 min at 2000 x g and the serum collected into clean 
microtubes. Liver was removed and flash-frozen on dry ice. All samples were stored 
at -80oC prior analyses. 
 
Brain monoamine analysis 
 Neurotransmitter concentrations were determined using a modification of 
a previously described procedure (O’Mahony et al., 2008). Samples were sonicated 
in homogenising buffer which consisted of mobile phase spiked with 2ng/20ul of 
the internal standard N-Methyl 5-HT (Sigma). The mobile phase contained 0.1 M 
citric acid, 0.1 M sodium dihydrogen phosphate, 0.01 mM EDTA (Alkem/Reagecon, 
Cork), 5.6 mM octane-1-sulphonic acid (Sigma) and 9% (v/v) methanol 
(Alkem/Reagecon), and was adjusted to pH 2.8 using 4 N sodium hydroxide 
(Alkem/Reagecon). The homogenates were centrifuged for 20 min at 14 000 x g 
with the temperature maintained at 4°C and 20 μl of the supernatant injected onto 
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the HPLC system. The system included SIL-10A autoinjector (with sample cooler 
maintained at 40C), LC-10AS pump, SCL 10-Avp system controller, CTO-10A oven, 
LECD 6A electrochemical detector (Shimadzu) and an online Gastorr Degasser (ISS, 
UK). A reverse-phase column (Kinetex 2.6 u C18 100 x 4.6 mm, Phenomenex) 
maintained at 30oC was employed in the separation at a flow rate of 0.9 ml/min, 
the glassy carbon working electrode combined with an Ag/AgCl reference electrode 
(Shimdazu, Japan) was operated a +0.8V and the chromatograms generated were 
analysed using Class-VP 5 software (Shimadzu). The neurotransmitters were 
identified by their characteristic retention times as determined by standard 
injections which were run at regular intervals during the sample analysis. 
Analyte/Internal standard peak height ratios were measured and compared with 
standard injections and results were expressed as ng of neurotransmitter per g 
fresh weight of tissue (O’Mahony et al. 2008). 
 
Serum analyses  
Commercial kits were used for measurement of GABA, metabolic markers 
and stress hormones in serum. GABA was determined using the GABA research 
ELISA kit (Invitech Ltd, UK). Glucose was determined using the QuantiChrom glucose 
assay (BioAssay Systems, Hayward, CA), triglycerides measured by using EnzyChrom 
Triglyceride Assay kit (BioAssay Systems) and cholesterol using LabAssay 
Cholesterol kit (Wako, Japan). Insulin, glucagon, c-peptide, peptide YY (PYY), active 
glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and leptin were 
measured using Rat Metabolic Hormone Magnetic Bead Panel (Merck Millipore, 
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Germany). Corticosterone and melatonin were measured using Rat Stress Hormone 
Magnetic Bead Panel (Merck Millipore). 
 
Liver analyses 
Hepatic lipids were extracted according to the method of Folch et al. (1957). 
After extraction, samples were dried under a stream of nitrogen and resuspended 
in 5% (v/v) solution of Triton X-100 in distilled water). Triglycerides concentration 
was determined using the commercial kit EnzyChrom Triglyceride Assay (BioAssay 
Systems) and cholesterol using LabAssay Cholesterol kit (Wako). 
 
Behavioural tests 
Behavioural tests were undertaken at end of Experiment 1 and along the 
course of Experiment 2 after STZ-injection. Open Field and Elevated Plus Maze 
(EPM) tests were included, as indicators of anxiety and locomotor activity. The 
Forced Swim Test (FST) was included to evaluate anti-depressants effects. The FST 
and the open field test were conducted in both Experiment 1 and 2. EPM was 
conducted only in Experiment 2. 
 
Forced Swim Test (FST) 
The modified forced swim test was conducted as previously described 
(Bissiere et al., 2006, Cryan et al., 2002, Cryan et al., 2005a and Cryan et al., 2005b). 
The rats were placed individually in 21 cm × 46 cm Pyrex cylinders filled to a 30 cm 
depth with 23–25°C water. Two swimming sessions were conducted: a 15 min pre-
test followed by a 5 min test 24 h later. After 15 min on day 1, the rats were 
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removed, towel dried and placed back in their home cage. The water in each 
cylinder was changed between animals. Twenty-four hours after their first 
exposure, rats were placed back in the swim apparatus for 5 min and a video 
camera positioned above the cylinders was used to monitor and record behaviour 
for subsequent analysis. The total duration of predominant behaviour in each 5 s 
period of the 300 s test was scored on day 2. Swimming, immobility and active 
climbing were the main behaviours scored with swimming described as horizontal 
movements throughout all 4 quadrants of the cylinder, climbing was defined as 
vigorous fore-paw movements directed toward the walls of the apparatus and 
immobility defined as floating, with only enough movement necessary for the rat to 
keep its head above water (see Cryan et al., 2002 for pictorial representations). The 
experiments were analysed by an observer blind to the experimental conditions. 
 
Open field  
The open field test was performed as previously described (O'Mahony et al., 
2009). Briefly, the open field consisted of a circular white arena, 90 cm in diameter, 
40 cm in height, 900 lux light. Testing was conducted between 9:00 a.m. and 1:00 
p.m. At the beginning of each trial, animals were placed gently into the centre of 
the arena and allowed to explore the arena for 10 min. The behaviour of the 
animals was recorded by an overhanging camera that was attached to a personal 
computer. Ethovision 3.1 (Noldus, The Netherlands) was used to track the 
movement of the animals. The total distance moved in the arena, time spent and 
distance moved in the inner zone of the arena were recorded. When rats are 
anxious they usually display freezing behaviour and stay close to the sides of the 
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arena, which will result in a reduction in the amount of time spent in the brightly lit 
inner zone and distance travelled.  
 
Elevated Plus Maze (EPM) 
Animals were acclimatized to the testing room for 30 min prior to testing. 
Animals were placed one at a time in a novel maze for 5 min. The maze consisted of 
two open arms and two closed arms (24 inches in height), elevated to a height of 28 
inches. Animals were placed in the centre of the maze facing an open arm to begin. 
Behaviour was videotaped for the duration of the test. Frequency of entry and time 
spent in each of the open and closed arms entries were scored. 
 
Statistical analysis 
To assess whether differences between treatment groups were significant, 
statistical analysis was performed by using one factor ANOVA followed by Tukey’s 
or Dunnett’s post hoc multiple comparison tests (Graph-Pad Software, San Diego, 
CA, USA). Treatment effects with p<0.05 were considered significant. Data in the 
text, tables, and figures are presented as mean values plus minus standard error of 
the mean (SEM). 
 
5.4 RESULTS 
Lb. brevis DPC 6108 survived the transit through the rat gastrointestinal tract 
Quantification of the numbers of the administered rifampicin-resistant Lb. 
brevis strain in the faeces of rats confirmed its survival during gastrointestinal 
transit. Stool recovery of Lb. brevis DPC 6108 was ~ 1.1 x 107 CFU/g faeces after 1 
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week of feeding and remained at similar numbers until the end of experiments. 
Colonies isolated from the plates were tested for GABA production in order to 
assess if gut transit affected the strain for GABA production. All such colonies tested 
produced similar amounts of GABA in vitro when compared to the wild type strain 
(data not shown). There was no cross-contamination between groups as Lb. brevis 
DPC 6108 was not detected in the stool of rats not receiving the strain.  
 
EXPERIMENT 1  
Lb. brevis DPC 6108 increased insulin serum levels but did not alter other 
metabolic markers in healthy animals 
After 5 weeks supplementation with Lb. brevis DPC 6108, there were no 
differences in body weight gain between groups (data not shown) and final body 
weight, liver cholesterol, basal corticosterone and serum glucose. However, serum 
insulin levels were increased (p<0.05) in rats receiving Lb. brevis DPC 6108, when 
compared with rats in the GABA and control groups (Table 5.1).  
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Table 5.1 Final body weight and metabolic markers concentrations in healthy rats 
receiving GABA powder, Lb. brevis DPC 6108 or placebo for 5 weeks 
 
Control GABA 
Lb. brevis 
DPC 6108 
Final body weight (g) 385.2 ± 9.7 380.5 ± 10.1 378.3 ± 6.7 
Glucose (mg/dL) 99.1 ± 4.8 94.3 ± 5.0 104.1 ± 7.2 
Insulin (ng/mL) 1.51 ± 0.19a 1.52 ± 0.19a 2.55 ± 0.35b 
Liver cholesterol (mg/g) 1.88 ± 0.15 2.16 ± 0.22 1.71 ± 0.13 
Corticosterone (ng/mL) 12.6 ± 3.0 12.1 ± 2.0 34.3 ± 10.6 
All values are means ± SEMs. Values in the same row with different superscript letters are significantly 
different, p<0.05 (ANOVA followed by post hoc Tukey’s multiple comparisons tests).  
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GABA and Lb brevis DPC 6108 supplementation did not change brain monoamines 
levels  
The monoamines noradrenaline (NA), dopamine (DA), serotonin (5-HT), and 
the monoamine metabolites 3, 4-dihydroxyphenylacetic acid (DOPAC), homovanillic 
acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) were measured in the cortex, 
hippocampus, amygdala, striatum, hypothalamus, cerebellum and brain stem. 
GABA and Lb. brevis DPC 6108 supplementation did not affect the levels of 
monoamines or their metabolites in any of the brain regions analysed. In addition, 
there were no differences in DOPAC/Dopamine, HVA/Dopamine and 5-HIAA/5-HT 
turnover ratios when comparing the treatments to the control (Table 5.2).
 Table 5.2  Brain concentrations (ng/g) of monoamines and their metabolites in the brain of healthy rats receiving  GABA powder, Lb. brevis DPC 
6108 or placebo for 5 weeks 
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GABA and Lb. brevis DPC 6108 interventions have an anxiolytic effect in healthy 
animals 
In the Open Field test, no differences in total distance moved by the animals 
were found, but significantly (p<0.05) higher time was spent by animals in the GABA 
group in the inner zone, and data approaching significance were recorded for the L. 
brevis DPC 6108 group (p=0.0511), compared with unsupplemented control group, 
suggesting an anxiolytic-like effect in the former two groups, compared with the 
latter group. The pre-swim results demonstrated no differences between any of the 
groups in immobility, swimming or climbing. However, the FST on day 2 revealed 
significant increase in immobility in the GABA treated group compared with control 
animals indicating depressant-like activity (Fig. 5.1). 
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Open Field 
 
 
 
Forced Swim Test 
 
 
 
Figure 5.1 Effects of GABA powder (2.6 mg/Kg BW) and Lb. brevis DPC 6108 
on behaviour of healthy animals (Experiment 1). Mean ± SEM (n=10) 
*p<0.05, **p<0.01, #p=0.051; One-way ANOVA followed by Dunnett's 
Multiple Comparison Test. 
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EXPERIMENT 2 
GABA and Lb brevis DPC 6108 supplementation did not alter changes in body 
weight, small intestine length, water and food intake induced by diabetes  
After STZ injection, animals that developed diabetes lost body weight 
continuously until the end of the experiment. Final body weight was significantly 
reduced in all diabetic animals including the diabetic control group and treatment 
groups, when compared with non-diabetic controls (p<0.001). Dietary 
supplementation with GABA and Lb. brevis DPC 6108 did not improve weight gain in 
diabetic animals. The abdomens of diabetic animals were distended, filled with a 
swollen intestine, and the small intestinal length significantly increased when 
compared to intestines of non-diabetic rats (p<0.001). Moreover, mean daily food 
and water intakes were significantly higher in diabetic rats when compared with 
rats non-diabetic control group (p<0.001) with no differences between treatments 
(Table 5.3). Diabetic rats exhibited polyuria and excessive faecal output (data not 
shown). 
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Table 5.3 Final body weight, small intestine length, food and water intake after STZ 
injection  
 Non-diabetic 
Control 
Diabetic 
Control 
Low 
GABA 
High 
GABA 
L. brevis 
DPC 6108 
Final body weight  
(g) 
372.6 ± 7.5a 247.0 ± 5.6b 246.3 ± 8.4b 247.2 ± 5.8b 238.7 ± 8.0b 
Small intestine length 
(cm) 
98.6 ± 2.8
a
 129.4 ± 4.0
b
 133.8 ± 4.6
b
 135.7 ± 3.7
b
 132.2 ± 4.7
b
 
Average food intake 
(g/100g BW) 
6.0 ± 0.1a 14.3 ± 0.4b 12.8 ± 0.6b 13.6 ± 0.4b 12.7 ± 0.5b 
Average water intake 
(mL/100g BW) 
12.1 ± 1.1a 72.2 ± 2.5b 68.7 ± 1.9b 66.3 ± 2.0b 62.6 ± 3.9b 
All values are means ± SEMs. Values in the same row with different superscript letters are significantly  
different, p<0.05 (ANOVA followed by post hoc Tukey’s multiple comparisons tests).  
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Supplementation with high doses of GABA increased GABA levels in serum 
Serum analysis results revealed a significant increase in GABA levels in the 
diabetic rats receiving a high dose of GABA (200 mg/Kg BW) relative to animals 
treated with lower dose of GABA, Lb. brevis DPC 6108 and both diabetic and non-
diabetic controls (p<0.05; Table 5.4). 
 
Lb. brevis DPC 6108 reduced serum glucose levels in diabetic rats but did not alter 
other metabolic markers 
Serum glucose levels were significantly increased in all diabetic groups when 
compared with the non-diabetic control group (p<0.001). However, lower glucose 
levels were observed in rats receiving Lb. brevis DPC 6108 supplementation relative 
to rats in the diabetic control group (p<0.01). Insulin and c-peptide levels were 
significantly decreased, whereas glucagon was increased in all diabetic groups when 
compared with the non-diabetic control group (p<0.05; Table 5.4). GLP-1 and GIP 
serum levels were not different between treatments. PYY was 4- to 5-fold higher in 
diabetic rats when compared with non-diabetic rats (p<0.05), with no differences 
between treatments. As expected, due to the lower adipose tissue mass in diabetic 
rats (data not shown), leptin levels were significantly decreased in all diabetic 
groups compared with the non-diabetic control group (p<0.001; Table 5.4). 
 
Lb. brevis DPC 6108 and high dose GABA increased serum cholesterol in diabetic 
rats  
Serum cholesterol was significantly higher in rats supplemented with Lb. 
brevis DPC 6108 and the high GABA dose when compared with rats in the diabetic 
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and non-diabetic control groups (p<0.05), whereas no differences in liver 
cholesterol were observed between groups. Moreover, serum and liver triglycerides 
were significantly higher in diabetic groups compared with non-diabetic control 
(p<0.05), but there was no differences between treatments (Table 5.4). 
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Table 5.4 Metabolic markers concentrations in non-diabetic rats and diabetic rats 
receiving GABA powder, Lb. brevis DPC 6108 or placebo for 9 weeks 
 Non-diabetic 
Control 
Diabetic  
Control 
Low 
GABA 
High 
GABA 
L. brevis 
DPC 6108 
Serum GABA (ng/mL) 144.1 ± 9.8a 145.0 ± 2.9a 157.7 ± 9.4a 195.1 ± 7.7b 137.4 ± 9.4a 
      
Glucose  
(mg/dL) 
125.8 ± 5.9a 579.5 ± 34.3b 513.9 ± 28.7b,c 508.6 ± 23.8b,c 444.5 ± 18.6c 
Insulin  
(ng/mL) 
1.45 ± 0.10a 0.12 ± 0.02b 0.13 ± 0.03b 0.19 ± 0.05b 0.11 ± 0.03b 
Glucagon  
(pg/mL) 
9.0 ± 3.2a 24.1 ± 1.8b 24.0 ± 3.7b 26.3 ± 3.8b 31.2 ± 3.8b 
C-peptide  
(ng/mL) 
1.23 ± 0.13
a
  0.20 ± 0.02
b
 0.21 ± 0.02
b
 0.23 ± 0.03
b
 0.19 ± 0.02
b
 
PYY 
(pg/mL) 
38.5 ± 4.3a 167.5 ± 30.3b 150.8 ± 10.0b 186.7 ± 22.9b 185.5 ± 33.7b 
GLP-1  
(pg/mL) 
80.5 ± 17.2 182.3 ± 41.4 113.5 ± 21.0 170.5 ± 20.8 151.9 ± 17.3 
GIP 
 (pg/mL) 
275.5 ± 37.1 230.5 ± 29.9 196.2 ±25.1 227.0 ± 42.9  237.7 ± 40.2 
Leptin  
(ng/mL) 
1.38 ± 0.20a 0.07 ± 0.01b 0.06 ± 0.01b 0.08 ± 0.01b 0.06 ± 0.01b 
      
Serum cholesterol 
(mg/dL) 
58.2 ± 3.0a 63.7 ± 3.4a 68.1 ± 6.0a 103.4 ± 13.4b 90.0 ± 7.4a 
Liver cholesterol 
(mg/g) 
1.81 ± 0.06 1.92 ± 0.06 1.81 ± 0.08 1.79 ± 0.05 1.94 ± 0.08 
Serum triglycerides 
(mg/dL) 
155.8 ± 9.1
a
 712.8 ± 87.1
b
 634.8 ± 106.3
b
 1034.5 ± 127.2
b
 1013.5 ± 114.9
b
 
Liver triglycerides 
(mg/g) 
1.83 ± 0.08a 5.38 ± 0.31b 5.10 ± 0.21b 5.30 ± 0.14b 5.46 ± 0.28b 
All values are means ± SEMs. Values in the same row with different superscript letters are significantly 
different, p<0.05 (ANOVA followed by post hoc Tukey’s multiple comparisons tests).  
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Lb. brevis DPC 6108 and GABA supplementation did not attenuate increase in 
corticosterone levels induced by diabetes  
Increased basal levels of serum corticosterone were found in diabetic rats 
when compared with non-diabetic rats (p<0.05), with no differences between 
treatments. Melatonin was increased in diabetic rats with a significant difference in 
the diabetic control group when compared with the non-diabetic control group 
(p<0.05; Table 5.5). 
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Table 5.5 Stress hormones concentrations in non-diabetic rats and diabetic rats 
receiving GABA powder, Lb. brevis DPC 6108 or placebo for 9 weeks 
 
Non-diabetic 
Control 
Diabetic  
Control 
Low  
GABA 
High  
GABA 
L. brevis 
DPC 6108 
Corticosterone 
(ng/mL) 
64.5 ± 11.8a 183.0 ± 23.4b 193.2 ± 20.7b 207.8 ± 29.1b 244.2 ± 14.6b 
Melatonin  
(pg/mL) 
138.7 ± 25.6 a 407.7 ± 104.1b 338.9 ± 38.9 a 373.8 ± 39.2 a 345.0 ± 68.4 a 
All values are means ± SEMs. Values in the same row with different superscript letters are significantly 
different, p<0.05 (ANOVA followed by post hoc Tukey’s multiple comparisons tests).  
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Diabetic rats displayed an anxiety-like behaviour that was not ameliorate by 
GABA or Lb brevis DPC 6108 interventions 
The Open Field test revealed no significant differences between groups in 
either the amount of time spent in the inner-zone or the distance moved in the 
inner zone. A significant reduction in the total distance moved in the arena was 
seen for diabetic-control, diabetic-high GABA and diabetic-L. brevis DPC 6108 
treated groups when compared with the non-diabetic control group (p<0.05). In the 
FST, diabetic L. brevis DPC 6108-treated group spent more time immobile when 
compared with the non-diabetic control group (p<0.05). Results seen in the EPM 
test showed significantly reduced entries into the open arms of all diabetic groups 
when compared with non-diabetic controls (p<0.001). Diabetic control, diabetic-
high GABA and diabetic L. brevis DPC 6108 treated groups spent less time in the 
open arms when compared with the non-diabetic control (p<0.05). Furthermore, 
the diabetic low GABA-treated group had reduced closed arm entries when 
compared to non-diabetic control (p=0.059) and all diabetic groups spent 
significantly more time in the closed arms, when compared with the non-diabetic 
control group (p<0.05) (Fig. 5.2). 
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Open Field 
 
 
Elevated Plus Maze 
 
 
 
Forced Swim Test 
 
 
Figure 5.2 Effects of GABA powder and Lb. brevis DPC 6108 on behaviour of diabetic animals 
(Experiment 2). Mean ± SEM *p<0.05, **p<0.01, ***p<0.001, #p=0.059; One-way ANOVA 
followed by Dunnett's Multiple Comparison Test. 
** ** * ** 
  # 
 *** *** *** *** 
  **  **  ** 
 *** 
 *  * *** 
    * 
 
  
5.5 DISCUSSION 
In the present study, we demonstrated that Lb. brevis DPC 6108 dietary 
intervention for 5 wk significantly increase (69%, p<0.05) serum insulin in healthy 
rats. Leading on from this data, we conducted a second experiment to investigate 
whether dietary GABA and Lb. brevis DPC 6108 would exert protective and/or 
regenerative effects on islet β-cells and reverse diabetes in Sprague Dawley rats in 
which diabetes was induced by streptozotocin-injection. Oral administration of 
GABA and Lb. brevis DPC 6108 for 9 weeks had no effect on the prevention or 
reversion of diabetes induced by streptozotocin on male Sprague-Dawley rats, and 
animals developed an overt basal hypoinsulinemia and extreme hyperglycemia, 
suggesting a drastic decrease in β-cells numbers. Our data support the results 
obtained by Adeghate and Ponery (2002), where pancreas isolated from STZ-
diabetic rats presented a significant decrease in cell mass with concomitant insulin 
depletion that were not restored by GABA treatment. However, they contradict 
studies showing that oral GABA administration attenuated hyperglycemia and 
oxidative stress in STZ-diabetic rats (Nakagawa et al., 2005), whereas GABA i.p. 
injections prevented and reversed high glucose levels caused by multiple low doses 
of STZ in mice (Soltani et al., 2011). GABA therapy was also reported to be 
beneficial in other models of diabetes, such as the non-obese diabetic (NOD) mouse 
model of T1D and high-fat diet (HFD)-fed mouse model of T2D (Soltani et al., 2011; 
Tian, Dang, Kaufman, et al., 2011; Tian, Dang, Yong, et al., 2011). In all these 
studies, the positive GABA effect was related to the modulation of the immune 
response present in diabetes, confirming the anti-inflammatory effects of 
GABAergic agents seen in other models of autoimmune diseases, such as 
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rheumatoid arthritis (Tian, Yong, Dang et al., 2011) and multiple sclerosis (Bhat et 
al., 2010). 
The results obtained in this study further support the hypothesis that the 
beneficial effect of GABA may be primarily due to modulation of immune cell 
function.  In animal models such as the NOD mouse, HFD-induced T2D mouse and 
the multiple low-dose STZ-induced diabetes (MDSD) mouse, pancreatic islets are 
partially damaged and the inflammatory process causes the further loss of β-cells. 
On the other hand, the procedure commonly applied in rats and used in this study 
induces T1D with one single dose of STZ, destroying the β-cells rapidly and 
completely, with absence of an immune response (Wu and Huan, 2008). In this 
case, GABA administration may have no effect, as there is no immune response to 
be attenuated. However, beside its anti-inflammatory effect, evidence suggest that 
GABA may stimulate β-cell replication and inhibit apoptosis in vitro (Soltani et al., 
2011) and in vivo (Tian et al., 2013), if a sufficient residual islet mass is present to 
permit the recovery.  In this study, the extremely high levels of glucose and low 
levels of insulin and c-peptide in diabetic animals indicate an extensive loss of β-cell 
mass that could not be reversed by dietary GABA. While STZ is known to be a highly 
selective β-cells cytotoxic agent, not affecting the other pancreatic islet cells, a large 
variation is observed between studies related to the extension of β-cell mass 
destruction and, consequently circulating levels of glucose and insulin. Several 
factors may interfere with STZ toxicity, such as animal age, sex, species and strain 
(Abeeleh et al., 2009; Blondel et al., 1989; Deeds et al., 2011; Wu and Huan, 2008). 
Furthermore, the preparation of STZ solution recommended by most protocols and 
used in this study seems to be inappropriate, leading to considerable 
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interexperimental variation. Following the protocol, STZ solution should be 
prepared fresh each time and injected within 5 min of being dissolved. However, 
STZ occurs in two anomeric forms, the ratio of α to β anomer varies considerably 
between lots, and freshly prepared solutions are unstable and may contain higher 
concentrations of the more toxic α anomer. Thus, diabetes induction using 
solutions prepared few hours before the injections instead of freshly prepared may 
be a better alternative, allowing anomeric equilibrium and yielding more uniform 
and reproducible results (Garza-Rodea et al., 2010).  
Previous studies investigating the benefits of probiotic administration in 
STZ-diabetic animals showed contrasting results on glucose homeostasis-related 
outcomes. Davari et al. (2013) and Lin et al. (2013) reported a significant decrease 
in glucose levels in animals receiving probiotic in relation to diabetic controls, as 
was seen in this study. Tabuchi et al. (2003) and Yadav et al. (2008) observed an 
improvement in glucose tolerance, whereas Zarfeshani et al. (2011) found no 
significant differences in blood glucose levels in the probiotic supplemented group. 
Increased serum insulin levels in probiotic-fed groups were demonstrated only in 
the studies by Davari et al. (2013) and Tabuchi et al. (2003). Although we observed 
a significant increase in serum insulin levels in healthy rats receiving Lb. brevis DPC 
6108 (Experiment 1; 69%, p<0.05), the same was not seen in diabetic rats in 
Experiment 2, most likely because the β-cell mass was considerably destroyed and 
could not be stimulated. However, although administration of Lb. brevis DPC 6108 
did not affect serum glucose levels in healthy animals, it caused a significant 
decrease in glucose levels in diabetic rats when compared with  diabetic controls 
(23%; p<0.05). The balance between glucose uptake, regulated mainly by the CNS, 
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and glucose production from the liver is complex and involves several mechanisms. 
Leptin has been shown to induce reduction of food intake in diabetic animals, 
lowering plasma glucose levels (Sindelar et al., 1999), and acting in the CNS 
inhibiting hepatic glucose production and increasing glucose utilization by other 
tissues (German et al., 2011). However, food intake and leptin levels were not 
altered in the diabetic group receiving the bacteria when compared to the other 
diabetic groups in the present study. Moreover, the levels of other metabolic 
markers involved in glucose homeostasis such as insulin, glucagon, corticosterone, 
GLP-1 and GIP were similar among all diabetic groups and could not account for this 
reduction in glucose levels in the Lb brevis DPC 6108-fed group. Bacteria produce 
several types of bioactive metabolites which affect the host’s health and, thus, 
there is the possibility that probiotic strains administered in different studies may 
produce compounds that may interfere with glucose homeostasis. For example, α-
glucosidase inhibitors, saccharides used as drugs to modulate glucose absorption in 
the treatment of T2D have been found to be produced by a wide range of marine 
bacteria (Pandey et al., 2013). Other mechanisms that could explain the difference 
in glucose level may be related to increased glucose excretion in the urine, reduced 
hepatic glucose production or increased glucose uptake by tissues. 
GABA released by β-cells has been shown to play a role in regulating 
glucagon secretion from α-cells (Bailey et al., 2007; Bansal et al., 2011). In this 
study, the extensive damage to the β-cell mass caused by STZ most likely reduced 
the amount of endogenous GABA (Adeghate and Ponery, 2002), stimulating 
glucagon release in all diabetic groups. Even though higher level of circulating GABA 
was detected in the diabetic group receiving high dose of GABA, this 
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supplementation did not contribute to glucagon suppression. The increased 
glucagon secretion together with high level of corticosterone and low level of 
circulating insulin seen in all diabetic rats, most likely caused insufficient 
suppression of hormone-sensitive lipase (HSL) activity in the adipose tissue leading 
to hyperglycemia and hypertriglyceridemia. Increased food intake is another 
probable factor that contributed to hypertriglyceridemia. Moreover, high levels of 
corticosterone and glucose may have stimulated hepatic triglyceride production 
leading to the fatty liver observed in diabetic rats (Dallman & Bhatnagar 2011; 
Tamura & Shimomura, 2005). 
The marked hyperphagia observed in diabetic animals has been associated 
with insulin and leptin deﬁciencies and high concentration of corticosterone 
(Dallman & Bhatnagar 2011; Sindelar et al., 1999; Sipols et al 1995). Hyperphagia 
leads to small intestine hypertrophy (Saudek & Young, 1981) as seen in all diabetic 
rats in this study.  With increased intestinal mass, the density of gastrointestinal 
cells also increases, altering gut motility and secretion/absorption (El-Salhy & 
Sitohy, 2001). We observed an increased faecal output and diarrhoea, and 
significantly higher PYY levels in serum in all diabetic groups. In a study by El-Salhy 
(2001), PYY secretion was shown to delay intestinal transit and gastric emptying 
and to be produced in order to reduce diarrhoea. Small intestinal hypertrophy is 
also associated with increased intestinal cholesterol synthesis and absorption in 
diabetes (Feingold, 1989; Gleeson et al., 2000). Interestingly, in this study, serum 
total cholesterol was increased only in diabetic rats receiving high dose of GABA or 
Lb. brevis DPC 6108 when compared with the non-diabetic control. As food intake 
and intestinal length were similar among all diabetic groups as well as hepatic 
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cholesterol levels, the mechanism by which Lb. brevis DPC 6108 and high dose of 
GABA mediated the changes in serum cholesterol observed in the current study is 
unclear and remains to be elucidated. 
In addition to high corticosterone levels, we observed an increase in 
melatonin level in diabetic rats, although the increase was significant only in the 
diabetic control group when compared with the non-diabetic control group. This is 
in agreement with results by Peschke et al. (2008) that showed increased levels of 
melatonin in STZ-induced diabetic rats and, further suggested that this change was 
due to the great reduction in insulin and increase in catecholamines (Peschke et al., 
2012). The group hypothesised that the increased melatonin levels in type 1 
diabetic rats could be a mechanism to protect β-cell mass damage, as melatonin 
has been shown to attenuate oxidative stress caused by STZ treatment (Aksoy et al., 
2003; Yavuz et al., 2003).  
In the present study, we also investigated behavioural effects of GABA and 
Lb. brevis DPC 6108 administration on healthy and diabetic rats.  In the first 
experiment, healthy animals receiving GABA powder or Lb. brevis DPC 6108 were 
less anxious in comparison with placebo control group, whereas rats receiving the 
GABA treatment displayed a depressant-like behaviour during the FST. The 
behavioural changes seen as a result of GABA administration in Experiment 1 in 
healthy rats were not observed in diabetic rats in Experiment 2. STZ-induced 
diabetic rats displayed an anxiety-like behaviour in comparison to non-diabetic rats 
in the open field and the EPM tests, and no differences were observed in rats 
receiving either GABA or Lb brevis DPC 6108. Furthermore, even though diabetic 
rats presented lower weight and appeared to be weaker than non-diabetic controls, 
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no differences were observed between groups in the FST, suggesting that the 
behavioural changes were related to anxiety rather than motor or energy deficits. 
Previous studies have reported the same increase in anxiety in STZ-induced diabetic 
rats and have correlated this behaviour change with altered catecholaminergic and 
serotonergic systems in different brain regions (Ramanathan et al. 1998; Thorré et 
al., 1997). The exacerbated hypothalamo–pituitary–adrenal (HPA) axis activation 
due to excess of corticosterone was another mechanism strongly associated to 
impaired cognitive performance and increased anxiety in rodents (Magariños et al., 
2000; Revsin et al., 2009; Stranahan et al., 2008).  
Diabetes has been associated to decreased neurogenesis, increased 
oxidative stress and demyelination of brain cells with effects on neural excitability 
and brain function (Alvarez et al., 2009; Davari et al., 2013; Malone et al., 2006; 
Suzuki et al., 2011). There are several reports about diabetes-induced neurological 
complications and behavioural/cognitive changes in animal models and humans 
(Reagan, 2012; Roriz-Filho et al., 2009). GABA and probiotic therapies have been 
studied as alternatives to attenuate diabetes metabolic and neurological symptoms 
by a range of different mechanisms. Indeed, GABA administration has been shown 
to affect the brain monoamine system improving the symptoms of depression after 
stress stimulation (Chuang et al., 2011), while GABAergic agents prevented and 
delayed experimental autoimmune encephalomyelitis (EAE) onset in mice by 
decreasing the severity of symptoms through modulation of the immune system 
(Bhat et al., 2010). In a study by Bravo et al. (2011), the strain L. rhamnosus (JB-1) 
was shown to consistently modulate mRNA expression of GABA receptors, exerting 
anxiolytic and anti-depressant effects in a manner dependent on the vagus nerve, 
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whereas Davari et al. (2013) demonstrated that feeding a probiotic mixture 
elevates antioxidant enzymes and protects the brain from cell damage, preventing 
memory impairments and electrophysiological deficits caused by STZ-induced 
diabetes. In this study, GABA or Lb. brevis DPC 6108 administration did not affect 
monoamines and their metabolites in the brain of healthy animals, and the 
elevated basal corticosterone levels observed in diabetic rats were not ameliorated 
by the treatments; therefore, further analyses are required to draw conclusions 
about the mechanisms involved in the anxiolytic and depressant effects seen in 
healthy animals.  
In conclusion, our results indicate that, although the use of GABA and 
probiotics have been shown to be effective in the prevention and attenuation of 
diabetes symptoms, a minimum number of healthy β-cells may be necessary for the 
efficacy of the treatment. Furthermore, as the main mechanism of action of GABA 
seems to be associated with anti-inflammatory activity, future studies using animal 
models of diabetes involving an autoimmune response will likely give better insights 
into the potential effects of GABA and Lb. brevis DPC 6108 on diabetes onset.  
Finally, additional studies are needed to understand the mechanisms involved in 
the glucose lowering effect caused by feeding Lb. brevis DPC 6108 to diabetic rats 
and the roles of GABA and probiotics on animal behaviour. 
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Chapter 6 
Evaluation of dietary bovine milk oligosaccharides versus a 
commercial prebiotic on microbiota composition and 
functionality in mice  
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analysis by gas chromatography. DK performed serum cytokine and caecal 
secretory IgA analysis, faecal pellet preparation for 454 pyrosequencing, and 
contributed to the analysis of sequencing results.   
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6.1 ABSTRACT 
Background: Human milk oligosaccharides exhibit an array of beneficial biological 
functions, including selective promotion of commensal bacteria and anti-adhesive 
activity against various pathogens.  Milk oligosaccharides from animal species are 
currently of potential commercial interest given that they may produce similar 
biological outcomes when ingested.   
Objective: To investigate the effect of dietary bovine milk oligosaccharides, 
6’sialyllactose and the commercial prebiotic, Beneo Orafti P95 oligofructose, on 
murine gut microbiota composition and functionality.  
Method: Animals received bovine milk oligosaccharides, 6’sialyllactose, P95 
oligofructose (1 mg/g body weight) or saline by oral gavage for 21 days. Caecal 
short chain fatty acids were determined by gas chromatography and caecal 
secretory IgA and serum cytokine levels using commercial kits. Faecal microbiota 
composition was assessed by 16S rRNA pyrosequencing, while Bifidobacterium was 
quantified by qPCR.   
Results: Caecal secretory IgA was reduced following treatment with P95 (62%; 
p<0.01) and BMO (61%; p<0.05). P95 and BMO supplementation did not influence 
SCFA content, whereas 6’SL supplementation resulted in reduced levels of butyrate 
by 41% (p<0.01) when compared with unsupplemented control. Moreover, P95 
treatment reduced IL-12 (18.1%; p<0.01) and IL-6 (21.1%; p<0.05) and BMO 
supplementation reduced levels of IL-12 (11.9%; p<0.05) compared with 
unsupplemented control. At phylum level P95 supplementation significantly 
reduced Cyanobacteria (p=0.003), while administration of 6’SL decreased relative 
proportions of Actinobacteria (p=0.017). Bovine milk oligosaccharide 
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supplementation was associated with increased proportion of Candidate division 
TM7 (p=0.002) and decreased proportions of Actinobacteria (p=0.0255) and 
Cyanobacteria (p=0.003) compared to the unsupplemented control. Significant 
changes were also observed at family and genus level when comparing animals 
receiving oligosaccharides supplementation versus unsupplemented animals. 
Overall, P95, BMO and 6’SL supplementations were associated with depletion or 
reduction of less favourable bacteria such as Moraxellaceae, Vibrionaceae and 
Porphyromonaceae. Indigenous Bifidobacterium was not detected in any of the 
groups tested. 
Conclusions: This study highlights the potential of bovine milk oligosaccharides and 
commercial whey streams containing them, as untapped nutritional resources of 
prebiotics for gut microbiota modulation.   
 
6.2 INTRODUCTION 
Oligosaccharides are the third largest solid component of human milk 
following lactose and lipids, with concentrations of 22-24 g/L in colostrum and 12-
13 g/L in mature milk (Urashima et al., 2013).  Human milk oligosaccharides (HMO) 
have been shown to have specific biological functions including prebiotic and anti-
adhesive activity, anti-inflammatory properties, modification of cell surface glycans, 
and modulation of growth-related characteristics of intestinal cells (for reviews see 
Bode, 2006; Hickey, 2009; Kunz & Rudloff, 2006; Newburg et al., 2005). However, 
few in vivo studies exist demonstrating the beneficial effects of HMO ingestion. 
Among these, Fuhrer et al. (2010) demonstrated that milk sialyllactose influences 
colitis in mice through selective intestinal bacterial colonization. Ingestion of milk 
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containing 3’sialyllactose (unaltered or 3’sialyllactose alone) resulted in reduced 
resistance to dextran sulphate sodium (DSS)-induced colitis, which was associated 
with the presence of clostridial cluster IV bacteria. Moreover, Newburg et al. (2004) 
showed that human milk containing higher content of 2-linked 
fucosyloligosaccharides is associated with lower risk of diarrhea in breastfed 
infants, whereas Ruiz-Palacios et al. (2003) demonstrated that fucosylated 
oligosaccharides present in human milk inhibit mice gut colonization with the 
pathogenic bacteria Campylobacter jejuni. 
The several benefits attributed to breast milk are probably related to the 
structural complexity of HMO (Barile & Rastall, 2013). However, there are very few 
commercial products on the market which capitalize on these functions. This is 
mainly due to the fact that large quantities of HMO are required for clinical trials 
and these are not commercially available. In contrast, commercial oligosaccharides, 
including short-chain galactooligosaccharides and long-chain fructooligosaccharides 
(scGOS/lcFOS) are supplemented in certain products such as infant formula, which 
are currently marketed based on prebiotic health claims (Fanaro et al., 2005). 
However, the structure and composition of commercial oligosaccharides differ from 
that of HMO. Many efforts are, therefore, being made to replicate the effects of 
HMO by searching for alternative compounds which may produce similar biological 
outcomes particularly for infant formula applications. 
Little information exists regarding the biological activity associated with 
alternative compounds, such as bovine milk oligosaccharides (BMO), for infant 
formula applications. However, a number of in vitro studies have already shown 
that bovine oligosaccharides possess anti-adhesive activity against certain 
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pathogens (Hakkarainen et al., 2005; Matrosovich et al., 1993; Wang et al., 2001).  
Moreover, studies demonstrated that sialylated oligosaccharides, such as 3’-
sialyllactose and 6’-sialyllactose, which are present in both human and bovine milk, 
are potent inhibitors of pathogen adhesion in the gut (Gopal & Gill, 2000; Lane et 
al., 2010).   
Given the potentially wide availability of BMO from dairy streams and the 
accumulating positive data from in vitro studies on their health-promoting effects, 
their inclusion in functional foods, such as infant formula may be a promising 
dietary strategy. Therefore, the objective of the current study was to assess 
physiological parameters (safety and tolerance) and modulatory effects of dietary 
supplementation with BMO or 6’sialyllactose (6’SL), and their effects on intestinal 
microbiota of healthy mice when compared with the commercial prebiotic fibre, 
Beneo Orafti P95 oligofructose (P95) and an unsupplemented control. 
 
6.3 MATERIALS AND METHODS 
Oligosaccharides 
P95 (composed of 95% FOS [Degree of polymerization 3 to 10]) was kindly 
provided by Beneo Orafti (Tienen, Belgium), and 6’SL was purchased from 
Carbosynth (Berkshire, UK).  BMO powder was kindly provided by Food for Health 
Ireland (FHI, Moorepark, Ireland). 
 
Animals and treatments 
All animal experiments were approved by the University College Cork 
Animal Ethics Committee, and experimental procedures were conducted under the 
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appropriate license from the Irish Government. BALB/c mice were purchased from 
Harlan (Becester, Oxfordshire, UK) and housed within the Biological Services Unit, 
University College Cork (UCC), under barrier-maintained conditions. Mice were 
delivered at 6 weeks of age and allowed to acclimatise for one week prior the 
beginning of the study. Animals were divided into four groups (n=10) and housed 
under standard conditions with access to standard chow and water ad libitum. P95, 
BMO or 6’SL were resuspended in saline solution and administered daily (1mg/g 
body weight) for 21 days by oral gavage. Unsupplemented group received the same 
volume of saline by oral gavage. Body weight was assessed weekly. Faecal pellets 
were collected at day-0 and day-21 of the trial and immediately placed on ice, and 
frozen at -80°C until bacterial DNA was extracted (see below). At the conclusion of 
the study, animals were sacrificed by decapitation, blood serum collected, and the 
liver, small intestine, and caecum harvested, washed with PBS, blotted dry on filter 
paper and weighed. Caecal content was divided for analysis of secretory IgA and 
short chain fatty acid (SCFA) composition.   
 
Caecal secretory IgA analysis 
Caecal secretory IgA concentration was determined using the mouse IgA 
ELISA quantification kit (Bethyl Laboratories, Cambridge, UK). Essentially, anti-
mouse IgA antibody is adsorbed on the surface of microtitre wells and blocked 
using BSA.  Following addition and binding of caecal secretory IgA, wells were 
washed and bound secretory IgA was detected using a biotinylated detection 
antibody, followed by streptavidin-linked horse radish peroxidase. Secretory IgA 
levels were colorimetrically detected using the TMB (3,3’,5,5’-
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tetramethylbenzidine) substrate and read on a BioTek plate reader at 450nm.  
Concentrations were determined based on a standard curve using the mouse IgA 
standard provided. 
 
SCFA analysis  
SCFA analysis was carried out according to previously published methods 
(Chapter 2 and Wall et al., 2012). 
 
Serum cytokine analysis 
Measurement of cytokines IL-1β, IL-6, IL-10, IL-12, IFN-γ, mKC, and TNF-α in 
serum was performed using the Meso Scale Discovery 7-plex mouse pro-
inflammatory kit (Meso Scale Discovery, Gaithersburg, MD, USA) following the 
manufacturer’s instructions. 
 
Microbial composition analysis 
DNA extractions and pyrosequencing were as described in Murphy et al. 
(2013).  Total metagenomic DNA was extracted from individual faecal samples using 
the QIAmp DNA Stool Mini Kit (Qiagen, Crawley, West Sussex, UK). Samples were 
initially bead-beaten and then processed according to the manufacturer’s 
instructions. For compositional analysis, isolated microbial DNA was subjected to 
pyrosequencing of 16S rRNA tags (V4 region; 239 nt long) amplified using universal 
16S primers. The forward primer, F1, (5’-AYTGGGYDTAAAGNG) and a mixture of 
four reverse primers, R1 (5’-TACCRGGGTHTCTAATCC), R2 (5’-
TACCAGAGTATCTAATTC), R3 (5’-CTACDSRGGTMTCTAATC), and R4 (5’-
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TACNVGGGTATCTAATC) (RDP’s Pyrosequencing Pipeline: 
http://pyro.cme.msu.edu/pyro/help.jsp) were used. To allow emulsion-based clonal 
amplification for the 454 pyrosequencing system, proprietary 19-mer sequences at 
the 5’end were incorporated into the primers. Unique molecular identifier (MID) 
tags were incorporated between the adaptamer and the target-specific primer 
sequence, allowing for identification of individual sequences from pooled 
amplicons. The resulting amplicons were cleaned using the AMPure purification 
system (Beckman Coulter, Takeley, UK) and sequenced within the Teagasc 454 
Sequencing Platform.  Raw sequences were quality trimmed using the Qiime Suite 
of programmes (Caporaso et al., 2010); any reads not meeting the quality criteria of 
a minimum quality score of 25 and sequence length shorter than 150 bps for 16S 
amplicon reads were discarded. Trimmed FASTA sequences were then BLASTed 
(Altschul et al., 1997) against a previously published 16S-specific database (Urich et 
al., 2008) by using default parameters. The resulting BLAST output was parsed by 
using MEGAN (Huson et al., 2007). MEGAN assigns reads to NCBI taxonomies by 
using the Lowest Common Ancestor algorithm. A bit-score of 86, as previously used 
for 16S ribosomal sequence data (Urich et al., 2008), was used within MEGAN for 
filtering the results before tree construction and summarisation. Phylum, family 
and genus counts for each subject were extracted from MEGAN.  Sequences were 
clustered into operational taxonomical units (OTUs), chimera checked and aligned 
using the default pipeline within Qiime (Kuczynski et al., 2011); subsequently alpha 
and beta diversities were generated. A phylogenetic tree was calculated using the 
FastTree software (doi:10.1093/molbev/msp077). Resulting Principal Coordinate 
analysis was visualised using KING.   
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Detection of Bifidobacterium  
To quantify Bifidobacterium in murine faecal pellets, a plasmid standard was 
first created. A PCR fragment from within the 16 rRNA gene of B.  longum subsp. 
infantis ATCC 15697 was generated using species-specific primers. The primers used 
were as follows: forward 5’- CTCCTGGAAACGGGTGG- 3’ and reverse 5’- 
GGTGTTCTTCCCGATATCTAC- 3’, according to Matsuki et al. (2002). Purified 
amplicons were cloned into the pCR®2.1-TOPO vector using the TOPO-TA cloning 
system (Invitrogen, Life Technologies, Carlsbad, California) in accordance with 
manufacturer’s instructions.  The complete vector was transformed into chemically 
competent TOP-10 Escherichia coli cells (Invitrogen, Life Technologies, Carlsbad, 
California) and harvested on LB media containing 50 μg/ml ampicillin. The cloned 
amplicon was confirmed by restriction analysis and DNA sequencing. Quantitative 
real-time PCR (qPCR) standards were prepared following the linearization of 
plasmid DNA with KpnI restriction enzyme and quantification using a Nanodrop ND-
1000 (Thermo Fisher Scientific Inc, USA). A standard curve was then generated via a 
series of dilutions from 109 to 102 copies/µl DNA. The LightCycler 480 SYBR Green I 
Master kit (Roche Diagnostics GmbH, Mannheim, Germany) was used for 
quantification according to the manufacturer’s instructions. Each PCR reaction 
contained 10 μl Sybr green master mix, 1 μl of both forward and reverse primer (10 
pmol), 1 μl of DNA and was made up to a final volume of 20 μl with nuclease free 
distilled water. The PCR conditions were as follows: denaturation at 95°C for 10 
min, followed by 35 cycles of denaturation at 95°C for 10 sec, annealing at 55°C for 
5 sec and elongation 72°C for 25 sec. To quantify by qPCR, it was necessary to 
correct copy number of 16S rRNA gene to cfu/ml. Based on the amplification of 
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DNA, which was isolated from Bifidobacterium cultures of known cfu/ml against a 
standard curve generated from the Lightcycler 480 (copy number/μl), a formula 
was used to correct copy number values for cfu/ml as outlined in Quigley et al. 
(2013). 
[(C/µl)*(TV)]/TCN x T cfu/ml = cfu/ml(S) 
Where; C/μl = Copy number/μl, TV = Template volume, TCN = Total copy number of 
the standard used, T cfu/ml = Total cfu/ml of standard used and cfu/ml(S) = cfu/ml 
of test sample.   
 
Statistical Analysis 
Data are presented as mean values ± standard errors of the mean (SEM).  
Statistical analysis was performed by ANOVA and the Student t-test (Graph-Pad 
Software, San Diego, CA, USA). For microbiota analysis, SPSS was utilised to 
establish non-parametric significance using the Mann-Whitney and Kruskal-Wallis 
tests.  P<0.05 was considered as statistically significant. 
 
6.4 RESULTS 
Oligosaccharides effects on body and organs weight, caecal secretory IgA, SCFA 
composition and serum cytokine levels 
BALB/c mice body weight did not differ significantly throughout the study as 
a result of dietary intervention with BMO, P95 or 6’SL compared to 
unsupplemented control. Following 3 weeks of dietary supplementation with 
oligosaccharides no differences on liver, caecum, or small intestine weight were 
observed (Table 6.1).   
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Caecal secretory IgA was assessed at day 21 and levels were reduced 
following treatment with P95 (62%; p<0.01) and BMO (61%; p<0.05), whereas 6’SL 
supplementation showed a similar trend but did not reach statistical significance 
(Fig. 6.1).   
To examine the effects of oligosaccharide supplementation on caecal SCFA, 
levels of butyrate, propionate, and acetate were determined (Fig. 6.2).  P95 and 
BMO supplementation did not influence SCFA content when compared with 
unsupplemented control. 6’SL supplementation resulted in reduced levels of 
butyrate by 41% (p<0.01) in comparison with the control, while levels of propionate 
and acetate were unaltered in caecal contents.   
Serum was isolated from collected blood and analysed for cytokine levels 
(Table 6.2), and results indicated that dietary supplementation with both BMO and 
P95 were not associated with changes in the levels of IL-1β, IL-10, IFN-γ, or TNF-α.  
P95 treatment was associated with a reduction in IL-12 (18.1%; p<0.01) and IL-6 
(21.1%; p<0.05) versus the unsupplemented control. BMO supplementation 
resulted in reduced levels of IL-12 (11.9%; p<0.05) versus the unsupplemented 
control, and increased mouse keratinocyte-derived chemokine (mKC) levels in 
relation to 6’SL (42.7%; p<0.01). 
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Table 6.1 Murine body and organs weights by treatment group 
  Control P95 BMO 6’SL 
Final body weight (g)  19.3  ± 1.0 19.4 ± 1.2 19.1 ± 1.1 19.5 ±0.9 
Liver weight (g) 0.77 ± 0.16 0.82 ± 0.15 0.88 ± 0.16 0.89 ± 0.09 
Caecal tissue weight (g) 0.06 ± 0.02 0.06 ± 0.02 0.07 ± 0.02 0.06 ± 0.01 
Small intestine tissue weight (g) 0.40 ± 0.09 0.39 ± 0.06 0.37 ± 0.09 0.32 ± 0.07 
All values are means ± SEMs.  
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Figure 6.1 Caecal secretory IgA measured following 21 days of oligosaccharide 
supplementation.  *p<0.05; **p<0.01 (ANOVA followed by post hoc Tukey’s multiple 
comparisons tests).  
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Figure 6.2 Caecal short-chain fatty acids measured following 21 days of oligosaccharide 
supplementation. **p<0.01. (ANOVA followed by post hoc Tukey’s multiple comparisons 
tests).  
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Table 6.2 Serum cytokines (pg/ml) detected following 21-day oligosaccharide 
supplementation 
 Control P95 BMO 6'SL 
IFN-γ 4.4 ± 0.4 3.9 ± 0.2 3.9 ± 0.2 4.3 ± 0.3 
IL-10 55.3 ± 3.0 54.7 ± 2.6 55.3 ± 1.6 56.5 ± 1.9 
IL-12 110.6 ± 3.3 90.6 ± 2.3** 97.4 ± 2.7* 99.6 ± 4.8 
IL-1β 15.6 ± 0.8 14.7 ± 1.9 15.6 ± 0.9 13.3 ± 1.1 
IL-6 57.7 ± 3.4 45.5 ± 2.3* 54.2 ± 2.7 55.7 ± 2.8 
mKC 103.2 ± 7.3 92.7 ± 6.8 121.3 ±10.0^ 85.0 ± 4.5^ 
TNF-α 16.2 ± 1.2 12.9 ± 0.3 14.7 ± 0.7 14.1 ± 0.8 
All values are means ± SEMs. Statistical significance was determined using one-way ANOVA 
followed by post hoc Tukey’s multiple comparisons tests; *p <0.05; **p<0.01; ***p<0.001 in 
relation to control; ^ denotes significance between two treatment groups. 
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Effects of oligosaccharide supplementation on murine intestinal microbiota 
At the conclusion of the 21-day trial, the relative proportions of gut bacteria 
among the treatment groups were assessed by DNA sequencing (Roche-454 
titanium, Roche Diagnostics Ltd, West Sussex, UK) of the V4-region of 16S rRNA 
amplicons derived from total faecal DNA and bioinformatic analysis. Sequencing 
resulted in a total of 421,986 reads with an average of 5540.481 reads per animal.  
Reads were quality trimmed and clustered into operational taxonomical units 
(OTUs) based on 98% sequence identity. Subsequently alpha diversity was 
estimated using 5 different metrics (Shannon, Simpson, Chao1, Phylogenetic 
diversity and observed species). There were some temporal differences in diversity, 
with a reduction in diversity over time (phylogenetic diversity p=0.019; observed 
species p=0.032; data not shown). However, no significant differences were 
observed in alpha diversity between the treatment groups at day-21 only.  
Rarefaction curves for each group were at or approaching parallel, indicating that 
sufficient depth of sequencing was undertaken. Principal coordinate analysis, based 
on unweighted Unifrac distances illustrated that the control and P95 samples 
cluster closer to each other than to the 6'SL and BMO samples (Fig. 6.3).   
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Figure 6.3 Unweighted Unifrac analysis of oligosaccharide treatment clustering on 
microbial composition.  Oligosaccharide treatments are denoted as follows: Control 
– black circle; P95 – white square; BMO – black square; and 6’SL – x symbol.   
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Consistent with previous studies, Firmicutes and Bacteroidetes were found 
to be the predominant gut microbiota in the BALB/c caecal content at the phylum 
level (Pedron et al., 2012) (Fig. 6.4). Proteobacteria, Deferribacteres, Actinobacteria, 
Viridiplantae, and Candidate division TM7 contribute to the remaining proportion 
(Fig. 6.4). A comparison of intestinal microbiota composition between 
unsupplemented control and oligosaccharide-treated mice revealed multiple 
alterations. At the phylum level, P95 supplementation was associated with a 
significant reduction in Cyanobacteria (p=0.003). BMO supplementation was 
associated with an increase in the relative proportion of Candidate division TM7 
(p=0.002) and decreases in Actinobacteria (p=0.0255) and Cyanobacteria (p=0.003) 
compared to the unsupplemented control, while administration of 6’SL was 
associated with a decrease in the relative proportion of Actinobacteria (p=0.017) 
(Fig. 6.4). 
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Figure 6.4 Microbial composition at the phylum level. Top panel refers to microbial 
compositions >2%, bottom panel refers to <1%.a denotes significance in comparison 
to control; b denotes significance in comparison to P95; c denotes significance in 
comparison to BMO; and d denotes significance in comparison to 6’SL.  Significance 
is determined as p<0.05. 
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At the family level, supplementation with P95 was associated with increased 
Enterobacteriaceae (p<0.0001), Enterococcaceae (p=0.016), Alcaligenaceae 
(p=0.018), a decrease in Porphyromonadacaea (p=0.04) in caecal content, and the 
non-detection of Moraxellaceae and Vibrionaceae in pair-wise comparisons against 
the unsupplemented control (Fig. 6.5). Supplementation with BMO resulted in a 
significant reduction in numbers of 3 families; Veillonellaceae (p=0.003), 
Succinivibrionaceae (p=0.001), Peptostreptococcaceae (p=0.038), an increase in 
Alcaligenaceae (p=0.006), and non-detection of Moraxellaceae and Vibrionaceae.  
6’SL supplementation was associated with a significant reduction in numbers of 
Moraxellaceae (p=0.003) and Porphyromonadaceae (p=0.016) and non-detection of 
Prevotellaceae (p=0.035), Vibrionaceae (p=0.003), Veillonellaceae (p=0.003), and 
Succinivibrionaceae (p=0.001). Moreover, Lactobacillaceae numbers were 
significantly reduced in the 6’SL-treated mice, compared with the unsupplemented 
control and P95 supplemented animals (p=0.001 and 0.005 respectively). 
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Figure 6.5 Microbial composition at the family level. a denotes significance in 
comparison to control; b denotes significance in comparison to P95; c denotes 
significance in comparison to BMO; and d denotes significance in comparison to 
6’SL. Significance is determined as p<0.05. 
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In pair-wise comparisons versus the control, P95 was associated with 
significantly increased numbers of Enterobacteriaceae spp.  (p<0.0001), 
Pasteurellales (p<0.0001), Sutterella (p=0.018), Parabacteroides (p=0.004), 
Ruminococcaceae Incertae Sedis (p<0.0001), Enterococcus (p=0.030), and 
Erysipelotrichales Incertae Sedis (p=0.001), and decreases in Lachnospiraceae 
Incertae Sedis (p=0.017), uncultured Lachnospiraceae (p=0.003), Marvinbryantia – 
Bryantella (p<0.0001), and Acetitomaculum (p=0.008) (Fig. 6.6). BMO was 
associated with a significant increase in Sutterella (p=0.006) and decreases in 
Anaerobiospirillum (p=0.001), uncultured Lachnospiraceae (p=0.016), 
Acetitomaculum (p=0.008), Anaerovibrio (p=0.018), and Ruminococcaceae Incertae 
Sedis (p=0.028).  6’SL was associated with an increase in Parabacteroides (p=0.008) 
and Ruminococcaceae Incertae Sedis (p=0.002), and the largest number of genus 
decreases; Anaerobiospirillum (p=0.001), Lachnospiraceae Incertae Sedis (p=0.049), 
uncultured Lachnospiraceae (p=0.009), Marvinbryantia – Bryantella (p<0.0001), 
Acetitomaculum (p=0.008), Anaerovibrio (p=0.018), and Lactobacillus (p=0.001).  
Notably, members of Ruminococcaceae Incertae Sedis were significantly increased 
in the P95 and 6’SL supplemented groups versus the unsupplemented control 
(p<0.0001 and p=0.002, respectively), while decreased in the BMO-supplemented 
mice (p=0.028).  Interestingly, members of Lactobacillus were significantly reduced 
in 6’SL supplemented group, compared with P95 and unsupplemented controls 
(p=0.006 and 0.001 respectively). Moreover, qPCR analysis of faecal pellets 
revealed absence of Bifidobacterium in samples taken at day 0 and day 21, with no 
differences among groups. 
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Figure 6.6 Microbial composition at the genus level. a denotes significance in 
comparison to control; b denotes significance in comparison to P95; c denotes 
significance in comparison to BMO; and d denotes significance in comparison to 
6’SL. Significance is determined as p<0.05. 
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6.5 DISCUSSION 
Dairy whey streams present an abundant resource from which to mine 
biologically active bovine oligosaccharides, offering an attractive alternative to 
HMO as functional food ingredients (Zivkovic & Barile, 2011). In the current study, 
we report the influence of carbohydrate supplementation (1 mg/g BW) of P95, an 
enriched BMO powder, or 6’SL on the composition of the murine microbiota.   
Following the 3-week administration period, individual carbohydrate 
interventions resulted in clustering of bacterial species detected, with similar 
effects on bacterial composition among the control and P95, and BMO and 6’SL.  In 
the current study, P95 demonstrated the ability to modulate the faecal bacterial 
populations of mice, promoting the growth of specific families, while reducing 
others.  P95 significantly increased the relative proportions of Enterococcaceae and 
Enterobacteriaceae, which have been demonstrated to be associated with the 
intestinal microbiota of preterm infants (Arboleya et al., 2012; Hoy et al., 2000; 
Magne et al., 2006).  The current study findings are in contrast to a prior study in 
which supplementation with oligosaccharides resulted in reduced concentrations of 
Enterococcaceae in the caecum (Pan et al., 2009), although this may be attributable 
to differences naturally present between the caecal and faecal microbiota (Marteau 
et al., 2001). Of interest, P95 supplementation was associated with non-detectable 
numbers of the Moraxellaceae and Vibrionaceae families of bacteria, both of which 
include notable human pathogens, Moraxella catarrhalis and Vibrio cholerae, 
respectively. 
Overall, BMO and 6’SL supplementations were generally associated with 
reductions in less favourable bacteria.  At the phylum level, BMO reduced the 
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proportion of Candidate division TM7, a currently uncultivable bacteria which has 
previously been isolated from periodontitis (Paster et al., 2001) and is thought to 
rely on group interactions within biofilms for survival (Wade, 2002).  BMO was also 
associated with a decrease in Actinobacteria, a diverse phylum to which the family 
Bifidobacteriaceae belong (Ventura et al., 2007). BMO treatment was also 
associated with the absence of Moraxellaceae and Vibrionaceae. In contrast to P95, 
BMO reduced Enterococcaceae, as well as Enterobacteriaceae, which are both 
predominant in the flora of preterm human infants (Arboleya et al., 2012).  Of the 
three treatments, BMO was the sole carbohydrate source to significantly reduce 
the Peptostreptococcaceae family.   
In contrast to P95 supplementation, 6’SL significantly reduced the 
proportion of Actinobacteria at the phylum level. At the family level, 6’SL reduced 
Moraxellaceae, Lactobacillaceae, and Porphyromonaceae, while 4 families of 
bacteria were no longer detected. The inability to detect Prevotellaceae was unique 
to treatment with 6’SL. Prevotellaceae are commonly linked to periodontal disease 
and abscesses along with bacteremia and upper respiratory tract infections (Tanaka 
et al., 2008).  Although investigation into the mechanisms of action was not carried 
out, the fact that 6’SL did not promote the growth of any bacterial families may 
suggest this molecule is acting in an anti-infective manner or as a decoy molecule, 
as reported for acidic oligosaccharides in previous studies (Coppa et al., 2006; 
Hester et al., 2013; Thomas & Brooks, 2004).  
The fact that indigenous Bifidobacterium were undetectable through both 
real-time PCR analysis and 454 pyrosequencing in baseline and 3-week faecal 
samples limited our ability to comprehensively assess the prebiotic nature of the 
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supplemented oligosaccharides, as prebiotic supplementation is often associated 
with increases in Bifidobacterium and Lactobacillus (Gibson et al., 1995; Kaplan & 
Hutkins, 2000; Roberfroid, 2000). Lactobacillus typically comprise 0.2-1% of the 
total microbiota in infant faecal samples (Mueller et al., 2006), and display 
adaptations to specific ecological niches.  Isolates from milk exhibit an adaptation 
for growth on lactose, while those isolated from the intestinal niche often encode 
pseudogenes associated with sugar internalization and metabolism (Makarova et 
al., 2006; Ventura et al., 2007). While FOS have been reported to act as fermentable 
substrates for Lactobacillus (Gänzle & Follador, 2012), FOS supplementation has 
been demonstrated to reduce levels of Lactobacillus in conventionally raised 
C57Bl/6J mice (Pachikian et al., 2011), while other studies have reported limited or 
no promotion of growth (Campbell et al., 1997; Petersen et al., 2010).  
Furthermore, digestion of sialyllactose and mixtures of complex HMO lie largely 
beyond the scope of their enzymatic activities (Idota et al., 1994; Schwab & Gänzle, 
2011), possibly accounting for the lack of effect of the supplemented 
oligosaccharides on the Lactobacillus numbers.   
While the murine model provides an accessible and comparatively cheap in 
vivo intestinal model for the study of prebiotic substances, there are several 
inherent and important differences to that of the human environment. The 
commensal flora of mice is adapted to the murine intestinal environment and daily 
diet (utilizing different nutrients, binding sites, and adhesins), and may respond 
differently to the provision of human/bovine oligosaccharides when compared to 
the human microbiota. For example, Lactobacillus likely employ different adhesion 
mechanisms depending on host tissue, given that a widespread mucus-adhesion 
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protein of Lactobacillus will bind to human, rabbit, and guinea pig tissues, yet does 
not adhere to the mucus of murine intestinal biopsies (Coïc et al., 2012), indicating 
significant differences in the murine mucosal composition.  Despite numerous 
studies demonstrating the presence and dominance of Bifidobacterium in human 
neonates, the microbiota in mice depends on the particular strain used (e.g. 
C57BL/6 or BALB/c) and the environment in the housing facilities (Buddington et al., 
2000). This may allow for variable inter-study intestinal microbiota composition, 
and in some cases, an absence or low levels of Bifidobacterium (Hasegawa et al., 
2010).    
The predominant bacterial fermentation end-products in the large bowel 
are butyrate, acetate, and propionate, which result from the breakdown of 
oligosaccharides, polysaccharides, proteins, peptides, and glycoproteins 
(Macfarlane & Macfarlane, 2002).  The production of SCFA relies on the number 
and type of bacteria present, as well as their associated ability to metabolize 
relevant precursors. Clostridium, Eubacterium and Ruminococcus genera are 
associated with the production of butyrate, while acetate is attributed to lactic acid 
producing bacteria of the Lactobacillus and Bifidobacterium genera (Gourbeyre et 
al., 2011). In the current study, levels of SCFA were generally unaffected, with the 
exception of 6’SL treatment, which resulted in decreased levels of butyrate. Faecal 
butyrate concentrations in breast-fed infants have been found to be lower than 
their formula-fed counterparts (Knol et al., 2005), potentially highlighting a 
similarity between breast-feeding and supplementation with 6’SL. This reduction in 
butyrate may be the result of elimination of a family or combination of families of 
bacteria which are involved in the production of butyrate. 6’SL and P95 treatment 
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were associated with increased proportions of Ruminococcus, with only the 6’SL 
treatment reducing butyrate concentrations. In addition, 6’SL significantly reduced 
the proportion of Lactobacillus, but did not affect caecal acetate concentrations, 
leading to the inference that the Lactobacillus populations did not significantly 
contribute to the observed levels of acetate in this particular study. It should be 
noted that in the current study caecal flow and volume were not assessed. An 
increased volume or rate of caecal transit could explain the lack of impact or 
reduced concentrations of SCFA detected (Cheng et al., 1987; Peuranen et al., 
2004). 
Blood serum cytokine levels were assessed to determine whether 
oligosaccharide supplementation would modulate the murine systemic immune 
response. Supplementation with oligosaccharides did not result in significant 
changes in the serum concentrations of the pro-inflammatory cytokines    IL-1β, 
IFN-γ, and TNF-α, or the anti-inflammatory cytokine, IL-10.  The production of these 
cytokines have been demonstrated to be enhanced in response to probiotic 
bacteria (reviewed in Gill, 2003), therefore the lack of significant change in their 
levels may be explained by the fact that Bifidobacterium were found to be absent 
during the present study and Lactobacillus were significantly reduced or otherwise 
unaffected following oligosaccharide supplementation. The stimulation of intestinal 
epithelial cells by pathogens is associated with the production of TNF- and IL-8 
(Kagnoff & Eckmann, 1997), both of which were unaffected by oligosaccharide 
supplementation. Therefore, despite the fact that it appears that probiotic-
associated cytokines were unaffected, there was also a lack of production of 
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pathogen-associated cytokines, possibly indicating that the oligosaccharide 
supplements did not result in an increased pathogenic burden. 
P95 supplementation led to significantly decreased levels of IL-12 and IL-6, 
while BMO decreased IL-12 levels. IL-12 is a pro-inflammatory cytokine (Shida et al., 
2002), while IL-6 may act as a pro- or anti-inflammatory cytokine, which is 
necessary to fight infection of Streptococcus pneumoniae in a murine model (van 
der Poll et al., 1997), thereby demonstrating both positive and negative properties 
associated with the two interventions. mKC is the murine analogue of human IL-8, 
which is associated with inflammation and is released in response to pathogenic 
stimulation of intestinal epithelial cells in vitro (Gill, 2003). 6’SL significantly 
decreased levels of mKC in relation to the BMO group, demonstrating the potential 
to modulate inflammation. As the exact mechanism of action of the 
oligosaccharides in this particular study is unknown, further studies would prove 
beneficial. 
The primary role of secretory IgA is in the prevention of pathogenic 
attachment to host tissues (Kagnoff, 1993). Furthermore, the induction of IgA 
antibodies and CD4+ regulatory T cells mediate oral tolerance to intestinal contents 
(Mowat, 2003).  In the current study, both P95 and BMO resulted in significant 
decreases in caecal secretory IgA, while 6’SL did not differ significantly from the 
unsupplemented control. In contrast to our current findings, previous studies 
typically report increased levels following the administration of prebiotics (Seifert & 
Watzl, 2007). Ingestion of RaftiloseR Synergy1 (a commercial blend of inulin and 
oligofructose) resulted in increased levels of caecal secretory IgA in a rodent model 
(Roller et al., 2004). Hosono et al. (2003) found a transient increase in faecal IgA 
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levels at week two, returning to control levels at weeks three and four, while 
Nakamura et al. (2004) found elevated levels throughout the small and large 
intestine, though feeding the mice nearly ten times as much oligofructose (50g/kg 
diet) as used in the current study. Although 6’SL supplementation did not induce a 
significant change, BMO and P95 reduced caecal levels of secretory IgA. Pathogens 
and probiotic bacteria are both able to stimulate the production of IgA, though 
typically differing on whether they are T-cell dependent or independent, 
respectively (Cerutti & Rescigno, 2008). The fact that P95 and BMO 
supplementation both significantly reduced the levels of caecal secretory IgA leads 
to several different hypotheses. Though many scenarios are possible, the most 
probable situation in agreement with the sequencing data is that the BMO and P95 
treatments are reducing either a particular bacterial group responsible for the 
production of IgA, or the overall bacterial numbers in the caecum, resulting in a 
decreased concentration of secretory IgA. Given the current findings, it appears 
likely that 6’SL supplementation does not produce a significant effect on intestinal 
and oral tolerance due to its negligible effects on levels of secretory IgA. Another 
hypothesis is that the amount of oligosaccharide used in this study was not enough 
to stimulate the production of IgA. 
The present study has demonstrated the gut-modulatory properties of 
oligosaccharides in a murine model. While BMO and 6’SL treatments have resulted 
in a significant reduction in proportions of less favourable bacterial families, next 
steps will include determining their effects upon probiotic bacterial strains, with 
specific emphasis on Bifidobacterium which were absent in the current study.  
Future studies would benefit from the use of mice colonized with a human-derived 
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microbiota, a synbiotic treatment (provision of Bifidobacterium and 
oligosaccharides) as implemented in previous studies (Bielecka et al., 2002; Furrie 
et al., 2005), or higher doses of oligosaccharides/longer period of supplementation 
to allow for a better interpretation of the interplay between supplemented 
oligosaccharides, their effects on pathogens, probiotic commensals, and overall 
host health. 
 
6.6 CONCLUSIONS 
The results from this study demonstrate the ability of BMO and 6’SL 
supplementation to significantly reduce or eliminate families of bacteria which 
potentially harbour pathogenic organisms.  Additionally, supplementation with 6’SL 
reduced caecal butyrate, which is primarily produced by Clostridium, Eubacterium 
and Ruminococcus, resembling the SCFA pattern commonly found in faeces of 
breast-fed infants. Finally, caecal secretory IgA was not significantly impacted by 
6’SL, demonstrating that supplementation with this specific oligosaccharide, which 
is naturally found in human and bovine milk, likely would not impact oral tolerance 
of the host. Despite the differences and limitations of the murine model, this study 
has demonstrated that ingestion of BMO is a safe and effective approach to 
modulate populations of the intestinal microbiota.   
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The adult intestinal microbiota comprises a microbial ecosystem of 
approximately 100 trillion organisms (Qin et al., 2010), the majority of these 
microorganisms being bacteria (Sommer & Backhed, 2013) with a collective 
genome containing at least one hundred times as many genes as the human 
genome (Barberan & Mine, 2013). This bacterial community has  huge metabolic 
activity (Bocci, 1992; O’Hara & Shanahan, 2006), producing bioactive compounds 
that may influence microbial community structure (McHardy et al, 2013) and may 
directly or indirectly affect the regulation of multiple host metabolic pathways 
(Roshchina, 2010), and  have a role in mood disorders and chronic diseases 
(Forsythe et al., 2010). Moreover, gut bacteria are responsible for the metabolism 
and energy harvest from nondigested nutrients entering the colon, generating a 
wide range of products, mainly SCFA (Macfarlane & Macfarlane, 2003).  
SCFA are among the most important gut microbial products, affecting a 
range of host processes from gut motility (Fukumoto et al., 2003; Grider & Piland, 
2007) to modulation of inflammation (Maslowski et al., 2009), fat metabolism (Ge 
et al., 2008; Hong et al., 2005) and appetite (Karaki et al., 2008; Samuel et al., 
2008). In Chapter 2, we optimized a gas chromatograpic method previously 
described by Tangerman & Nagengast (1996) for analysing SCFA in human and 
animal intestinal samples. A high polarity capillary column specific for aqueous 
samples, with a programmed oven temperature and a narrow glass liner to 
simulate on-column injection was used to create a rapid and efficient assay for 
SCFA analysis with better resolved chromatograms. The optimized method proved 
to be efficient for the detection of faecal/caecal acetate, propionate, isobutyrate 
and butyrate with good recovery and reproducibility rates, provided that sample 
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storage at -20oC did not exceed 2 weeks. The method was then applied for 
quantifying SCFA production in animals as a response to dietary interventions with 
t10, c12 conjugated linoleic acid (CLA) (Chapter 3), probiotics (Chapter 4) and 
prebiotics (Chapter 6).  
The gut microbiota play an important role in host health, being involved in 
nutritional, immunological and physiological functions. Recent evidence from 
animal and human studies indicates that changes in gut microbiota composition 
may be involved in inflammatory bowel disease (IBD) (Maynard et al., 2012), 
necrotizing enterocolitis (NEC) (AlFaleh et al., 2012) and extra-intestinal disorders 
such as obesity (Backhed et al., 2004; Ley et al., 2006; Turnbaugh et al., 2006), 
insulin resistance (Cani et al., 2008) and non-alcoholic fatty liver disease (NAFLD) 
(Dumas et al., 2006). In Chapter 3, we investigated the effects of dietary t10, c12 
CLA supplementation on intestinal microbiota composition and production of short 
chain fatty acids in mice. T10, c12 CLA has been shown to affect body composition 
by reducing body fat and increasing lean body mass in mice. However, in most 
studies using mice, this anti-obesity effect has been accompanied by such adverse 
effects as hepatic steatosis and hyperinsulinemia (Clément et al., 2002; Liu et al., 
2012). Recent studies indentified the gut microbiota as an environmental factor 
with an important role in host fat metabolism and the development of hepatic 
steatosis (Le Roy et al., 2012). Indeed, we found that dietary t10, c12 CLA 
supplementation was associated with altered gut microbiota composition with 
greater proportions of Bacteroidetes (p=0.027), when compared with 
unsupplemented controls. Bacteroidetes are known to produce LPS and induce 
inflammation, whereas Porphyromonadaceae, also observed at higher proportions 
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(p=0.002), have previously been linked with negative effects on lipid metabolism 
and induction of hepatic steatosis (Henao-Mejia et al., 2012). Moreover, SCFA levels 
were altered, with higher levels of caecal acetate, propionate and isobutyrate in 
mice receiving t10, c12 CLA supplementation. These data indicate that the 
mechanism of dietary t10, c12 CLA on lipid metabolism in mice may be at least 
partially mediated by alterations in gut microbiota composition and functionality. 
Future studies comparing the effects of dietary t10, c12 CLA with dietary c9, t11 
CLA and other trans-fatty acids on human microbiota composition would give 
important information about the mechanisms of action of these fatty acids on 
metabolic pathways, especially considering that the severe collateral effects seen in 
rodents while feeding t10, c12 CLA have not yet been confirmed in humans. 
The maintenance of the homeostasis in the gut ecosystem is essential for 
health and diet has been shown to be the main environmental factor contributing 
to human gut microbiota modulation (De Filippo et al., 2010; Wu et al., 2011). 
Dietary strategies such as probiotics and prebiotics may be used to impact 
positively on microbiota composition and consequently, host health. In Chapter 4 
we compared the effect of dietary supplementation with CLA-producing 
Bifidobacterium breve strains on fat distribution and composition and on the 
composition of the gut microbiota in mice. Both B. breve DPC 6330 and B. breve 
NCIMB 702258 survived gastrointestinal transit and were detected in faecal 
samples (~1.1 x 106 CFU/g faeces and 8.2 x 106 CFU/g faeces, respectively). After 8 
weeks supplementation, visceral fat mass and brain stearic acid, arachidonic acid 
(AA), and docosahexaenoic acid (DHA) were higher in mice supplemented with B. 
breve NCIMB 702258 than in mice receiving no supplementation (p<0.05), but these 
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changes were not observed in mice supplemented with B. breve DPC 6330. Caecal 
propionate was significantly higher in mice fed B. breve DPC 6330 and B. breve 
NCIMB 702258 than in unsupplemented mice (p<0.05). However, administration of 
these strains altered the composition of the gut microbiota differently at the 
phylum, family, and genus levels. PCoA analysis showed that mice fed B. breve DPC 
6330 had a more divergent clustering pattern and were separated from the 
unsupplemented mice and from mice fed B. breve NCIMB 702258, suggesting a 
greater effect of B. breve DPC 6330 on murine microbiota composition. The study 
showed that the response of fatty acid metabolism to administration of 
bifidobacteria is strain-dependent and furthermore highlighted the importance of 
intra strain differences in modifying the gut microbiota composition of the host. 
Potential future studies could involve the investigation of the contrasting effects of 
B. breve NCIMB 702258 and B. breve DPC 6330 administration on human 
microbiota composition. Moreover, since ARA and DHA are neuroprotective agents, 
involved in the improvement of cognitive function including memory and learning 
(Henriksen et al., 2008; Yurko-Mauro et al., 2010), and administration of B. breve 
NCIMB 702258, as outlined in this chapter, led to increased concentrations of both 
fatty acids in brain, it would be interesting to evaluate its effects in humans with 
psychiatric conditions.  
In Chapter 5, we investigated metabolic and behavioural effects of dietary 
administration of GABA-producing Lb. brevis DPC 6108 and pure GABA (as 
commercial powder). GABA is the major inhibitory neurotransmitter in the central 
nervous system (CNS) and plays a role in the sensation of pain and anxiety (Erdo, 
1992). In the endocrine pancreas, GABA is produced by β-cells and modulates 
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insulin and glucagon secretions (Bailey et al., 2007; Bonaventura et al., 2007; Dong 
et al., 2006). Using healthy animals, we observed a significant increase (p<0.05) in 
serum insulin in rats receiving Lb. brevis DPC 6108 for 5 weeks, compared with 
placebo controls. Following on from the observation that ingested GABA-producing 
Lb. brevis DPC 6108 led to increased serum insulin, we investigated the potential of 
this probiotic for prevention of the onset of diabetes in streptozotocin (STZ) 
induced type-1-diabetic (T1D) rats, in comparison to dietary GABA. The dietary 
interventions were not effective and diabetic animals developed an overt basal 
hypoinsulinemia and extreme hyperglycemia compared with animals receiving 
placebo.  However, similar to previous observations in studies investigating the 
benefits of probiotic administration in STZ-diabetic animals (Davari et al., 2013; Lin 
et al. , 2013),  probiotic Lb brevis DPC 6108 caused a significant decrease in glucose 
levels in diabetic rats when compared with  diabetic controls (23%; p<0.05). 
Moreover, although healthy animals receiving GABA powder or Lb. brevis DPC 6108 
were less anxious in comparison with the placebo control group, they did not 
ameliorate the anxiety effect caused by diabetes.  However, the beneficial effect of 
GABA therapy has been shown in other models of diabetes, such as the non-obese 
diabetic (NOD) mouse model of T1D and high-fat diet (HFD)-fed mouse model of 
T2D (Soltani et al., 2011; Tian, Dang, Kaufman, et al., 2011; Tian, Dang, Yong, et al., 
2011). Considering that in all these studies, the protective effect of GABA was 
related to the modulation of the immune response present in diabetes, we then 
hypothesised that induction of diabetes with a single-dose of streptozotocin may 
not be appropriate for studying GABA treatment, as in this method β-cells are 
rapidly and completely destroyed, with absence of an immune response. Future 
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studies are required in order to determine the mechanisms by which orally 
administered Lb. brevis DPC 6108 mediated the changes in host levels of insulin and 
glucose. Moreover, administration of Lb. brevis DPC 6108 to animal models of 
diabetes involving an autoimmune response would give better insights on the 
potential effects of this strain on the prevention or reversion of diabetes. 
Breast milk is an important dietary source of nutrients for the healthy 
growth and development of infants and promotes optimum microbiota 
development. It contains a complex and diverse mixture of oligosaccharides (Barile 
& Rastall, 2013; Zivkovic et al., 2011) that may exert anti-adhesive effects, inhibiting 
the binding of pathogenic bacteria and toxins and may selectively support the 
establishment of a healthy intestinal microbiota (Zivkovic et al., 2011). As human 
milk oligosaccharides (HMO) are not commercially available, many efforts are being 
made to replicate their beneficial effects using alternative compounds. Therefore, 
in Chapter 6 we investigated the effects of dietary bovine milk oligosaccharides 
(BMO), 6’sialyllactose (6’SL) and the commercial prebiotic, Beneo Orafti P95 
oligofructose (P95), on murine gut microbiota composition and functionality. 
Following 3 weeks oligosaccharide supplementation, significant changes in gut 
microbiota composition were observed. Overall, BMO and 6’SL supplementations 
were associated with reductions of less favourable bacteria. Dietary 
supplementation with BMO was associated with the absence of Moraxellaceae and 
Vibrionaceae, while administration of 6’SL was associated with reduced proportions 
of Moraxellaceae (p=0.003), and Porphyromonaceae (p=0.016) among the gut 
microbiota. As indigenous Bifidobacterium were undetectable in baseline and 3-
week faecal samples, the ability to comprehensively assess the oligosaccharides 
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prebiotic nature was limited. Moreover, SCFA levels were unaltered in animals 
receiving P95 and BMO with only 6’SL administration being associated with 
decreased levels of butyrate (p<0.01). The results from this study demonstrated the 
potential of BMO and 6’SL supplementation for significantly reducing or eliminating 
families of bacteria which potentially harbour pathogenic organisms, and indicate 
that BMO and 6’SL have potential as alternatives to commercial prebiotics such as 
P95. However, future studies using synbiotic treatment (oligosaccharides and 
Bifidobacterium), higher doses or longer periods of dietary supplementation would 
be necessary to assess prebiotic properties of these oligosaccharides. Since this 
study has demonstrated that ingestion of BMO and 6’SL is safe, human studies 
comparing their effects with breast milk or infant milk formula on microbiota 
composition could give important information for their future use as functional 
food components.  
While we are still at the early stages of understanding the complex 
communication systems between gut microbiota and host metabolism, it is now 
apparent that certain bacteria species and strains have the ability to produce 
molecules with a range of bioactive functions. The data presented in this thesis 
have demonstrated the impact of some diverse dietary strategies on gut microbiota 
composition and thus host metabolism. Further in vivo studies are required to 
elucidate the role of metabolite-producing probiotics on host metabolism in health 
and disease. Such studies should address what effect these metabolite-producing 
bacteria and their components have on the host, including effects on nervous 
system function and behaviour.  
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